UWOMJ Volume 79, Issue 1, Spring 2010 by Western University
Western University
Scholarship@Western
University of Western Ontario Medical Journal Digitized Special Collections
2010
UWOMJ Volume 79, Issue 1, Spring 2010
Western University
Follow this and additional works at: https://ir.lib.uwo.ca/uwomj
Part of the Medicine and Health Sciences Commons
This Book is brought to you for free and open access by the Digitized Special Collections at Scholarship@Western. It has been accepted for inclusion in
University of Western Ontario Medical Journal by an authorized administrator of Scholarship@Western. For more information, please contact
tadam@uwo.ca, wlswadmin@uwo.ca.
Recommended Citation
Western University, "UWOMJ Volume 79, Issue 1, Spring 2010" (2010). University of Western Ontario Medical Journal. 17.
https://ir.lib.uwo.ca/uwomj/17
The University of Western Ontario Medical Journal 
Volume 79, Number 1 
Endocrinology 
TOO MANY 
UPS AND DOWNS? 
Glucema nub'ltlonal drink can help manage diabetes at meal or snack time. 
It Is clinically shown to help smooth sugar spikes compared to 
a standard nutritional drink. 1 
Glucema Is low In saturated fats and free of trans fat to help support heart health. 
NEW, IMPROVED GLUCERNA 
• Contains a slowly-digested carbohydrate blend1 
• Complies with Canadian Diabetes Association 
nutritional guidelines2 
• Ideal as a snack, good as a meal replacement 
Clinically shown to help smooth sugar spikes.1* 
Adjusted mean change in plasma glucose over time1 
30 60 
Time 1n m1nutes 
tAt 60 mmutes only 
• Standard nutritional drink 
• Current Glucerna 
• New Glucema 
P<O 001" 
34% lower 
than the current 
Glucerna 
240 
It contains Omega-3 and Omega-6 fatty acids, plus 26 essential vitamins and minerals. 
Available In 4 delicious flavours: Vanilla, Chocolate, Strawberry and Wild Berry. 
Visit www.Giucema.ca for valuable tools, recipes and meal plans. 
lleflrlncll: 
1. Data on file Abbott Laboratorie8. Umlled. 
2 Canadian Dlabetel Auoclatlon 2008 Cllnlcal Practice Guidelines for the PI'Mfltlon 
IIIII M8J11118111811t of Dlabelllln Clnada, Nutrttlon T1rtrlpy. S40·S45 
• Compar8d 10 1 atandatd nutriUonal drink. 
0 Abboll L.aboralor1es, Umlted 
UWOM 
The University of Western Ontario Medical Journal 
Volume 79, Number 1 
Spring 2010 
ADMINISTRATIVE STAFF T ABLE OF CONTENTS 
EDITOR-IN-CHIEF TIFFANY KWOK (MEDS 2010) 2 Editorial 
Endocrino logy : more than just a sli ding scale 
SENIOR ASSOCIATE EDITORS LAURA HINZ (MEDS 2011) 4 Clinical procedures 
PAT MONTALEONE (MEDS 2011} Bariatric surgery: Lots to lose, much to gain 
jUNIOR ASSOCIATE EDITOR PENCILLA LANG (MEDS 2011} 8 Diagnostic review 
Metabolic syndrome 
LAYOUT EDITOR EDWARD W EISS (MEDS 2012} 11 Ethics 
DEPARTMENTAL EDITORS 
Addressing the new teen trend of "diabulimia": Moral 
quandaries of a pediatric endocrinologist 
14 Health promotion 
CLINICAL PROCEDURES EDWARD WEI SS (MEDS 2012) Self-monitoring of blood glucose for type 2 diabetes 
SANDEEP DHALIWAL (M EDS 2013} mellitus patients 
DIAGNOSTIC REVIEW j ULIE HUANG (MEDS 2012} 16 History of medicine 
)AI )AYAKAR (MEDS 2013} "Vo ice and very forme becometh womanish" : 
Contemporary medical views of the Castrati 
ETHICS jULIE HUGHES (MEDS 2012} 20 In terdisciplinary collaboration 
HANG SHI (MEDS 2013) Diabetes and the built environment: Contributions from an 
HEALTH PROMOTION jENNY SHU (MEDS 2012} 
emerging interdisciplinary research programme 
PAUL KUDLOW (MEDS 2013) 23 Medicine and technology 
The sports doping race 
HISTORY OF M EDICINE KATE MACKERACHER (MEDS 2012} 25 Medicine and the Jaw 
ISAAC ELIAS (MEDS 2013) Gender verification testing: Necessary for the integrity 
INTERDISCIPLINARY COLLABORATION ALLANAH Ll (MEDS 2012} 
of international athletics, or inexcusable breach of personal 
EMMA FARLEY (MEDS 2013) 
privacy? 
ASHLEY KIM (MEDS 2013} 28 Profiles 
Profile of Dr. Robert Hegele 
MEDICINE AND TECHNOLOGY STEPHEN CHOY (MEDS 2012) 30 Thinking on your feet 
MAYOORENDA RAVICHANDJRAN (MEDS 2013) Common side effects of diabetes medications 
MEDICINE AND THE LAW COLIN MEYER-MACAULAY (MEDS 2012} 33 Zebra files 
MOSKA HAMIDI (MEDS 2013) McCune-Albright syndrome: An unusual case of nasal 
obstruction 
PROFILES GORDON TSANG (MEDS 2012} 38 Feature article- Brett Howe, Meds 2010 
jOYCE CHEUNG (MEDS 2013) Small bowel intussusception from mestastatic melanoma 
THINKING ON YOUR FEET KALPA SHAH (MEDS 2012} 40 Feature article- justin Chia, Meds 2012 
Yams for breakfast, lunch, and libido? A critical look at 
ZEBRA FILES ANNA BURIANOVA (MEDS 2012} bioidentical hormone therapy 
jULIE LEBERT (MEDS 2013} 43 Feature article - Laura Hinz, Meds 2011 
COVER ART BY JULIE HUANG (MEDS 2012) 
Why did Harvey Cushing misdiagnose Cushing's Disease? 
The enigma of endocrinological diagnoses 
"To me, endocrinology means complex pathways, complicated axes, 
47 Feature article- Kareem jamani, Meds 2010 
feedback loops - stimulatory /inhibitory craziness that some~ow all Management of hyperlipidemia in patients with statin 
works out In trying to find an appropriate analogy, the first thmg that intolerance 
came to mind was a football play diagram. This work is a tongue in 
cheek representation of how I visualize the endocrine sy~tem ... Please 50 Feature article - Kathryn Mcintyre, Meds 2012 
note, however, that this diagram is in no way accurate or reliable. Cystic fibrosi s-related diabetes 
2 
Endocrinology : more than just a sliding scale 
The study of hormones is one of the more nascent and 
elusive branches of medicine. The idea that invisible 
chemicals released from diminutive glands can cause 
darkening of the skin, racing metabolism, and growth of 
gigantic proportions is as mystifying to the lay patient as it 
is to most physicians. 
The general public confusion about what endocrinol-
ogy entails became apparent to me on several clinical 
rotations. During a paediatric endocrinology consult for a 
child with short stature, the mother 
inquired about her daughter's 
diabetes. When I expressed surprise 
that the child was diabetic, she 
replied that she was not, but 
assumed that this was the role of an 
endocrinology consult. As diabetes 
comprises a substantia l portion of 
the endocrinology practice, many lay 
people assume that this condition 
and subspecialty are interchange-
able. As further illustration, an 
elderly patient informed me that she 
regularly saw her "bone doctor." 
She was unfamiliar with the term 
endocrinology; her understanding of 
the person who treated her osteopo-
rosis was that she was a bone specialist. 
The public confusion about the practice of endocri-
nology is understandable if one cons iders the history of the 
subspecialty. The word 'hormone' was not conceived until 
1905, when Starling described "the chemical messengers, 
which speeding from cell to cell along the bloodstream, may 
coord inate the activities and growth of different parts of the 
body."1 As early as Hippocrates (400s BC), physicians had 
an idea that certain glands could produce surprising effects 
on the entire body. However, the thymus gland was not 
discovered until the time of the Alexandrians (300s BC) ; the 
pituitary, pineal, and thyroid glands were noted by Galen in 
170 AD; Eustachi discovered the adrena ls in the 1500s; 
Langerhans found the pancreatic insula in 1869, and the 
parathyroids were unknown until the work of Sandstrom in 
1880.2 It is thus unsurprising that the field of endocrinology 
is one of the more unfamiliar subspecia lti es as the glands 
that control this system had on ly been described 130 years 
ago. In comparison to a field such as cardio logy, whose 
organ and effects have had the benefit of centuries of study; 
endocrino logy is only beginning to be unravelled. 
As a medical subspecialty, endocrinology began to 
gain recognition in North America in 1916 when the Society 
of Interna l Secretions was formed.3 Today, The Endocrine 
Society (USA) and The Society of Endocrino logy (UK) are 
two of the main governing bodies. These organizations have 
recognized the confusion that the concepts of hormones and 
endocrino logy can produce and have designed websites to 
educate the public. Our role as physicians is to do the same. 
One of the keys to compliance with therapy and a strong 
doctor-patient relationship is patient understanding. If our 
patients do not understand what the pituitary gland is, 
where it is located, and what effects it has, they are unlikely 
to be satisfied with a diagnosis of pituitary dysfunction, nor 
will they have confidence in our proffered therapies. One of 
the central roles of the endocrinologist is thus that of 
educator. 
Familiarity with the field of endocrinology is 
necessary not only for budding 
hormone speciali sts, but for all 
physicians. A common ward miscon-
ception is that the endocrinology 
consult service exists to manage the 
insulin sliding scale. Our patients will 
be better served by an understanding 
that hormones play a role in every 
organ system, in every disease, in 
every patient. The Endocrine Society 
has summarized this central role of 
endocrinology in their Strategic Plan-
Vision for the Field of Endocrinology: 
"Endocrinology will be widely accepted as the funda-
mental science of molecular, cellular, and systems com-
munication that underpins human health and disease. 
It will be recognized as an interdisciplinary scientific 
and clinical specialty that integrates basic and clinical 
research with patient care. It will define the ways in 
which the body's communication systems signal organ 
coordination,function and dysfunction. "3 
This issue of the UWOMJ is dedicated to the stimulat-
ing field of endocrinology. The feature and departmental 
articles in this issue display the breadth of issues and 
challe nges encountered in an endocrinology practice. 
As in clinical practice, the topic of diabetes remains a 
major focus of articles in this issue. Commonly-presenting 
scenarios, such as the evidence for blood glucose self-
monitoring, diagnosis of metabolic syndrome, diabetes 
associations with coronary artery disease and managing 
laboratory va lues and side effects of common medications 
taken by those with diabetes will help consolidate our 
knowledge in the area. These articles are published 
alongside more uncommon issues in diabetes management, 
such as cystic fibrosis-related diabetes, 'diabulimia,' and 
how urban planning influences diabetes. 
There are many current 'hot topics' within the 
domains of endocrinology. This issue's articles on bioidenti-
cal hormone therapy, bariatric surgery, drug doping and 
gender testing in athletes shed light on current develop-
ments and may help us better educate our patients on the 
evidence behind the often-sensationalized media stories. 
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We wish to extend a large thank you to the depart-
mental ed ito rs, feature article writers and facu lty reviewers 
for their commitment to educating others about endocrinol-
ogy. Special thanks to Pencilla Lang, Ed Weiss, and Pat 
Montaleo ne, for their tireless work in overseeing the 
compi lation, layout, print and online publication, awards 
and finances for the journal. Enjoy! 
Tiffany Kwok 
Editor-in-Chief 
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Bariatric surgery: Lots to lose, much to gain 
Edward S. Weiss (Meds 2012) and Sandeep Dhaliwal (Meds 2013) 
Faculty reviewer: Dr. Andreana Butter, Department of Surgery, UWO 
Introduction 
The treatment of obesity has long been considered to fall 
under the rubric of "lifestyle modification," with diet and 
exercise making up a large part of the prescription to the 
patient seeking to lose extra pounds. Unfortunately, it has 
been shown that behavioural modification has only a 
modest effect on long-term maintenance of weight loss, with 
the average dieter losing less than 5kg with diet and 
exercise alone.1 
In recent years, it has become increasingly clear that 
more aggressive therapy may be a superior option to treat 
obesity, especially when overweight and its sequelae 
preclude the pursuit of exercise, or when the behavioural 
milieu is such that modification is unlikely to succeed. While 
pharmacological treatment of obesity has shown some 
limited success/ it is bariatric surgery that appears, at this 
time, to offer obese people the highest probability of drastic 
and permanent weight loss, with its attendant benefits on 
physical, as well as emotional health. 
Types of bariatric surgery 
Surgical interventions for the obese are not new, having 
been mentioned by early sources such as the Talmud (circa 
500 CE) and the Greek historian Claudius Aelian (circa 200 
CE).2•3 However, the modern age of bariatric surgery began 
in the 1950s, when surgeons at the University of Minnesota 
began removing variable lengths of small bowel to try to 
reduce the absorption of food in obese patients. The 
untoward side effects of this procedure- diarrhea, micronu-
trient deficiencies, kidney stones, polyarthritis, and even 
cirrhosis4 - led to experimentation with alternate surgical 
strategies. In the 1960s, surgeons attempted gastric bypass, 
based on the observation that patients who underwent 
partial gastrectomy for the treatment of peptic ulcers were 
unable to gain significant weight following their operationss 
In this procedure, the stomach was asymmetrically split, 
with only a small upper pouch remaining in continuity with 
the small bowel. Patients found that the reduced size of 
their stomachs caused them to become satiated early, with 
overconsumption becoming particularly unpleasant. 
These early procedures are, respectively, represen-
tative of the two primary strategies in bariatric surgery: 
malabsorptive procedures, which aim to lower the rate of 
absorption of ca lories consumed; and restrictive proce-
dures, which aim to limit the actua l intake of food by 
provoking early satiety. Further refinement has led to three 
different procedures which are now commonly performed 
as a method of treating obesity (Figure 1). 
Adjustable 
gastric band 
(AGB) 
Vertical sleeve 
gastrectomy 
(VSG) 
Roux-en-Y 
gastric bypass 
(RYGB) 
Figure l . lllustration of three common bariatric surgical 
procedures. 
Adjustable gastric banding 
Gastric banding was introduced as a bariatric procedure in 
the late 1970s. In its first incarnation, the gastric band was a 
non-adjustable plastic mesh applied circumferentially 
around the upper portion of the stomach, creating a sma ll 
pouch which restricted overconsumption. Refinement in the 
years following led to the creation of the adjustable gastric 
band (AGB), which consists of a hollow silicone ring 
connected by a narrow tube to a subcutaneous access port. 
In this manner, the size of the upper stomach pouch can be 
adjusted by the infusion of saline through the port and into 
the band. If, for example, the rate of weight loss is deemed to 
be too slow, the band can be tightened and the pouch made 
smaller. Conversely, if a patient with a gastric band were to 
become pregnant and require a higher caloric intake, the 
band can be loosened by removing fluid . 
There are several relative benefits to AGB. Although 
performed laparoscopically like most modern bariatric 
operations, band placement is relatively less invasive. It 
involves no staples, transections, or anastomoses, and is 
thus associated with the lowest rates of post-operative 
complications and mortality compared to other proce-
dures .6·7 Weight loss is more gradual than with more 
invasive malabsorptive procedures, but the percentage of 
excess weight lost has been found to be similar in some 
long-term studies.8 The adjustability of the band and the 
potential for easy reversability are additional factors that 
make the gastric band an attractive choice. 
Although major complications from gastric banding 
are quite rare, there are, nonetheless, some drawbacks to 
the procedure. Studies have reported unwanted pouch 
enlargement as a complication in 10-15% of patients, as 
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well as band slippage and distal stomach prolapse in 2-4%; 
these often necessitate reoperation or band removal.8 
Additionally, it has been found that in patients classified as 
"super-obese" (8MI > 50), weight loss and improvement in 
comorbidities such as type 2 diabetes are superior in other 
types of procedures.9 
Vertical sleeve gastrectomy 
Vertical sleeve gastrectomy (VSG) evolved in the milieu of 
increasing recognition of the effectiveness of restrictive 
procedures, combined with the rapid adoption of automated 
surgical staplers in the 1970s. In this procedure, the fundus 
and greater curvature of the stomach are removed through 
vertical stapled resection, resulting in a tubular or banana-
shaped sleeve with a volume of around 15% of the original 
stomach.10 Although purely restrictive in intent, it is thought 
that lower circulating levels of ghrelin, a hunger-inducing 
hormone produced in the gastric fundus, may contribute to 
the weight loss seen by patients.11 
The benefits of VSG are similar to those of other 
restrictive procedures. Although long-term results have not 
yet been published' , studies suggest that short-term weight 
loss is comparable or superior to that of patients who have 
undergone gastric bandingY The procedure also spares the 
absorptive function of the small bowel, although it is recog-
nized that there is a potential for impaired vitamin 812 
absorption due to the lack of intrinsic factor production. 
Technically, a partial gastrectomy is simpler than many of the 
malabsorptive procedures, and it can also be converted to a 
gastric bypass in the event of failure to lose weightY How-
ever, it appears that more long-term results will be required 
before VSG is a standard part of the bariatric repertoire. 
Roux-en-Y gastric bypass 
The Roux-en-Y gastric bypass (RYG8) is widely becoming one 
of the most popular surgical options for weight loss. A 
technically complex procedure, it involves the creation of a 
small restrictive stomach pouch, but additionally recon-
structs the small bowel to promote a malabsorptive state. In 
the traditional procedure, the jejunum is transected approxi-
mately SOcm distal to the ligament of Treitz. The distal limb 
of the jejunum is anastomosed to the reduced upper stomach 
pouch, while the proximal limb, which transmits bile and 
pancreatic secretions from the duodenum, is anastomosed 
approximately a meter down the distal limb. Unlike a sleeve 
gastrectomy, an RYG8 leaves the rest of the stomach in situ, 
making the operation potentially reversible if necessary. 
Weight loss stimulated by RYG8 has been found in 
some studies to be superior to that of purely restrictive 
procedures, and health-related quality of life has also been 
shown to be significantly betterY This benefit over other 
procedures has been attributed partially to the malabsorp-
tive state, but also to changes in taste preference and the 
aversive sequalae of the dumping syndrome, which is an 
unpleasant combination of gastrointestinal and vasovagal 
disturbances that often results from the ingestion of sugar-
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laden meals following gastric bypass. Furthermore, the exact 
extent of intestinal bypass can be adj usted in order to 
promote ever further weight loss, though this does run the 
risk of developing micronutritional deficiencies. 
Complications following RYG8 are, as expected, 
somewhat higher than with purely restrictive procedures. 
However, operative mortality has been reported to be less 
than 1%/4 and the primary complications are related to 
malabsorption of vitamin 812 and iron; these can be easily 
corrected with supplementation.9 
Benefits of bariatric surgery 
There is little doubt that bariatric surgery is effective for 
weight loss. A meta-analysis looked at the outcomes of 
22,000 patients who underwent some sort of bariatric 
surgery, and found that the average loss of excess weight was 
61.2%.14 The study also reported that the majo rity of patients 
also experienced a resolution of pre-existing type 2 diabetes, 
hypertension, hyperlipidemia, and obstructive sleep apnea. 
Operative mortality was, on average, less than 1%, which is 
deemed to be much lower than the risk of premature 
mortality from the health consequences of obesity. 
Aside from the physical health benefits of bariatric 
surgery, it appears that treatment can also have a substantial 
impact on emotional and mental health as well. Numerous 
studies have shown that people living with obesity have 
significantly higher rates of mood and anxiety disorders, as 
well as decreased se lf-esteem and self-acceptance. 15•16 
Successful weight loss following bariatric surgery often 
results in improvement in these domains as well. 16 
While at first glance it may appear that surgical 
management of obesity has the disadvantage of being 
relative ly expensive, severa l studies have borne out the 
assumption that the increased expense in the short term is, in 
fact, less costly than the medical management of severe 
obesity and its comorbidities, which can often amount to 
$10,000 per patient per year or more in Ontario. 17 Addition-
ally, it has been found that obese patients who undergo 
bariatric surgery are more likely to be employed and not 
dependent on social welfare support compared to before 
their surgeries, which only furthers the case for surgery in 
the very obese.18 
Access to bariatric surgery 
With the alarming reminders of the growing "obesity 
pandemic" forefront in the public mind, and the growing 
awareness of bariatric surgery as an effective treatment 
option, it is not surprising that demand for surgical treatment 
is far higher than the available supply in Canada. A recent 
study that polled Canadian bariatric surgeons found that the 
average wait time for publicly-funded procedures performed 
locally is around five years. 19 In response to the extreme 
demand, provincial governments have been increasingly 
funding bariatric surgery performed out-of-province and out-
of-country. Ontario, for example, funded over 1,500 out-of-
country procedures in 2008-2009, at a cost that far exceeds 
UWOMJ 179:1 I Spring 2010 
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the comparable cost in Canada.20 Meanwhile, those with 
suitable financial means often take advantage of privately-
run clinics, which offer procedures not funded by provincial 
health plans. Gastric banding, for example, is ava ilable at a 
cost of around $16,000, with wait times in the range of 
weeks to severa l months. Others, seeking a less-expensive 
alternative, have been known to travel to Mexico and India, 
where the procedures can be done in short order at a 
fraction of the Canadian price. 
Perhaps in recognition of the dire situation sur-
rounding the inequity of access to bariatric surgery, several 
provincial governments have announced new funding 
strategies to increase access to weight loss procedures. 
Ontario is investing $75 million to increase its bariatric 
surgical capacity by nine-fold in the next few years/ 0 and 
Quebec intends to shorten waiting times to six months 
through a significant infusion of new funds .21 These sorely-
needed expansions are expected to make a vast difference in 
the morbidity and mortality of those suffering from severe 
obesity. 
Conclusion 
In the absence of effective primary prevention, bariatric 
surgery appears to be the most promising treatment option 
for obesity and its resultant comorbidities. While the 
optimal surgica l approach has yet to be decided, it is clear 
that procedures for weight loss will continue to evolve in 
order to maximize benefit and reduce the risk of complica-
tions. Inequitable access to these procedures represents a 
major barrier to successful treatment of severe obesity on a 
population level, but the recognition by provincial funding 
agencies that these treatments are beneficial is leading to 
positive change and an overall increase in the well-being of 
Canadians suffering from obesity. 
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H ome to some of the finest physicians in Canada, Humber River Regional Hospital's physician team includes internationally-recognized experts who lecture at conferences and medical schools around the globe. As 
diverse a patient population both in terms of culture and medical concerns as any other hospital in the world , last 
year Humber River treated patients from 140 countries, speaking over 90 different languages. So if you 're looking 
to grow your career at a hospital that will challenge you with a wide diversity of patient concerns, but will support 
your professional development inside and outside the organization , then consider Humber River Regional Hospital. 
With our new hospital approved and in the final planning stages, you will be joining an organization with a bright 
future. The RFP for our new hospital building will be out to market in 2010, and in 2014 we will move into Ontario's 
first digital hospital , a modern showcase featuring the finest and most innovative technology possible. 
How innovative? - our robots will have their own elevators! 
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Introduction 
Metabolic syndrome (MetS) is a common disorder charac-
terized by the clustering of risk factors for developing 
cardiovascular disease (CVD) and type 2 diabetes mellitus 
(T2DM). Though the idea of MetS has existed for over 80 
years, the concept was not further developed until 1988; 
since then our understanding of this disorder has been 
continuously evolving. The precise definition and criteria 
for diagnosis of MetS has been rapidly changing in recent 
years.1·3 
The s igns that characterize MetS include central 
obesity, dyslipidemia, hyperglycemia and hypertension. It is 
believed that the diagnosis of MetS is a greater predictor for 
the development of CVD a nd T2DM than the consideration 
of these risk factors independently.4 In keeping with its 
classification as a 'syndrome,' there has not been a single 
cause identified in the etiology of MetS, and there is still 
much that is unknown about its pathophysio logy. Indeed, it 
is even unclear whether MetS is a 'true' syndrome where the 
symptoms are related by pathophysiology, or whether the 
diso rder is simply a collection of common independent risk 
factors from differing disease phenotypes.4 Nevertheless, 
insulin resistance is the most commonly accepted mecha-
nism through which MetS develops.5 
There have been many definitions of MetS released 
by separate institutions s ince the WHO released the first 
formalized criteria in 1999. Each of the criteria considers 
similar parameters that reflect both our understanding in 
the pathophysiology of MetS, as well as the clinical presen-
tation of the disorder. There are differe nces between 
guidelines in cutoff values and the combinations of symp-
toms that will allow a diagnosis. This article will review 
three guidelines - the WHO, ATPIII a nd the IDF - as these 
appear to be the most commonly used criteria in the cu rrent 
literature. 
Current guidelines- review and comparison 
The specific deta il s of the criteria are summa rized in Table 1 
for comparison. The first set of diagnostic crite ria was put 
forth by the WHO diabetes group in 1999. Insulin resistance 
or impaired glucose to lerance or diabetes, hypertension, 
dyslipidemia, obesity a nd microa lbuminuria were defined 
as the components of MetSl These criteria were felt to be 
difficult to measure in the clinic; the ora l glucose tolerance 
test a nd albumin measurement were not feasible tests that 
could be easily done in the clinic. In response, the US 
National Cholesterol Education Program : Adu lt Treatment 
Panel Ill (NCEP:ATP III or ATPIII) in 2001 released a new 
set of criteria where insulin resistance was measured by a 
fasting glucose test, a simpler test tha n the oral gl ucose 
tolerance test. The combination of risk factors and cut-off 
levels also differed from the WHO criteria. The ATPIII 
criteria, however, still had their shortcomings. Although 
easier to use in the clinic, the ATPIII guidelines were not 
suitable for an international population; for example, ethnic 
differences in BMI were not addressed. 
In 2004, in order to clear the confusion between 
multiple guidelines and to create an internationally applica -
ble guideline, the International Diabetes Federation re-
leased a unified definition in 2005 (updated in 2006V Like 
the ATPIII, the IDF used criteria that could be easily tested 
in the clinic. The most significant change in the IDF criteria 
was the use of central obesity as a necessary component for 
diagnosis. Also important was the attempt to make the 
criteria applicable for a worldwide population by releasing 
cut-off levels for central obesity that were specific for 
different ethnicities. The cutoff values were generally lower 
than leve ls present in the other criteria, and the specific 
values were obtained using anthropometric studies of 
different populations.2 
In addition to the three guidelines that have been 
outlined, it is important to note other guidelines released by 
institutions such as the American Association of Endocrinol-
ogy, the National Hea rt, Lung, and Blood Institute (NHLBI) . 
These are all s imilar, but differ s lightly in cutoff levels. 
Prevalence and predictive value 
MetS is a very common disorder. The literature suggests a 
preva lence ranging from 14-32%.3·6•7 Specific prevalence 
depends on geographic location, population characteristics 
such as ethnicity, and the criteria used to define MetS. The 
majority of studies suggest that a higher prevalence of MetS 
is identified using the IDF criteria than the ATPIII criteria.6·7 
The importance of MetS lies in its abi lity to predict 
more significant disease, primarily T2DM and CVD. While 
the re is strong evidence to suggest that MetS is a good 
predictor of T2DM, the ability to predict CVD in MetS is 
controvers ial.8 In addition to T2DM and CVD there have also 
been studies suggesting that MetS can predict other 
diseases and outcomes, including chronic kidney disease, 
sexual dysfun ction, hypogonadism, polycystic ovarian 
ovarian syndrome (PCOS) , fatty liver and all-cause mortal-
ity.9·11 
The litera ture suggests that MetS is a strong predic-
tor of developing T2DM . The specific predictive ability 
differs between different s tudies and between criteria. A 
number of separate studies have compared the ability of the 
ATPIII criteria and the IDF criteria in predicting diabetes in 
different populations. In the articles reviewed, the predic-
tive value of MetS ranges, with articles listing an increased 
RR of 3.08 all the way to 10.10?· 11 ·12·13 Comparing sets of 
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WHO ATP Ill IDF 
Impaired glucose tolerance or insulin Central obesity w / ethnic specific 
resistance or a diagnosis ofT2DM values or BMI> 30 
Plus any two of the following: Any three or more of the following: Plus any two of the following: 
Dyslipidemia Raised Triglycerides Raised Triglycerides 
Triglycerides ~ 1.7 mmoljL ~ 1.7mmoljL ~ 1.7mmoljL 
or HDL<0.9 mmoljL (males) 
or HDL<1.0 mmoljL (females) Reduced HDL cholesterol Reduced HDL cholesterol 
< 1.03 mmol/L (males) < 1.03 mmoljL (males) 
Microalbuminuria < 1.29 mmoljL (females) < 1.29 mmoljL (females) 
Albumin excretion > 20119/min 
Hypertension Hypertension 
Hypertension ~130 systolic or ~85 diastolic (mmHg) ~130 systolic or ~85 diastolic 
>140/90 mmHg (mmHg) 
Raised fasting plasma glucose 
Obesity Raised fasting plasma glucose 
BMI > 30 or waist:hip ratio > 0.9 in Central Obesity Fasting plasma glucose ~100mgjdL 
males, >0.85 in females >102 em (male), >88cm (female) or previously diagnosed T2DM 
Table 1. Summary of the WHO, ATPIII and IDF criteria for metabolic syndrome 
criteria, it has been suggested that the ATPIII criteria 
appears to be more effective at predicting diabetes but these 
results are not necessarily definitive.6·7.1° In comparison to 
established methods for predicting diabetes, studies have 
found no advantage. 12 MetS using the ATPIII criteria shows 
a lower sensitivity and a higher false-positive rate when 
compared to the Diabetes Risk Score, a standard method to 
measure risk of developing diabetes.11 
Whether MetS is able to predict CVD is unclear and 
controversial. The MetS criteria does not include absolute 
CVD risk factors that are included in standardize·d risk 
assessment methods such as age, smoking, and family 
history.8 Regardless, studies have shown that individuals 
diagnosed with MetS do show a statistical increase in 
developing CVD, and that it is an important risk factor for 
CVD cause and mortality.14·15 This calculated increase in risk 
is fairly consistent between different criteria - the WHO, 
ATPIII and the IDF.14 When compared to existing methods 
for predicting CVD, one study demonstrated that a diagnosis 
of MetS had a lower sensitivity and higher false-positive rate 
compared to the Framingham Score in predicting CVD. 11 
Other studies suggests that despite the ability of MetS to 
predict CVD mortality, it does not do so beyond the ability of 
its individual components.13 
Discussion 
MetS identifies individuals that are at risk of developing 
CVD and T2DM, but its ability to do so is confounded by the 
existence of multiple criteria, and a lack of knowledge of this 
disorder. A formal definition of MetS was created only in the 
last 10 years, and there have been few long-term studies on 
MetS. The resulting lack of evidence and an incomplete 
knowledge of its pathophsyiology are also significant 
sources of confusion. While MetS is able to predict diabetes 
and CVD to an extent, its efficiency and effectiveness are 
controversial. For instance, the JDF criteria has been 
criticized for missing high risk patients that do not show 
central obesity.7 The ability of MetS to predict disease has 
been shown to be no more effective than existing meth-
ods.11.12 Other studies suggest that the risk associated with 
MetS is no greater than the risk associated with its individ-
ual components. 13 This brings into question the clinical 
value of diagnosing MetS. 
Nevertheless, there is convincing evidence for the 
use of MetS. Recently, a report has been published support-
ing the use of MetS as an important public health tool. 16 It 
acknowledges the limitations that MetS has in predicting 
DM and CVD, but it also stresses that combined with other 
clinical tools and other existing guidelines, MetS can be 
useful in helping patients understand their level of risk and 
its potential impact on their health in the future . Underlin-
ing how separate risk factors can be interrelated can have 
an important role in helping both clinicians and patients 
address risk factors, especially if lifestyle modification is the 
goal. 
Recent research has been focused on addressing the 
limitations and confusion that surrounds MetS. Most 
recently, in October, the IDF and AHA have jointly released a 
new guideline that attempts to unify the MetS criteria.17 
Other areas of recent research include establishing more 
evidence to better refine the MetS criteria, with a particular 
focus in different subpopulation and ethnic groups. With 
the incidence of childhood T2DM on the rise, there is a need 
to develop standardized criteria for MetS diagnosis in the 
pediatric population.18 
In summary, MetS is a useful tool to identify indi-
viduals at risk for developing T2DM and CV. There are many 
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issues that limit its clinical value, including confusion 
between the existence of multiple guidelines, controversy in 
the research, lack of evidence, and a poor understanding of 
its pathophysiology. Nevertheless, it is important to 
appreciate the function of MetS, especially as the incidence 
of CVD and T2DM continues to rise in today's society. 
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Addressing the new teen trend of "diabulimia": Moral quandaries of a pediatric 
endocrinologist 
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The management of diabetes mellitus in adolescents has 
grown increasingly nuanced as insu lin resistance appears at 
ever-younger ages and technology advances into hitherto 
unattainable realms. Hence, it is in the midst of an already 
complex milieu that a new syndrome has managed to 
emerge largely unnoticed. This rarely researched and thus 
largely mysterious condition has been dubbed "diabulimia" 
by the media; the scientific community has yet to name it. 
Diabulimia refers to the practice of withholding insulin in 
order to lose weight. 1 It typically co-exists with other 
disordered eating behaviour (DEB; e.g., extreme restriction, 
use of laxatives, etc.) or fu ll-scale eating disorders.2 DEB is 
particularly worrisome in the context of pediatric diabetes 
for two reasons: 
(a) It is dangerous. Eating disorders in diabetics are 
associated with poor metabolic control, greater need 
for hospitalization, a higher rate of microvascular 
complications (in particular retinopathy and 
nephropathy), and premature mortality.1· 3· 4· 5· 6 
(b) It is common. A startling 51% of adolescents in a 
Toronto study reported DEB, and over 10% met 
diagnostic criteria for an eating disorder.2 The root 
of this rather extraordinarily high prevalence is 
unknown, but there have been postulations: diabetic 
children are encouraged to pay a great deal of 
attention to their diets and also tend to have higher 
BMls than their peers, which may increase anxiety 
about weight.7 The problem seems to increase with 
age: deliberate insulin omission is reported by 
roughly 2% of preteens, 15% of mid-teens, and 30-
39% of older teens.u 
The remainder of this paper will focus on ethical 
concerns that may arise in the care of these patients. As 
Carney insightfully notes, "Behavioural disorders accompa-
nied by questionable beliefs ... expose the frailties of medico-
legal knowledge.''8 If we attempt to understand these 
frailties and grapple with those issues for which "there is no 
'right' decision, only a decision that is thoughtfully made 
and perhaps 'more right' than the alternatives,"we will 
gradually strengthen the ethical foundations on which 
medicine relies.9 
Case 1 
You receive an urgent page informing you that Erica, 
a 15-year-old patient of yours, is in diabetic ketoaci-
dosis at the hospital. You go to see her and discover 
that she has been skipping many of her insulin doses 
for months and does not wish to be treated for her 
ketoacidosis with insulin. She is terrified at the 
prospect of gaining weight and equates taking insulin 
with weight gain and loss of control. What should you 
do? 
Though literature on diabulimia is scant, much has been 
written on the ethics of compulsory treatment for anorexia 
nervosa, and the essential difficulty in both circumstances is 
the same. It li es in balancing two of the most sacredly held 
principles of bioethics: beneficence and autonomy.8· 10• 11 Put 
in another fashion, this is a tension between positive rights 
(i .e., the right to health) and negative rights (i.e., the right 
not to be hospitalized or treated aga inst one's wi ll) .8 
Before moving on any further, it is crucial to get the 
question straight. In this case, there is in fact more than one 
question. The first is this : should a clinician respect a 
competent patient's autonomy if his or her own vision of the 
patient's best interests differs from the patient's (assuming 
that what the patient desires the clinician to do lies within 
ethical bounds)? That question has been considered in 
depth and resolved.12 It is not a very difficult one when well -
being is considered from a holistic point of view, since "a 
respect for autonomy clearly emerges from a beneficence-
based ethic"Y In the case of eating disorders, however, we 
have a cluster of more complicated questions, ones in which 
beneficence and autonomy truly do conflict: they are 
questions regarding the nature of competence, how mental 
illness can affect it, and what to do when it is fragi le or 
absent. 
Competence requires the ability to understand and 
remember information about treatment options, appreciate 
the personal reality of relevant benefits and risks, weigh and 
consider various possibilities, and express a choice.11· 14• 15 
While an eating disorder certainly does not automatically 
remove a patient's capacity to make medical decisions, 
concern is valid and needs to be explored on a person-by-
person and task-by-task basis. Anorexia, the most studied of 
the eating disorders, has variable and unpredictable effects 
on concentration, beliefs, and information processing.U· 16· 17• 
18
· 
19 Patients frequently express contradictory convictions: 
for example, they usually do not want to die, yet they also do 
not want to eat enough to live.20 Whether these difficulties 
are of a nature that can be adequately captured on standard 
tests of competence (e.g., the MacCAT-T) is a matter of 
debate. 18· 19· 21 Some propose that pathological values derived 
from the eating disorder may cause a cognitive impairment 
greater than that detected by current tests.18• 21 
The extent to which the cognitive distortions of 
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anorexia are present in diabulimia is unknown and difficult 
to surmise, since both severe malnutrition (which may or 
may not be present in diabulimia) and the mental illness 
itself contribute to them. The latter should not be underesti-
mated, for "the types and range of relationships that 
patients may have with the eating disorder are similar to 
the relationships they may have with people".14 Thus, 
establishing the competency of a patient with any eating 
disorder requires a careful and thoughtful evaluation. In 
Ontario, a hearing before the Consent and Capacity Review 
Board is sometimes necessary, though this is impractical 
when urgent care is required .22 
If it is determined that a patient is not competent to 
refuse a specific medical intervention, the treatment team 
must then discuss the issue with a substitute decision maker 
(in pediatrics, usually the parents) and offer appropriate 
counsel. For patients who do not have an advance directive, 
the guiding standard generally applied is that of "best 
interests".18· 23 This raises a new question: even with legal 
permission, is it good judgment to treat Erica against her 
will? Forced treatments are highly psychologically distress-
ing and may jeopardize recovery if used excessively.20·24 All 
costs must be counted and the patient's wishes should be 
respected whenever possible, even if he or she is not 
competent.25 
Nonetheless, in Erica's case, we suggest that the 
standard of best interests would involve administering 
insulin. There is good rationale, indeed probably better 
rationale than for forced feeding in anorexia: she is in an 
acutely life-threatening situation, the intervention is of 
known medical benefit, there are no viable alternatives, and 
her true wishes cannot be reliably ascertained due to the 
cognitive effects of her illness.8· 10· 11 · 14· 20· 25 Further, because 
an eating disorder is normally an expression of emotional 
distress rather than a genuine attempt at a slow suicide, 
there is a particularly strong "duty to protect".8·10·11 This 
scenario is not akin to withdrawing care at end-of- life; 
patients with eating disorders do recover and frequently go 
on to lead full, happy lives. 11·14·15 
It goes without saying that Erica will need other 
care. Her ability to consent to (or refuse) each intervention 
should be considered independently by a clinician attuned 
to possible changes over time.14' 24 The process of eva luating 
competence can be given more thought and time once she is 
stable. Fortunately, compulsory treatment given sensitively 
does not seem to negatively affect the therapeutic relation-
ship. IO,t4 
Conceptually, perhaps the most important point here 
is that the underlying rationale is not a lack of respect for 
autonomy but a beli ef that true autonomy is occasionally 
impossible. Hence, the goal is not to privilege the clinician's 
view over the patient's, but to give what the patient's 
genuine self, rather than her mentally ill se lf, wou ld want, 
with the ever-present hope that in the future she will regain 
the ability to choose freely and even healthfully. Clinicians 
should strive for the model achieved in a British Columbia 
eating disorders program in which "the team is always 
working towards empowering the patient to achieve her 
own agency and at the same time must remain cognizant of 
the power of the anorexia, which may mask the authentic 
wishes of the patient to seek wellness."14 A blind and 
unconsidered adherence to the wishes of a patient who is in 
severe psychiatric distress and desperate medical need 
helps no one. 
Case 2 
You head back to your office. Laura, a 12-year-old 
with Type I diabetes, is coming to see you for a 
routine check-up. Upon reviewing her chart, you 
discover that her sugar levels are rather high and she 
has lost about 10 pounds. What is your approach? 
This particular scenario is not ethically complex, yet it is 
important, because if you were to discover that Laura has a 
full-scale eating disorder, you would have a window of 
opportunity to simultaneously avert suffering and avoid the 
ethical complexities of the previous case. Call it 
"preventative ethics", if you will. You might accomplish 
these goals by (a) treating her early, and (b) working with 
Laura, her family, and an interdisciplinary team to prepare 
an "advance directive" that could be used to guide treatment 
if she should lack decision-making capacity in the future.14 
Evidence suggests that DEB persists for at least five years in 
over 90% of cases; a "wait-and-see" approach is not wise.1 
Unfortunately, physicians feel that they lack training 
in caring for adolescents with these difficulties, and routine 
care is likely inadequate.5 Recommendations for those 
hoping to achieve successful early intervention include 
yearly screening questions beginning in the preteen years, 
attempts to normalize eating behaviour and bolster self 
esteem early in the course of illness, and a low threshold for 
referral to specialized eating disorder services.1·15 Last but 
never least, according to patients, the "key to a meaningful 
intervention is to be recognised by the therapist as a 
person".26 
In sum, "diabulimia" illuminates the ethical impor-
tance of early intervention in mental illness and raises 
important moral issues that the field of pediatric endocri-
nology will need to address in coming years. Such discus-
sion is an integral part of the rapid evolution of society and 
medicine, for as Macdonald so aptly put it, "Ethics - the 
making of va lue judgments, of weighing our actions against 
shared standards- is a task inherent to clinicallife."25 
References 
1. Colton P, Rodin G. Eating disorders and depression 
in women with diabetes. In: Tsatsoulis A, Wyckoff J, 
Brown FM, editors. Diabetes in women: pathophysi-
ology and therapy. Totowa (NJ): Humana Press; 
2009. p. 127-143. 
2. Colton PA, Olmstead, MP, Daneman, D, Rydall, AC, 
Rodin, GM (2007). Five-year prevalence and persis-
tence of disturbed eating behaviour and eating 
disorders in girls with type 1 diabetes. Diabetes 
UWOMJ 179:1 I Spring 2010 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
Takii M, Uchigata Y, Tokunaga S, Amemiya N, Nozaki 
T, Iwamoto Y, et al. The duration of severe insulin 
omission is the factor most closely associated with 
the microvascular complications of type 1 diabetic 
females with clinical eating disorders. International 
Journal of Eating Disorders. 2008;41:259-264. 
Tierney S, Deaton C, Whitehead J. Caring for people 
with type 1 diabetes mellitus engaging in disturbed 
eating or weight control : a qualitative study of 
practitioners' attitudes and practices. Journal of 
Clinical Nurs ing. 2008;18:384-390. 
Crow SJ, Peterson CB, Swanson SA, Raymond NC, 
Specker S, Eckert ED, et al. Increased mortality in 
bulimia nervosa and other eating disorders. Ameri-
can Journal of Psychiatry. 2009; 166:1342-1346. 
Smith FM, Latchford GJ, Hall RM, & Dickson RA. Do 
chronic medical conditions increase the risk of 
eating disorder? A cross-sectional investigation of 
eating pathology in adolescent females with scoliosis 
and diabetes. Journa l of Adolescent Health . 
2008;42:58-63. 
Carney T. Anorexia: a role for law in therapy? 
Psychiatry, Psychology, and the Law. 2009;16(1) : 
41-59. 
Hill M, Glaser K, Harden J. A feminist model for 
ethical decision making. In : Rave EJ, Larsen CC, 
editors. Ethical decision making in therapy: feminist 
perspectives. New York: Guilford Press; 1995. p. 18-
37. 
Werth JL, Wright, KS, Archambault RJ, Bardash, RJ . 
When does the "duty to protect" apply with a client 
who has anorexia nervosa? The Counseling Psy-
chologist. 2003:427-450. 
Giordano S. Anorexia nervosa and refusal of nasa-
gastric treatment: a response to Heather Draper. 
Bioethics. 2002;17(3):261-278. 
Annas GJ, Densberger JE. Competence to refuse 
medical treatment: autonomy vs. paternalism. 
University of Toledo Law Review. 1984;15:561-596. 
Loewy EH. Social contract, community structure, and 
obligation. In: Suffering and the beneficent commu-
nity: beyond libertarianism. Albany (NY): State 
University of New York Press; 1991. p. 54-86. 
Manley RS, Smye V, Srikameswaran S. Addressing 
complex ethical issues in the treatment of children 
and adolescents with eating disorders : application of 
a framework for ethical decision-making. European 
Eating Disorders Review. 2001;9:144-166. 
Celio AA, Bryson S, Killen JO, Taylor CB. Weight 
control behaviour and attitude questions: implica-
tions for consent procedures. International journal 
of Eating Disorders. 2003;34(2) :251-254. 
Vollmann J. "But I don't feel it": values and emotions 
in the assessment of competence in patients with 
anorexia nervosa. Philosophy, Psychiatry, and 
Psychology. 2006;13(4):289-291 . 
Tan JOA, Hope T, Stewart A, Fitzpatrick R. Compe-
tence to make treatment decisions in anorexia 
Addressing the new teen trend of "diabulimia" 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
nervosa : thinking processes and values. Philosophy, 
Psychiatry, and Psychology. 2006;13(4): 267-282 . 
Tan JOA, Doll HA, Fitzpatrick R, Stewart A, Hope T. 
Psychiatri sts' attitudes towards autonomy, best 
interests and compulsory treatment in anorexia 
nervosa: a questionnaire survey. Child and Adoles-
cent Psychiatry and Mental Hea lth . 2008;2:40. 
Grisso T, Appelbaum, PS. Appreciating anorexia: 
decisional capacity and the role of values. Philoso-
phy, Psychiatry, and Psychology. 2006;13(4) :293-
297. 
Hebert PC, Weingarten MA. The ethics of forced 
feeding in anorexia nervosa. Canadian Medical 
Association journal. 1991;144(2):141-144. 
Charland LC. Anorexia and the MacCAT-T test for 
mental competence: validity, value, and emotion. 
Philosophy, Psychiatry, and Psychology. 2006; 13 
(4) :283-287. 
Geist R, Katzman OK, Colangelo JJ . The Consent to 
Treatment Act and an adolescent with anorexia 
nervosa. Hea lth Law in Canada. 1996;16(4) :110-114. 
Kopelman LM. The best-i nterests standard as 
threshold, ideal, and standard of reasonableness. 
journal of Medicine and Philosophy. 1997;22 
(3):271-289. 
Draper H. Anorexia nervosa and respecting a refusal 
of life-prolonging therapy: a limited justification. 
Bioethics. 2000;14(2) :120-133. 
Macdonald C. Treatment resistance in anorexia 
nervosa and the pervasiveness of ethics in clinical 
decision-making. Canadian Journal of Psychiatry. 
2002;4 7(3) :26 7-270. 
Fedyszyn IE, Sullivan GB. Ethical re-evaluation of 
contemporary treatments for anorexia: is an 
aspirational stance possible in practice? Australian 
Psychologist. 2007 ;42 (3) : 198-211. 
UWOMJ 179:1 I Spring 2010 
13 
14 
Self-monitoring of blood glucose for type 2 diabetes mellitus patients 
Jenny Shu (Meds 2012) and Paul Kudlow (Meds 2013) 
Faculty reviewer: Dr. Ruth McManus, Department of Medicine, UWO 
Introduction 
Among the many rising global health epidemics, diabetes 
mellitus can be argued to be one of the most concerning 
ones with over 246 million people affected worldwide 
currently and 380 million people expected by 2025.1 Type 2 
diabetes mellitus (T2DM), or non-insulin dependent 
diabetes, accounts for 95% of all cases of diabetes/ and 
results in significant morbidity and long-term complications 
affecting multiple organ systems, such as microvascular 
pathology in the retina, peripheral neuropathy, nephropa-
thy, and most importantly, macrovascular disease affecting 
arteries supplying the heart, brain, and lower extremities.2 
In fact, the risk of developing cardiovascular complications 
in T2DM is two- to fourfold higher for men and women 
respectively, relative to a non-diabetic population.2 
Tight blood glucose control is one of the pillars of 
patient-centred self-management, but the role for testing 
glucose levels in order to achieve tight control has been met 
with many challenges and debate. Technology that allows 
for self-monitoring of blood glucose levels has only been 
commercially viable since the early 1980's.3 While there has 
been evidence to suggest the benefit of using self-
monitoring of blood glucose (SMBG) for diabetic individuals 
on insulin (patients with either TlDM or T2DM on insulin) , 
there has been limited research and controversy on 
whether the high personal and financial cost burden of 
SMBG is beneficial for most non-insulin dependent T2DM 
patients.4 This article will explore the challenges and gaps of 
knowledge in using SMBG for the management of patients 
with T2DM, as well as identify recommendations and 
improvements that can be made to aid patients in their 
disease management. 
Current evidence 
The current clinical evidence supporting the use of SMBG on 
improving the outcomes of non-insulin dependent T2DM 
patients is controvers ial and inconclusive. Most published 
trials of SMBG use the glycosylated hemoglobin (AlC) 
(HbAlC) levels as a surrogate marker for overall glycemic 
control and risk of secondary complications, but the 
methods utilized with respect to the intervention (e.g. 
frequency of SBGM, follow-up, and education) have been 
heterogeneous and hence difficult to generalize.5 
A recent key study conducted by the DiGEM 
(Diabetes Glycemic Education and Monitoring) Trial Group 
used an open, parallel group randomized control trial 
methodology. It was concluded that there was no convinc-
ing evidence to recommend routine SMBG for all T2DM 
patients, nor any evidence of improved glycemic control 
relative to usual care monitored by HbAlC levels.6 
However, in contrast, a meta-analysis conducted by 
jansen et al. looking at 13 randomized controlled trials was 
able to report conclude that SMBG improved the HbAlC by 
more than 0.40% and this reduction nearly doubled after 
providing medical feedback. 7 Similarly, Towfigh et al. 
concluded from their meta-analysis of 9 randomized control 
trials that T2DM patients not on insulin using SMBG had a 
statistica lly significant although modest improvement in 
glycemic control relative to those without SBMG.8 
Moreover, a study by McGeoch et al. suggested that 
there may be a subset of T2DM patients who benefit from 
SBMG.9 Specifically, they conducted a systemic review of 3 
randomized trials and 13 observational studies published 
since 1990. Based on results from a patient group managed 
with oral hypoglycemic agents and/or diet alone, their 
conclusion was that only larger studies with a higher initial 
HbAlC of > 8% showed improvement in glycemic control 
with SMBG. 
Challenges and Limitations 
It has been difficult to consolidate data and compare 
research on SMBG in T2DM patients due to inconsistency of 
outcome measures, as well as a lack of using other measures 
beyond the HbAlC value to monitor efficacy. Welschen et al. 
suggest that additional factors such as quality of life, well-
being, patient satisfaction, and hypoglycemic episodes 
should also be comprehensively incorporated into the 
outcome measures.10 
Another limitation of the current literature is that 
many studies have not reported use of a validated or 
standardized algorithm for patients to implement changes 
in therapy. For example, in the juvenile Diabetes Research 
Foundation study, patients were instructed to calculate 
their insulin dose and adjust it according to their blood 
glucose levels according to standardized protocols.U Use of 
such protocols not only allows for more consistency by 
reducing confounding factors affecting the outcome meas-
ures, but also helps to encourage patient self-education and 
interpretation around SMBG. Accordingly, both education 
and ongoing support have been cited as areas requiring 
further development in adopting a SMBG intervention for 
T2DM patients who need more guidance on the course of 
action when observing a high blood glucose level. 12 In fact, 
patients with chronic hyperglycemia may develop increased 
anxiety, feel more burdened with their health care, and even 
perform inappropriate actions if they do not possess an 
adequate understanding of normal fluctuations of blood 
glucoseY 
Recommendations 
While there has been a lack of consensus on whether to 
adopt SMBG as part of routine care for all T2DM patients, 
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there has been some agreement that certain subpopulations 
may benefit from regular SMBG. Specifically, tight glycemic 
control is very important during pregnancy as preventing 
fetal malformation, stillbirth, neonatal hypoglycemia, and 
respiratory distress.13 Furthermore, changes in HbA1C 
levels are too slow and retrospective to be used as an 
accurate measure of glycemic control during this sensitive 
time period.14 Similar parallels can be drawn with other 
special circumstances such as new diagnosis of T2DM, 
initiation or change in medication, or concurrent illnesses 
where SMBG may prove to be ofbenefit.9 
Given that a goal of SMBG is to promote self-
management skills in the T2DM patient, identification of 
behavioural and personal characteristics which may 
predispose a patient to maximally benefit from SMBG would 
likely result in improved and long-term outcomes. For 
instance, "ideal" patients have been identified as those who 
know how to take a reading, interpret the reading relative 
to target values, formulate a connection between deviant 
readings and prior behaviour, create and implement action 
plans, and evaluate glucose readings in a non-judgmental 
framework. 15 
Conclusion and Future 
Tight glycemic control is an important goal of self-
management in T2DM in order to prevent secondary 
complications. While there has been evidence supporting 
the use of SMBG for insulin-dependent diabetes, most 
research studies lack sufficient consistency and homogene-
ity in methodology, clinical follow-up, and patient popula-
tions to make a conclusive recommendation for its use in 
the routine daily management ofT2DM patients. 
Future areas for productive research in this area 
include developing more educational and ongoing support 
for T2DM patients to improve understanding of blood 
glucose readings and their associated clinical implications. 
Also, defining other relevant outcomes for SMBG beyond the 
A1C would be relevant. There may be subpopulations of 
T2DM patients who would benefit more from SMBG due to 
their need for tighter glycemic control during special 
circumstances, such as during pregnancy, new diagnosis, a 
change of medications, or other co-morbidities. Despite the 
current challenges with consolidating evidence on the 
benefits of SMBG for the T2DM patient population, it 
remains possible that SMBG can play an important role in 
the glycemic control with the appropriate supportive 
clinical education and follow-up of patients. 
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During the 17th and 18'h centuries, surgeons and parents 
attempted a bizarre endocrinologica l experiment: the 
castration of prepubescent boys for the preservation of 
their treble voices. The Baroque passion for highly orna-
mented, technically difficult, soprano-range music, com-
bined with social restrictions to the training and perform-
ance of fema le singers, created unique opportunities for the 
castrati, or as they were more euphemistically call ed, the 
musici.1 Church choirs offered a reliable income and noble 
patrons promised prestige and influenceY At the same 
time, Italian opera seria was becoming an internationally 
popular entertainment, opening up fantastic possibilities of 
wealth and renown for its castrati stars. 1 Accordingly, 
ambitious families with slender means and abundant 
offspring chose to castrate younger sons with promising 
voices - openly through the 17'h century, and with increas-
ing shame and secrecy into the 19'h century.3 
From the perspective of modern endocrinology, the 
effects of removing both testes before puberty are signifi-
cant. Without testes, a castrato would not pass through 
puberty, resulting in a prepubescent penis, sexual dysfunc-
tion, and sterility. More systemically, he would have no 
male-pattern body or facial hair and a "eunuchoid" body 
habitus (long limbs relative to torso, as the long bone 
epiphyses would not fuse) . A lifetime of low testosterone 
would bring dry skin (arising from low sebaceous gland oil 
secretion), fine wrinkles, osteoporosis, a higher than 
average fat to muscle ratio, decreased libido, and possibly 
an increased risk of depression. The larynx would remain 
small, with short vocal chords, while the pharynx and lungs. 
dependent on growth hormone, rather than testosterone, 
for development, would reach adult proportions. resulting 
in a high frequency voice with adult power and resonance.4 
Such is the lens 21" century medicine might use to view the 
castrati. 
Yet this radical redesign of human male develop-
ment occurred four centuries before the discovery of 
testosterone. What were contemporary medical percep-
tions of the castrati? What explanations did physicians offer 
for the effects of castration? In short, what did they see, and 
how did they make sense of it? 
Technique 
Although medicine at this time brought new attention to the 
study of anatomy, its practitioners still operated without 
reliable anaesthesia or sterile technique. Furthermore, 
castration was a somewhat clandestine medical procedure; 
it contravened Roman law in Italy, where the majority of 
castrati were made, and amputation of any part except 
when medically required was punishable with excommuni-
cation under ecclesiasticallaw.5 Early in the Baroque period 
church and state turned a blind eye to castration for musical 
purposes, but over time it became necessary to invent 
medical excuses for the operation.1 Italian medical texts 
tended to avoid the subject,6 and existing contemporary 
accounts of the procedure come mainly from hostile 
sources. 
An influential 7 Dutch physician and anatomist, 
Reginer de Graaf (1641-1673), provides a critical descrip-
tion of castration. He gives two techniques: compression of 
the spermatic cords with a split stick until they were 
crushed, and complete removal of the testes "by the roots." 
He notes with disapproval that "certain men earned a rich 
living" offering castration as a cure for hernias, but observes 
that "this cruel and dangerous way of curing hernias has 
gone so much out of fashion ... that you will hardly find 
anyone who earns even a crust of bread by castrating men.''8 
In Italy, however, hernias were offered as an excuse for 
castrating young singers for centuries after de Graafs text 
was published.3 
"Eunuchism Display'd", an anonymous English 
pamphlet circulated in the early 18th century, adds further 
details to de Graafs account. In addition to noting two 
techniques sim ilar to those above, the author describes 
attempts at anaesthesia: administration of opium, which the 
author reports to have a high mortality, and compression of 
what the text terms "the jugular veins," perhaps meaning 
the carotid arteries, to render the patient "stupid and 
insensible."9 Both authors are at pains to express their 
disapproval of castration; their emphasis upon the suffering 
and danger of the procedure may partly arise from their 
underlying moral objections, as circumstantial evidence 
suggests the operation may have been relatively safe and 
mild .1 
Effect 
Although accounts of castration itself are scarce, medical 
writers often devoted space to describing its effects. 
Predictably, many noted an effect on voice; the British 
surgeon john Marten ( d.1737) claimed castration was 
"[e]xperimentally known to change and advance the 
smallness and sweetness of the Voice."10 Other writers 
described the castrato voice in less fl attering terms, for 
example, "squealing" in "Eunuchism Display'd," and "soft 
and shirle" in a mid-17 th century translation of the "workes" 
of the French surgeon Ambroise Pare (1510-1590) .11 
Medical writers a lso noted a lack of beards among 
castrati, and there was general consensus about their 
inferti lity. The sexuality and sexual function of castrated 
men, however, was a much more controversial topic. For 
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example, one contemporary British physician implies 
castration removes both ability and desire for sex, 12 while 
another claims quite the opposite: 
Eunuchs love Women passionately, and being of a 
weaker Mind after than before Gelding, are the more 
susceptible of thi s Passion ... It cannot be expres'd to 
what Point they will push their irregular Desires 
when their Fancy is once inflam'd ... 10 
This confusion mirrors castrati's reputation in 
popular culture, which both mocked them as impotent13 and 
credited them with a myriad of lovers of both genders.3 
As implied in the above quotation, contemporary 
physicians considered castration to profoundly shape mind 
and behaviour, as well as body. A castrato, according to 
john Marten, has diminished "Strength, Activity, and Vigour 
of his body, and acuteness of his Reason and judgement."10 
The author of "Eunuchism Display'd" further claims that 
castrati have "no Courage or Bravery of Soul, but [are] ever 
timerous and fearful," 9 and contemporary medical authors 
tend to agree.10•12•14 The Dutch physician Ysbrand van 
Diemerbroek (1609-1674) succinctly summarizes the 
general view by concluding that castration makes one 
"slower in all the Exercises both of Body and Mind."14 
Different authors emphasise different attributes of 
castrati, but a general outline of 17'h and 18'h century 
medical descriptions would include a high voice, beardless-
ness, infertility, altered sexuality, physical and mental 
weakness, and cowardice. 
Explanations 
Medical rationales for this collection of castrati traits are 
complicated by the somewhat chaotic state of European 
medicine during the 17'h and 18th centuries. The classical 
tradition, centred around the works of Galen of Pergamum 
(129-199 CE), had guided academic medicine through the 
Middle Ages, but new ideas from anatomy, alchemy, and 
various branches of natural philosophy were beginning to 
change medical writers' understanding of the body.15 
The central problem was how castration could have 
such profound effects in apparently unrelated parts of the 
body. According to Galen, the testes help to convert blood 
into semen - the source of fertility and of sexual desire, in 
Galenic physiology - and aid the heart in producing the 
body's strength and ':innate heat." Castrated men therefore 
are not only sterile, but also "chilled ... and all their strength 
collapses." Their cool, weak bodies are not able to produce 
a deep voice, beard, or body hair, which spring from heat 
and strength. 16 
In Galenic physiology, gender difference arises from 
differences in bodies' heatjcold, and to a lesser extent, 
dryness/moisture ratios : "The female is less perfect than 
the male for one, princpal reason - because she is colder."17 
Castration removes a man's heat advantage, bringing him 
down the spectrum of gender towards "imperfect" women: 
"the whole body is made feminine by excision of the 
Contemporary medical views of the Castrati 
testicles." 16 Yet the castrated man does not become a 
woman; he is "not female or male but some third kind ." 17 
The ideas of loss of heat and a shift towards a 
feminine body inform the work of many 17'h and 18'h 
century medical authors. The British physician john Bulwer 
(1606-1656) directly cites Galen's explanations, especially 
for the high voice of castrati. He also alludes to a "certain 
aire" - perhaps similar to Galen's "strength" or "power" -
given off by the testes, "by whose mediation virility is 
reconciled, the body acquires strength and firmenesse, is 
made more lively; at length, the principall members do 
more perfectly execute their office." Loss of the testes is 
therefore a loss of "well-being."12 
It also makes the castrato more like a woman, which 
is by no means a value-neutral transformation. Bulwer 
contends that to castrate a man for any reason except an 
"otherwise incurable disease" is unconscionable: "willingly 
to degenerate into the Nature of women, suffering them-
selves to be transformed from the Masculine to the Femi-
nine appearance (a false Copy) is to offer as great an Injury 
to Nature as the malice of mans refractory wit can be guilty 
of." 12 Ambroise Pare, too, cites Galen's views on the subject, 
and elaborates upon the significance of degenerating "into a 
womanish nature": "for they remaine without beards, their 
voice is weake, their courage failes them, and they turne 
cowards; and seeing they are unfit for all humane actions, 
their life cannot but be miserable." 11 Loss of heat brings not 
only female physical characteristics, but also moral ("they 
turne cowards") and social ("unfit for all humane actions") 
dimensions of 17'h and 18'h century femininity. 18 
john Martin also relies on Galen's ideas about the 
testes producing heat, but diverges from Galen and Bulwer 
about the effect of castration on sexuality. Since he consid-
ered semen to be the source of sexual desire, Galen held that 
castrated men would be essentially asexual. Martin explains 
his claims about the "irregular Desires" of the castrati by 
suggesting organs newly described by anatomists could be 
additional sources of semen: "the kind of aqueous Seed in 
the prostata or seminal bladders irritates their Privities ." 
This "aqueous Seed," combined with castrati's "weaker" -
that is, more female - mind, makes them more susceptible 
to desire. 10 A belief that emasculation could undermine 
sexual restraint is in keeping with contemporary ideas 
about female sexuality in medical writing and in popular 
imagination.18 For example, Shakespeare's King Lear 
describes his unfilial daughters as sexually voracious, 
despite an outward show of chastity: 
Behold yond simpering dame ... 
That minces virtue, and does shake the head 
To hear of pleasure's name; 
The fitchew, nor the soiled horse, goes to 't 
With a more riotous appetite. 
Down from the waist they are Centaurs, 
Though women all above. (IV, ii, 132-9)19 
Like the castrati, women have weak minds and 
ineffectual "seed" (ovaries were commonly - although not 
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ineffectual "seed" (ovaries were commonly - although not 
universally- viewed as imperfect testes).18 
Diemerbroek is not content to use heat alone as his 
explanation for the consequences of castration. He employs 
more complicated reasoning partly drawn from the al-
chemy-inspired physiology of the radical medical theorist 
Paracelsus (1493-1541) .15 According to Diemerbroek, the 
testes exude a "lustful seminal Breathing," which travels 
through the body, heating the blood and making the 
"Spirits" (active principles conveyed by nerves from the 
brain) more "smart and vigorous." Without this breathing, 
the blood grows cold, and the "sulphury and oily Particles of 
the Blood" cannot be separated from the "more dry and 
salter Particles," resulting in more languid Spirits. Further-
more, the blood that would normally have been consumed 
in producing semen builds up, with the "effeminate" result 
of"extraordi nary Corpulency" and a "more dull" mind.14 
The British physician Thomas Willis (1621-1675) 
combines Paracelsian alchemy with ideas about fermenta-
tion from contemporary natural philosophy to explain the 
castrati. The principles of salt, sulphur, and spirits are 
concentrated and fermented by the testes, as grapes are 
fermented to make wine; and from this "Seminal Ferment" 
arises "abundance of heat, great strength, a sounding Voice, 
and a manly eruption of Beard and Hair." As a result of 
castration, "men grow womanish," being cold, weak, high-
voiced, and without a beard. 
As an anatomist, de Graaf focuses on the anatomical 
basis for the way the testes affect the rest of the body. He 
suggests the newly-discovered lymph vessels "draw from 
the testicles, along with the thinner and more watery part of 
semen, other more noble parts and give a share of these to 
the heart and other parts of the body." Without these 
"nobler parts" of semen, a castrated male "changes in such a 
way as almost to acquire the physical condition of a fe-
male.''8 
Although these exp lanations for the effects of 
castration diverge in the details, a few common elements 
emerge. They all postulate some mechanism for action at a 
distance - vital heat seminal breathing, seminal ferment, 
noble parts of semen - in order to explain what the authors 
see as castration's dramatic changes to the body and mind. 
They also tend to portray these changes as a shift from a 
male state of being towards (but not to) a femal e one. 
Significance 
From this perspective, the prudent-seeming deci sion of a 
large, financially-strained family to have a musically-gifted 
son castrated becomes more radical. It would mean taking a 
child destined to be a "perfect" (that is, male) representative 
of what it means to be human - strong, bearded, rationa l, 
and brave - and debasing it to a more imperfect (female) 
creature. How much of academic medical writers' learned 
opinion would have been familiar to the parents and 
surgeons intimately involved in the operation is unclear. At 
the very least, Galen's views about the body had been 
circulating in Europe since the 12'h century - and yet the 
voice of a castrato was worth "cut[ting] out the strength of 
the entire body."16 
Quite apart from the philosophical implications, 
making a son more like a daughter had significant social and 
economic consequences. Castrati were technically forbid-
den to enter the priesthood (although exceptions were 
made) , and professions outside music which did not admit 
women were not welcoming of "womanish" men.1 Since 
their transformation into women was incomplete, they 
could not claim a female social role, such as marriage or 
joining a convent.1 Consequentially, castrati had a profound 
incentive to succeed as singers; an application from a young 
castrati to a famous conservatorio in Naples makes this 
point clear: "since he is a eunuch, music ... is the only 
profession to which he wishes to apply himself." 1 This 
desperation, combined with the extremely rigorous early 
training it motivated, may have contributed as much as 
physiology to the voices contemporary audiences consid-
ered incomparable. 
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Introduction 
Diabetes has become a global epidemic and rates continue 
to increase. Over 3 million Canadians have diabetes and 
approximately 90% of them have type 2 diabetes. Diabetes 
can lead to a reduced life expectancy and quality of life, and 
an increased risk of cardiovascular disease, kidney disease, 
blindness, and amputation. In addition to these personal 
health costs, diabetes may cost the Canadian healthcare 
system $16.9 billion per year by 2020.1 
The epidemic of type 2 diabetes is closely associated 
with a rise in obesity, poor diet quality, and physical 
inactivity. The failure of individual-level interventions such 
as medications and dietary counselling to forestall the 
epidemic has led to a strong interest in population-level 
approaches.2 There is growing recognition that aspects of 
the physical and social environment can have a powerful 
influence on health and health-related behaviours, at the 
individual, neighbourhood, and population levels. This 
article will explore the emerging interdisciplinary study of 
health with respect to the built environment and will 
discuss some of the important contributions of this field to 
understanding and addressing the diabetes epidemic. 
What is the study of the built environment? 
An interdisciplinary programme of study has emerged in the 
literature that examines the influence of the built environ-
ment on health outcomes. The built environment describes 
the physical layout of communities and encompasses land-
use patterns, homes, schools, workplaces, stores, parks, 
roads, and transportation systems.3 Studies of the built 
environment acknowledge that aspects of our physical 
surroundings can shape choices about diet and physical 
activity - both important contributors to the development 
of diabetes. 
Research in this field involves many diverse disci-
plines, including public health, epidemiology, nutrition, 
urban planning, geography, economics, sociology, anthro-
pology, and leisure studies. Each of these disciplines has its 
own approach, expertise, and methodology when it comes 
to examining the relationship between health and the built 
environment. This article focuses particularly on the 
contributions of urban planning and geography. Study 
methodology genera lly falls into three categories: 1) 
interviews or questionnaires on residents' perceptions of 
their environments; 2) systematic observations of area 
characteristics (i.e. number and type of restaurants in a 
given neighbourhood); and 3) analysis of existing data sets, 
often using Geographic Information System (GIS) .4 GIS 
allows the integration, presentation, and analysis of data 
with spatial references, for example overlaying a database 
of supermarkets with a map of census boundaries. These 
disciplines and methodologies can reveal unique informa-
tion about the diabetes epidemic and provide potential 
targets for intervention. 
What can studies of the built environment tell us about 
patterns of diabetes? 
One of the key associations between diabetes and the built 
environment is through food choices and diet. Studies have 
looked at how the food environment, which includes 
supermarkets, food stands, convenience stores, and restau-
rants, can differ by neighbourhood and how this relates to 
various health outcomes. One study of food store availabil ity 
and neighbourhood racial composition found that none of 
the predominantly African-American census blocks exam-
ined in East Harlem had supermarkets or grocery stores.5 
Another study found that fast-food restaurants were more 
likely to be found in lower income and higher traffic areas in 
King County, WA.6 Neighbourhood fast-food exposure has 
been associated with poorer diet quality and increased body 
mass index (BMI) , particularly for local residents who do 
not own cars.7·8 According to a 2009 review article, resi-
dents with more access to supermarkets and limited access 
to convenience stores and fast-food generally have better 
diets and lower obesity rates.9 Moreover, those most 
affected by disparities in access to healthy food tend to live 
in low-income, minority, and rura l neighbourhoods.9 These 
studies suggest that food choices and diet are influenced by 
multiple aspects of the built environment, including number 
and type of food stores, and that differences in neighbour-
hood access to healthy foods often reflect other demo-
graphic features (i.e. race, socioeconomic status). 
The built environment has also been studied in 
relation to physical inactivity, another important contribu-
tor to obesity and the development of diabetes. Aspects of 
the built environment related to physical activity include 
access to recreation facilities, neighbourhood safety, open 
spaces, walking and cycling infrastructure, and length and 
nature of commute.4 Researchers in California established 
an association between obesity, physical inactivity, and 
commute time, as well as between obesity and vehicle miles 
of travel.10 One study found that greater neighbourhood 
physical activity resources were associated with lower 
insulin resistance, even after adjusting for age, sex, race/ 
ethnicity, family history of diabetes, education, and in-
come.11 The same study found that insulin resistance was 
a lso inversely related to neighbourhood healthy food 
resources, a lthough this association was less robust. 11 
Furthermore, a longitudinal study found that better 
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neighbourhood resources, based on a composite score for 
healthy foods and physical activity, were associated with a 
38% lower incidence of type 2 diabetes.2 Thus, certain 
features of contemporary North American urban design, 
such as a strong dependence on motorized trans port and 
neighbourhood features that exclude opportunities to stay 
active, may be fuelling the diabetes epidemic. 
A highly comprehensive s tudy of di abetes and 
neighbourhood environments was conducted in Toronto 
and released in 2007.12 It received attention in the popular 
press, reflecting the nation's growing recognition for 
interdisciplinary solutionsY The researchers examined 140 
Toronto neighbourhoods, and assessed the relationship 
between diabetes and factors such as socioeconomic status, 
ethnic composition, crime rates, car ownership, public 
transportation, access to healthy food , opportunities for 
physical activity, and access to health care and other 
services. Neighbourhoods with high rates of diabetes tended 
to have a higher proportion of visible minorities, immi-
grants, and low socioeconomic status residents. 14 Features 
of the built environment, however, played a significant role 
in mediating these effects . For example, poor, immigrant 
neighbourhoods had lower rates of diabetes than expected 
if they were found to be activity-friend ly with good infra-
structure, whereas more affluent neighbourhoods tended to 
have low rates of diabetes regardless of whether they were 
activity-friendly or had good access to healthy foods .15·16 
Neighbourhoods with the highest rates of diabetes were in 
the more suburbanized northwest and east parts of the city, 
where there were not only high levels of poverty and visible 
minority residents, but also worse public transit, few 
opportunities for physical activity, poor access to healthy 
food, and low concentration of family physicians and 
diabetes education programmesY The complex relationship 
between diabetes, socioeconomic status, and neighbour-
hood resources was also shown in a Scottish study in the 
year 2007. Deprived areas were found to have lower than 
expected rates of type 2 diabetes when they were sur-
rounded by less deprived areas with better resources.18 
What are the implications of built environment re-
search on controlling the diabetes epidemic? 
Urban sprawl has been linked to a variety of health-related 
concerns including air pollution, water quality, traffic 
accidents, and mental health issues. 19 The studies described 
above indicate that urban design and aspects of the built 
environment can also play an important role in the develop-
ment of type 2 diabetes and its risk factors. Tackling the 
diabetes epidemic will require more than simply advising 
people to lose weight, eat better, and exercise more. There 
are features of our physical surroundings that can shape our 
individual and collective health and health-related deci-
sions. These features include proximity of grocery stores, 
safe and pleasant opportunities for physical activity, and 
time spent commuting. The implications of this research are 
that changes can be made to the built environment to 
positively influence health outcomes. Neighbourhoods could 
Diabetes and the built environment 
be made more activity-friendly by improving sidewalks and 
bicycle paths, building recreation spaces, and instituting 
mixed land-use patterns in more suburban areas to provide 
better wa lking destinations. Diets may be improved by 
providing incentives for grocery s tores to move into high-
need areas, improving public transit so at-risk people can 
access healthy food, and developing policies that promote 
healthier choices at fas t-food res taurants. 17 The Ontario 
Profess iona l Planners Institute has recognized the impor-
tant relationship between community design and public 
health .20 However, making these kinds of changes would 
require co llaboration between a diversity of stakeholders a t 
a ll levels, including city planners, public health researchers, 
policymakers, community organizations, and grassroots 
initiatives. 
Conclusion 
The interdisciplinary s tudy of health and the built e nvi ron-
ment is an important and growing field that can offer a 
unique contribution to chronic disease research. The built 
environment affects hea lth at the individual, neighbour-
hood, and population level and can account for many of the 
spatial and demographic patterns in diabetes prevalence. 
Looking at diabetes rates from the perspective of the built 
environment can enhance our understanding of the emer-
gent epidemic and can identify new targets for disease 
control and prevention. 
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Introduction 
Drug doping has a long history in sports. As the medical 
world introduced new pharmaceutical agents to restore 
muscle mass or improve blood oxygenation, the sports 
world in turn has sought to use these agents for similar 
gains. The progress in sports doping has catalyzed a parallel 
effort to detect doping abuse, with research labs explo iting 
new and improving old analytical technologies. The result is 
an endless race where each side tries to stay one step ahead. 
The next showdown will be at the 2010 Olympics in 
Vancouver, which will feature the most elaborate anti-
doping program in the history of the Games. A new $8.9-
million anti-doping lab will test about 2,400 urine and blood 
samples-- twice as many as the previous winter Olympics in 
Torino.1 While the lab wi ll be testing traditional doping 
agents like testosterone, it is also equipped to deal with two 
doping agents that have recently plagued the sports world: 
analogues of erythropoietin (EPO) and human growth 
hormone (hGH). This article will outline the current 
methods to detect EPO and hGH doping, and discuss the 
future of the sports doping race. 
Erythropoietin 
Erythropoietin is a glycoprotein hormone primarily 
produced in the kidneys that stimulates red blood cell 
production. Recombinant human erythropoietin (rHuEPO) 
has been available since the 1990's for clinical use in 
patients with anem ia; however, its therapeutic benefits have 
also extended to the sports world. rHuEPO can bolster an 
athlete's red blood cell count and greatly improve his or her 
aerobic capacity.2 It has additional appeal as a doping agent 
because it is difficult to distinguish from naturally occurring 
EPO, and its therapeutic benefit lasts well after the original 
hormone clears from the body. 
While rHuEPO was swiftly banned by the World 
Anti-Doping Association (WADA) in the 1990's, no method 
of detection was approved until a few months before the 
2000 Sydney Olympics. A French anti-doping lab developed 
the method based on isoelectric focusing and a novel double 
immunoblotting technique.3 Some forms of rHuEPO have 
different patterns of glycosylation than endogenous EPO, 
resulting in different sets of isoelectric points (the pH at 
which a molecule has neutral charge). When placed in a gel 
with a pH gradient and an electric fie ld, they will focus into 
bands where the pH is equivalent to their isoelectric point. 
These bands can later be marked by immunoblotting with 
monoclonal anti-Epo antibodies. The gel is blotted a second 
time under acidic conditions, which transfers only the anti-
Epo antibodies to the second gel for subsequent visualiza-
tion. 
This direct method of detecting rHuEPO abuse has 
several shortfalls. For one, epoetin-omega and epoetin-
delta, two available forms of rHuEPO, cannot be distin-
guished from endogenous EPO. Secondly, the detection 
window is roughly 7 days before circulating rHuEPO levels 
become too low.4 To overcome these limitations an alterna-
tive strategy has been proposed that looks at secondary 
blood markers ofrHuEPO abuse. 
The first attempts at detecting rHuEPO abuse in 
sports relied on simple tests such as measuring the hema-
tocrit or hemoglobin. By 1993, sophisticated hematological 
analyzers came to market that allowed labs to make 
comprehensive measurements of secondary blood markers 
such as hemoglobin, percent reticu locytes, serum soluble 
transferrin receptors, EPO concentrations and percentage 
hypochromic red cells.5 The lack of sensitivity and specificity 
of these individual markers for detecting rHuEPO abuse led 
to the development of multiparametric models, which 
examine changes in groups of markers. Some models have 
been shown to detect EPO abuse after 14 days ofwashout.6 
Indi rect testing of rHuEPO abuse has not been 
favoured over direct testing. A positive result is not evi-
dence that an ath lete has taken the banned substance, since 
variability in blood marker profiles has been seen naturally 
and in athletes who train at high altitude. At the moment 
indirect testing has been relegated to serve as a screening 
tool for rHuEPO abuse. 
Human growth hormone 
Human growth hormone (hGH) is produced naturally by the 
pituitary gland to stimulate growth in the human body. 
Patients with hGH deficiency were originally treated using 
hGH obtained from cadavers, but now are treated with 
recombinant hGH (rhGH). Starting in the 1980s, athletes 
have been using rhGH to increase lean muscle mass, reduce 
fat content and increase strength. However, the Interna-
tional Olympic Committee (IOC) placed hGH on its list of 
forbidden substances in 1989. Similar to erythropoietin, 
rhGH abuse is difficult to detect because of its similarity in 
structure to hGH . Furthermore, detection tests cannot rely 
on hGH levels since hGH secretion is pulsatile and a plethora 
of factors, such as exercise, stress, hypoglycemia and 
increased temperature, can naturally increase levels. 
Detecting rhGH abuse is considered the current greatest 
challenge to the anti-doping community.7 
Recent research and advances in technology have 
allowed for some success in detecting hGH misuse as of the 
2004 Olympic Games in Athens, Greece. Since hGH is a 
peptide with a very short half-life and less than 0.1% is 
excreted into urine, the most effective doping tests have 
been restricted to blood samples. Urine samples can be used 
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to detect hGH using highly sensitive immunoassays. 
However, the problem of confounding factors causing 
variability in hGH levels can only be accounted for by 
performing out-of-competition tests to allow for compari-
son. 
Blood tests have proven more effective and powerful 
and two methods are currently being eva luated. The first is 
a direct method for detecting rhGH in serum. This approach 
uses the fact that injected rhGH is exclusively a 22 kDa 
isoform, a pure molecular substance, while natively circulat-
ing hGH is present as a mixture of many forms. The test 
looks for an increase in the ratio of the 22 kDa isoform of 
hGH to the total hGH in the blood beyond a pre-determined 
threshold.8 For it to be effective, the test must be adminis-
tered 24-36 hours after hGH injection. The second method 
tests for an increase in marker proteins influenced by hGH 
levels. These marker proteins have longer half-lives than 
hGH, making them much easier to detect. 
A sure-fire method for detection and control of hGH 
doping remains elusive. The direct approach is the one 
currently accepted by WADA. However, promising research 
may yield a test using the marker-based approach in the 
near future. Genomic and proteomic profiling are currently 
being researched to discover new markers of rhGH abuse. 
One pilot study looked at the ge ne expression in leucocytes, 
which are altered directly by both GH and IGF-1. The hope is 
to characterize a gene fingerprint for rhGH abuse. Proteomic 
methods are being applied in a sim ilar manner to create 
protein profiles using two dimensional electrophoresis and 
surface-enhanced laser desorption/ionization time of flight 
mass spectrometry (SELDI-TOF MS).9·10 
The race continues - next generation sports doping 
New methods of doping are on the horizon and anti-doping 
labs will need to respond . Two new classes of experimenta l 
drugs, selective androgen receptor modulators (SARMs) and 
myostatin inhibitors, have been shown in clinical trials to 
boost lean muscle m ss without the side effects seen in 
testosterone or steroid use. While neither drug is on the 
market yet, the substances have already been banned by 
WADA and work is underway to detect their abuse. 11 
A new frontier of sports doping is approaching with 
progress made in gene therapy technology. The idea is to 
introduce exogenous ge nes into an ath lete's cell s to produce 
virtually any protein or hormone in vivo. Current gene 
therapy trials are purely experimenta l and human use is still 
a long time away; however, the potential of this technology 
has a lready been demons trated and has drawn much 
attention . Gene doping presents the ultimate doping 
detection chall enge since the newly expressed protein is 
identical to the endogenous protein in terms of structure 
and mechanism of synthesis.12 To date, no definitive method 
of detection is available, a lthough work is being done using 
DNA microarrays and gene express ion profiling. 
At the moment the doping community has an edge 
over anti-doping efforts despite the immense progress 
made over the last decade in detection technology. In some 
regards thi s result is a testament to the wide. range of 
pharmaceutical products developed to combat d1sease. As 
the medical community tirelessly works to advance thera-
peutics, the doping race will still carry on. 
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Faculty reviewer: Dr. Cheril Clarson, Department of Medicine, UWO 
On August 19, 2009, South African middle distance runner 
Caster Semenya set a world record in the women's 800m 
event at the world championships in Berlin. Closely follow-
ing her stunning victory, the world athletics governing body, 
the International Association of Athletics Federation (IAAF) 
ordered her to undergo a process known as "gender 
verification testing." A relative unknown just three weeks 
prior, Caster was unceremoniously thrust onto the world 
stage and has become a poster victim for a controversia l 
practice that has been going on for decades .U Subsequently, 
Australian newspapers announced that Caster had no 
ovaries or uterus, but did have undescended testes, and was 
in fact "intersex."2•3 In order to explore the potential social 
and legal implications of such testing it is important to 
understand the history of so-called gender verification, as 
well as its medical advantages and pitfalls. 
Science and medicine 
The term "gender verification" is problematic because, as 
was detailed out in an open letter to South African journalist 
Mercedes Sayagues, gender is "the dominant society's views 
on how women and men should look, behave, what roles 
they should play in society, how they should perform ... "4·5 
Sex refers to a biological dichotomy, whether one is male or 
female. 5 Normal sexual differentiation is initially deter-
mined by chromosomal pattern, XX usually being female 
and XY usually being male. The presence of the SRY gene on 
the Y chromosome induces the undifferentiated gonad to 
commit to testis generation. The differentiated testis then 
begins to secrete hormones that lead to the promotion of 
the male internal genitalia, and the regression of the 
primitive female internal genitalia. Subsequent conversion 
of testosterone to dihydrotestosterone (DHT) in the skin of 
the external genitalia leads to virilization of these structures 
and a complete male phenotype. The absence of the SRY 
gene leads to the regression of the male internal genitalia 
and a female phenotype.6 Of course, sexual differentiation is 
a complex process, and disorders of sexual differentiation 
(DSDs) may be chromosomal, gonadal or phenotypic 
(hormonal), leading one or more of these elements to be 
misaligned. 6·7 
In 1968, in an effort to prevent male imposters from 
competing in the Olympics the IOC implemented mandatory 
"gender verification" of all female competitors.6·7·8 The test 
was a simple buccal smear that was then analyzed for the 
presence of sex chromatin (inactive X chromosomes or Barr 
bodies). The Barr-body test, though enticing in its simplicity 
raised significant concerns in the medical community. The 
test screened out XY females with no advantage over other 
females as is the case with complete androgen insensitivity 
(CAIS) or 46 XY jXO gonadal dysgenesis, whi le allowing 
those athletes with potentially advantageous conditions 
such as XX females with inadequately treated congenital 
adrenal hyperplasia (CAH) or XXY males to compete.5·6·7·8 
Furthermore, the test was inappropriate in the first place 
since women with DSDs do not exhibit "characteristics 
relevant to sports performance .. . outside the range of 
possibility for XX females ." 6·7 
History 
Given what we now know to be true of DSDs, it may seem 
preposterous that the practice of sex verification was 
routine at the Olympics for more than 30 years. However, 
instances of subversion are not unheard of. In 1957 Herman 
Ratjen of Germany confessed he had been forced under the 
Nazi regime to compete as a female in the 1936 Berlin 
Olympics.6·8 Suspicion subsequently turned on hyper-
masculine female ath letes from the Eastern Bloc following a 
number of female athletes undergoing gender reassignment 
surgery and subsequently living as men in the 1950s and 
60s. Finally, in possibly the most high profile example, the 
1932 women's lOOm sprint gold medalist Stella Walsh was 
revealed to have chromosomal mosaicism and ambiguous 
genitalia during an autopsy following her death in 1980.7·9 
Initial attempts at gender verification in 1966 and 
'67 involved parading female athletes in front of a panel of 
medical experts in the nude, or even direct gynecological 
examination.6•7·8·9 This method of sex verification was 
fraught with ethical dilemmas and was ultimately aban-
doned in favor of the simpler and "less demeaning" buccal 
smear in 1968. The Barr-body test, originally conceived as a 
screening tool, became the definitive test of an athlete's 
femininity was used by the IAAF and IOC until 1992 when 
the IAAF abandoned the practice.6·8·9 Rather than follow the 
IAAF's example, the IOC switched from chromatin testing to 
analysis for Y chromosome material using PCR amplifica-
tion, which it continued unabashedly until 2000. It is worth 
noting that since the advent of laboratory sex testing, no 
male imposter has ever been caught trying to infiltrate 
women's athletic events.6·9•10 
Social and legal implications of sex testing 
Dr. Renee Richards, a nationally ranked men's tennis player, 
underwent a sex reassignment operation in 1975. In 1976 
she attempted to enter the United States Tennis Open as a 
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woman. The United States Tennis Association (USTA) 
informed Dr. Richards that in order to enter, she had to pass 
a gender verifi cation test; the first time such a test had been 
implemented by the USTA. Dr. Richards a rgued to the New 
York Superior Court successfu lly that the test was adopted 
for the sole purpose of preventing her from competing in 
the Open, and that moreover, the medical community 
regarded the test as "insufficient.. .and grossly unfair".10 
Although this is the on ly case that rules on the issue of 
gender verification in sports as a matter of law, in 1985 
Spanish national hurdler champion Maria Patino was 
disqualified from the World University Games and banned 
from international competition. Subsequently she went on 
to become the first woman to publicly protest this method 
of disqualification, and was eventua lly reinstated.6·8 
Given the IAAF and IO Cs deplorable record of 
defending the rights of female athletes it should come as no 
surprise that as recently as 2006 an Ind ian woman, Santhi 
Soundarajin, was stripped of her silver medal at the Asian 
Games after failing a gender test. Ms. Soundarajin was later 
diagnosed with complete androgen insensitivity syndrome 
and was so psychologically traumatized by the experience 
that she has not competed since. 11·12•13 Further confusing the 
matter is the fact that in the same year the IAAF released a 
policy on gender verification listing women with CAIS 
(among other conditions) as eligi ble to participate in 
international competition.13 In fact, the IAAF listed women 
with virtually all DSDs as eligib le to compete, even those 
with conditions that theoretically might accord some 
physical advantages (i.e. CAH, androge n producing tumours, 
and PCOS).14 In light of this, the IAAF's policy statement then 
begs the question: What is the validity or necessity of 
gender verification in the first place, and why does the IAAF 
persist in using it? 
Strict anti -doping rules guarantee that a ll winners 
and a random se lection of other competitors provide urine 
samples under the supervision of officials. These rules likely 
provide enough dis-incentive for men to masquerade as 
women that such an issue is very unlikely to arise at 
ali.5·6·7Granted, the current guide lines for gender verification 
are substantially different than they were in 1968. They 
include stipulations that there be no compulsory standard 
gender verification, that determination of sex not be done 
solely on laboratory based testing, and a medical evaluation 
be performed by a gynecologist, endocrino logist, psycholo-
gist and an internist. 14 What is unclear upon reading the 
IAAFs policy on gender verification are the circumstances 
under which a challenge of a competitors gender may be 
legitimately raised. Article 12 of The United Nations 
Universal Declaration of Human Rights (UNUDHR) guaran-
tees a person against "arbitrary interference w ith his 
privacy ... and attacks upon his honor and reputation ."15 Since 
the criteria for a legitimate chal lenge to a competitor's 
gender are not outlined in the IAAFs policy, it can be said 
that gender verification testing represents an arbitrary 
interference with an ath letes' privacy. In 1996 the Norwe-
gian parliament passed a law making genetic testing for the 
purposes of gender verification in sport illegal in Norway.7 
Furthermore, as argued by Pamela Fastiff, gender testing (as 
it was originally conceived and undertaken between 1968-
1992 or 2000 in the case of the IOC) likely violates the 
fourth amendment of the American Constitution, as we ll as 
female ath letes' rights to equal protection under the law.10 
The fourth amendment guarantees "the right of the people 
to be secure in their persons ... against unreasonable search 
and seizures".10 The ruling in the Renee Richards case 
upheld as a matter of law that the USTA could only use the 
gender test as a means to prevent fraud, and not to disqual-
ify women with DSDs or transsexuals.9 Given this ruling and 
the arbitrary way in which gender verification testing 
continues to be applied, there are no valid circumstances 
under which a female ath lete should have to fear disqualifi-
cation on the grou nds of failing a gender test. 
Since no man has ever been caught masquerading as 
a female, it would appear that gender testing in any format 
is neither achieving its ostensible goal, nor serving athletes' 
best interests. Singling out young women with rare disor-
ders and publicly humiliating them not only causes lasting 
psychological damage, but demonstrates the stunning 
insensitivity of the IAA F and IOC. From thi s analysis, it is 
clear that the only valid reason for conducting gender 
verification of any kind would be to ensure that young 
women like Caster receive the medical attention and 
psychological support they need, rather than to expose 
them to public scrutiny and scandal. 
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Profile of Dr. Robert Hegele 
Gordon Tsang (Meds 2012) and Joyce T. W. Cheung (Meds 2013) 
Dr. Robert Hegele has been working in London, Ontario as a 
clinician-scientist with the University of Western Ontario 
(UWO) and the Robarts Research Institute since 1997. He 
obtained his medical degree from the University of Toronto 
in 1981, and went on to do a residency in Internal Medicine 
and sub-specialization in Endocrinology and Metabolism. He 
pursued further training in cardiovascular disease and 
genetics by doing fellowships at Rockefeller University in 
New York and the Howard Hughes Medical Institute in Salt 
Lake City, Utah. Dr. Hegele then returned to Canada, 
beginning his career at St. Michael's hospital in Toronto 
before finally settling in London, Ontario as a clinician-
scientist at UWO. Dr. Hegele is the current Director of the 
Blackburn Cardiovascular Genetics Lab and runs a tertiary 
referral lipid clinic. Throughout his career, he has won 
numerous awards for his genetics research, and has made 
numerous discoveries. 
Robert Hegele was born in Toronto to parents who 
emigrated from Russia. He recalls having a wide range of 
interests in his youth and demonstrated this by going on to 
pursue an undergraduate degree in music. Though Dr. 
Hegele did not have any early strong aspirations towards 
medicine, he cites his parents an influence in steering him 
and his brother towards pursuing medicine (his brother, Dr. 
Richard Hegele, is currently the Chair of the Department of 
Laboratory Medicine and Pathobiology at the University of 
Toronto). His mother was a medical student herself in 
Europe, but her studies were unfortunately interrupted due 
to World War II. Becoming a physician was also a logical 
choice for Dr. Hegele, providing him the opportunity to earn 
a comfortable living while giving him enough time for the 
pursuit of activities outside of his medical career. 
We asked Dr. Hegele if there were any mentors that 
stood out during his time in medical school, and memorable 
experiences that he cou ld recall. 
"I still remember patients I saw in medical school, the 
first time I did a physical exam, a psychiatric eva lua-
tion of a depressed patient. What later propelled me 
were my personal relationships with patients, but 
also teachers and colleagues." 
The presence of mentors guided Dr. Hegele's 
interests in medical school, playing an important part in 
influencing him to choose endocri nology as a specialty. He 
also fell into a role of a researcher serend ipitously. Initially 
desiring to teach, Dr. Hegele was told that in order to work 
at an academic centre, he had to also participate in research. 
"People such as Dr. Hollenberg (1970-81) and Dr. 
Burrow (1981-88) were the Chairs of Medicine while 
I was in schoo l. This tradition of endocrinologists as 
departmental chairs goes back to the discovery of 
insulin. So almost every chair of medicine in Toronto 
in the 20th century was an endocrinologist. Many of 
my mentors at Toronto General Hospital were 
endocrinologists, and they were the ones who 
encouraged me to pursue endocrinology." 
We asked Dr. Hegele how he was able to endure 
through the many years of training to become an academic 
physician. 
"It's a balance and reward [system], so we've all 
learned, but it's a different level [in doing research], 
your reward system is spread over a much longer 
time frame. Surgeons are the opposite, they need to 
be gratified almost moment to moment, and that's 
instantaneous. Somebody who is involved in re-
search, you need to defer that gratification for years." 
A typical week for Dr. Hegele involves teaching, 
research and seeing patients in his clinic. Approximately 
80% of his time is spent in research and 20% in the clinic 
setting where he sees patients and teaches medical students 
and post-graduate trainees rotating through the lipid clinic. 
In the lab, Dr. Hegele and his team at the Blackburn Cardio-
vascular Genetics Lab work to understand the function of 
genes that are changed by disease. Where he differs from 
most physicians and researchers is that even though his 
position requires that he spend more time writing grants 
than filling in charts, he is never far away from his patients 
and truly has a unique perspective on their disease. 
"Every research project started with a patient. 
Cardiology refers people with heart disease or severe 
cholesterol disorder or diabetes. We can now read 
the patient's whole genome profile using their spit or 
blood on a microarray. It a llows me to try and find 
the molecular basis of their disease. Instead of 
indirectly deducing that a patient has inherited a 
gene from their family history, we can now know 
more definitively by screening their personal genetic 
profiles. We first started to look at two to three genes, 
now we're up to more than 30 genes for heart 
disease. Many genes that had no known function 
before recently; we try to learn what the gene 
product does, hoping to work backwards and 
eventually come up with a treatment. 
"We see patients with lipid problems that are right off 
the scale. Often the usual drugs in the typical 
cardio logy or community practice don't work [for 
these patients] . Studying their genetic profile to help 
come up with some new treatment, that would be 
[my goal]. Whether it's a drug or completely novel 
treatment plan, my goal in the next 5 years is to come 
up with something brand new for my patients with 
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severe dyslipidemia." 
Many researchers are often poached by other 
universities, lured away by various reasons. Dr. Hegele is no 
stranger to recruitment, but has fortunately chosen to 
remain at UWO. 
" .. . One thing I like about London is that I have almost 
2000 patients, and have established a personal 
relationship with each one. I wouldn't want to 
suddenly leave and not have the chance to say 
goodbye. I already did it once in Toronto, and it was 
difficult. The second thing is that I have a great 
balance and quality of life here. It's very manageab le, 
the medical school and students are great, colleagues 
are great, my family is happy, I live close to work and 
I have a really nice house ... we' re really enjoying living 
in London." 
The recent economic downturn has affected the 
distribution of federal funding in many ways. We asked Dr. 
Hegele whether the recent downtown has affected hi s 
research. 
"My time [spent in research] has increased. It's 
tougher to get research funding now, but I am a co-
applicant on an NIH (National Health Institute) grant, 
part of the Obama stimulus package to NIH . I'm lucky 
to be a part of that. It's not quite the same in Canada. 
In general, I personally haven't felt it as badly, but 
research-like all aspects of the economy-has been 
hurting a little more." 
We thought it would be interesting to get his 
thoughts on what he would like to see happen in the future, 
both in his career and in endocrinology. 
"''d really like trying to do something directly 
tangible (i .e. guidelines and clinical trials of new 
medications), so the bench research and experiments 
may diminish as I get older. I will focus more on 
translating the benefit to patients and health care 
providers on the front line. I liked the fact that 
endocrinology as a subspecia lty was scientific ... when 
I was training, a lot of clinician-scientists were 
endocrinologists. That has changed now to some 
extent. I also am committed to training. But there is 
an increased need for clinician-scientists in all fields 
in Canada. There need to be talented people who can 
speak both the language of medicine and of basic 
research. So I would want to see more MD/PhDs in 
the future and would try to foster that. I have three 
MD/PhDs working with me now - Piya Lahiry, Matt 
Lanktree and Chris Johansen. I want to make sure 
that there is a new generation of medical trainees 
who maintain an interest in science." 
Outside his career in medicine, Dr. Hegele enjoys 
Profile of Dr. Robert Hegele 
exercis ing and music. He also travels frequently to various 
conferences and meetings around the world, but sti ll takes 
the time to enjoy hi s experi ences. One memorable event he 
recounted for us was an opportunity to see a footba ll match 
in Manchester, England ea rli er this year. 
Before leaving hi s lab, Dr. Hegele showed us a piece 
of med ica l memorabilia that he inherited from Dr. James 8. 
Collip, a former dean of Medicine at UWO (1947-1961) and 
the famo us biochemist who worked with the Banting, Best 
and Macleod research team to purify insulin so that it cou ld 
be used for testing in clinica l trials. It was Dr. Collip's desk 
from his years at UWO. 
This desk-where Dr. Collip worked-serves as a 
source of inspiration for Dr. Hegele in his scientific research, 
and a reminder of his ultimate goal of improving the quality 
of life for his patients. 
Does he have some last words of advice for cu rrent 
medical students? 
"Work hard, and play hard. Don 't cut corners, but 
when you're relaxing, fully enjoy relaxing as well. You 
need to get exposure of a wide range of career 
options from the beginning ... try to identify what you 
really like to do because that's what matters over the 
long term." 
Dr. Robert Hegele 
(Seen in the background is a photograph of Dr. james B. Collip.) 
Additional information 
Read more about Drs. Gerard Burrow and Charles Hollenberg and 
the development of academic medicine at the University of Toronto 
at: http:/ jwww.deptmedicine.utoro nto.ca/ About_Us/History.htm 
Read more about Dr. Hegele's research at the Robarts Research 
Institute website: http :/ /www.robarts.cajrob-hegele 
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Common side effects of diabetes medications 
Kalpa Shah (Meds 2012) 
Faculty reviewer: Dr. Terri Paul, Department of Medicine, UWO 
In Canada an estimated 3 million individuals are affected by 
diabetes and the incidence of type 2 diabetes mellitus 
(T2DM) is expected to continue to rise.1 As the prevalence of 
T2DM rises, a larger portion of the population will be using 
diabetic medications, which underscores the importance of 
being familiar with the side effects of these therapies. The 
article will discuss some of the main classes of diabetic 
medications, their side effects and contraindications to use. 
The side effects of commonly used diabetic medications will 
be explored and discussed through a series of vignettes. 
Case 1 
An 82-year-old woman who lives alone is found by 
her daughter one morning confused, disoriented and 
sweating profusely. Her daughter is concerned that 
she is having a heart attack and calls the ambulance. 
The paramedics arrive and, on discovering the 
patient has diabetes, check her blood sugar. It is 2.0 
mmol/L. She is given glucose and transported to the 
ER. As the physician treating her in the ER, you ask 
her the following: 
• How long have you had DM? 
2 years 
• What medications are you taking? 
Metformin and glyburide 
• Have you been eating appropriate meals? 
You find out that she has often just been 
having tea for breakfast but has been 
routinely taking her diabetes medications. 
She admits to often feeling "shaky" in the mid 
morning. 
The patient is hypoglycemic which is confirmed by 
her low blood sugar. Although hypoglycemia is commonly 
associated with patients using insulin to control their 
diabetes, it is a lso a major adverse effect of insulin secre-
tagogues - medications that s timulate the beta cells in the 
pancreas to produce insulin. There are two classes of insulin 
secretagogues: sulfonylureas and meglitinides. Sulfony-
lureas have been a mainstay of oral therapy for T2DM since 
the 1950s. They exert their effect by binding to the potas-
sium channel in the pancreatic beta cells, which increases 
the resting potential of the cell. As a result, the cell is more 
sensitive to depolarization leading to a calcium influx and 
insulin secretion.2 Since sulfonylureas cause insulin release 
their major side effects are hypoglycemia, as seen in this 
case, and weight gain. 
In this case, the patient was more prone to hypogly-
cemia since she was elderly and ate a very light breakfast 
when she took her medication. Other situations when 
hypoglycemia is more likely to occur include: 3 
• 
• 
• 
• 
• 
after exercise or a missed meal 
when the drug dose is too high 
with the use of longer-acting drugs (such as glyburide) 
in patients who are undernourished or abuse alcohol 
in patients with impaired renal or cardiac function or 
gastrointestinal disease 
Other side effects associated with the use of sulfony-
lureas include weight gain, rash (including photosensitivity) 
and nausea. Contraindications to the use of these drugs are 
sulfa allergy, pregnancy or lactation, type 1 diabetes 
mellitus (since there needs to be some functional beta cells 
in the pancreas for the drug to act on), cardiovascular 
disease, and impaired liver or renal function. 4 
Case 2 
A 65-year-old man has had diabetes for 8 years. He 
was initially treated with metformin and glyburide 
but as his control worsened, his glyburide was 
stopped and he was switched to insulin 30/70 taking 
50 units BID along with his metformin. He comes to 
clinic complaining that he has gained 40 lbs over the 
past 3 months. His blood sugars before meals at 
breakfast are in the range of 5- 8 mmol/L. He only 
occasionally checks at supper time but they are often 
7 - 10 mmol/L. he says that he feels shaky and 
sweaty every morning at 10 am and must have a 
snack. He has been eating a sandwich and cookie as a 
mid morning snack. The same thing happens after 
supper, in the early evening when he feels that he 
must snack throughout the evening. 
After asking him to check some blood sugars 2 hours 
after eating, you discover that he is having a low 
blood sugars of 2.5 mmol/L. 
He is having symptomatic lows that he is over 
treating by snacking excessively and this is contributing to 
his weight gain. You could suggest switching to a shorter 
acting insulin analogue mixture such as Mix25 (humalog 
and NPH) or Novomix (novorap id and NPH) and adjusting 
dose. The ultra fast acting insulin will not last as long as the 
regular insulin 30/70 and he will no longer have the urge 
for a morning and evening snack. Another alternative is to 
transfer him to multiple daily injection (MDI), with fast 
acting insulin before meals and a long-acting insulin at 
bedtime. 
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f! . a.- Prototype drugs Action in the body Side effects 
Sulfonylureas Glyburide, increases insulin secretion Hypoglycemia 
glipizide, glime- Weight gain, nausea, rash, GI 
piride symptoms, blurred vision 
Meglitinides repaglinide, increases insulin secretion Hypoglycemia 
nateglinide upper respiratory infection, head-
ache, diarrhea, weight gain 
Biguanides metformin enhances insulin sensitiv- GI symptoms, lactic acidosis 
ity 
Thiazolidinediones rosiglitazone, enhances insulin sensitiv- Cardiac events, heart failure, 
pioglitazone ity edema, weight gain, fractures 
alpha-glucosidase inhibi- acarbose, miglito l reduces absorption of GI symptoms (diarrhea, flatulence 
tors glucose from gut cramping) 
DPP-4 inhibitors sitagliptin inhibits breakdown of upper respiratory infection, head-
GLP-1 (a gut hormone that ache, sore throat 
enhances insulin secre-
tion) 
Table 1. Summary of major classes of diabetic medications. Adapted from Th e Medical Letter.11 
He returns in 1 month after starting the new 
regimen and has lost 5 lbs. 
Case 3 
A 45-year-old woman presents with newly diagnosed 
diabetes and is started on metformin 500 mg TID. She 
returns 1 week later saying she cannot tolerate the 
medication due to upset stomach and diarrhea. 
There are two classes of insulin sensitizers - medica-
tions that improve insulin action in the body: biguanides 
(which include metformin) and thiazolidinediones. Met-
formin is a first line oral hypoglycemic agent and some of 
the mechanisms through which it exerts its effects are: 1) 
decreasing hepatic glucose output 2) increasing insulin-
mediated glucose utilization in muscle and liver 3) lowering 
serum free fatty acid concentrations thus reducing substrate 
availability for gluconeogenesis. It is believed that these 
effects are mediated through the activation of AMP-
activated protein kinase. 5 
The most common side effects of metformin are 
gastrointestinal (GI) and include a metallic taste in the 
mouth, diarrhea, abdominal discomfort, nausea and mild 
anorexia. These effects are reversib le upon stopping the 
drug or reducing the dosage.5 Metformin should be started 
slowly and with food to minimize side effect of Gl upset as is 
ill ustrated in Case 3. Patients should be started with one pill 
or ha lf a pi ll at mealtime once per day and this dose should 
be increased slowly as the patient tolerates it. The patient 
can titrate their dose themse lves every 5- 7 days up to a 
maximum of 4-5 tablets daily. 
Another rare but serious side effect of metformin is 
lactic acidosis. As a result the following are contra indica-
tions to starting metformin therapy: impaired renal func-
tion, liver disease, alcohol abuse, heart failure, past history 
of lactic acidosis, decreased tissue perfusion or hemody-
nam ic instability.5 
Case4 
A SO-year-old man with newly diagnosed type 2 
diabetes mellitus has blood sugars in range of 8-12 
mmol/L. He is started on Metformin and pioglitazone 
as initial therapy. He returns to your clinic in 3 
months for follow up and his blood sugars are under 
much better control with fasting blood sugar of 5-7 
mmoljL. However, he complains of a weight gain of 
10-11 lbs (5 kg) and says his ankles and legs are 
puffy. You examine him and discover he has signifi-
cant pedal edema that extends up his calves. He is not 
short of breath and has no signs of heart failure. 
Pioglitazone has been associated with fluid reten-
tion, weight gain, heart failure, loss of bone mineral density 
and fractures.6·7·8 This patient is experiencing side effects of 
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weight gain and edema from his pioglitazone therapy. His 
weight ga in is due in part to fluid retention; the rest may be 
due to the proliferation of new ad ipocytes. 
Pioglitazo ne belongs to the thiazolidinedione class of 
drugs. Thiazolidinediones are insulin sensi tizers that 
increase the action of insulin by acting on adipose, muscle 
and liver to increase glucose utilization and reduce glucose 
production. It is believed that the thiazolidinediones exert 
their effect by binding to peroxisome proliferator-activated 
receptors (PPARs), which regulate gene expression.9 Fluid 
retention is caused by the binding of PPAR receptors in the 
nephron, which causes reabsorption of sodium and resul-
tant fluid retention.10 This fluid retention often manifests as 
peripheral edema and may a lso precipitate heart failure in 
susceptible patients. PPAR receptors are a lso found in 
skeletal muscle, adipose tissue, pancreatic beta cells, liver, 
heart, and kidneys, which accounts for the varied effects of 
thiazolidinedione therapy.9 
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Introduction 
Nasal obstruction is one of the most common symptoms 
pediatric patients present to their physicians with. These 
symptoms are most often caused by allergic rhinitis and 
inflammation associated with viral upper respiratory tract 
infection, and thus it is easy to attribute all cases of nasal 
congestion to the more common entities in a busy clinical 
practice. The following case1 describes a patient with 
McCune-Albright syndrome (MAS), which presents as a rare 
cause of nasal obstruction. It is used to illustrate the need to 
maintain a high index of suspicion and a broad differential 
diagnosis, especially for cases not responding to initial 
treatment measures . Furthermore, it emphasizes the need 
to consider the presentation of the overall patient, and not 
just the presenting symptom. 
Case report 
An otherwise healthy 14-year-old girl presented with 
complaints of right-sided nasal obstruction. She failed to 
improve with a regimen of decongestants care as well as a 
course of antibiotics and mucolytics. Therefore, a computer-
ized tomographic (CT) scan was ordered which revealed an 
enlarged inferior turbinate bone with significant right nasal 
obstruction, and a "ground glass" appearance of the inferior 
turbinate, middle turbinate, ethmoid sinus, sphenoid sinus 
and crista galli. 
She was further referred to the Department of 
Surgery and Pediatrics, where a review of systems found 
commencement of menstruation at 10.5 years, with a 
growth spurt of 8.5 inches in her 12th year. Her physical 
examination revealed a larger right inferior turbinate and 
an irregular shaped 1.5 x 0.5 em cafe-au-lait macule on her 
right forearm. Based on these findings, a diagnosis of MAS 
was suspected. Further laboratory results showed normal 
growth hormone and prolactin levels. No distant sites of 
additional bone involvement were identified on bone scan, 
and all ophthalmologic tests were normal. 
An endoscopic (submucosal) turbinoplasty was 
performed to relieve the nasal obstruction, and the subse-
quent histopathologic analysis of the biopsy displayed 
curvilinear trabeculae of woven bone surrounded by 
moderately cellular fibroblastic proliferation, again consis-
tent with fibrous dysplasia. On follow-up evaluations, 
endoscopy revealed a stable inferior turbinate with no 
recurrence of the nasal obstruction. The post-operative 
follow-up CT scan demonstrated no change in size or shape 
of the lesion at 2 years following biopsy, and formal oph-
thalmologic examinations every 6 months have since 
revealed no change in vision. 
Discussion 
Epidemiology and clinical presentation 
McCune-Albright Syndrome (MAS) has historically been 
identified based on the presentation of the typical triad of 
symptoms observed in this case: polyostotic fibrous 
dysplasia, cafe-au-lait pigmentation and precocious pu-
berty.2 It is a rare disease which has been described in all 
races, with an estimated prevalence between 1/100,000 
and 1/l,OOO,OOOY Females are more often affected than 
males with a ratio of 2-6:1, and are also more often ob-
served to have sexual precocity.4•5 However, because 
autonomous hyperfunction of nearly every endocrine organ 
has been associated with MAS, a more clinically relevant 
definition which is broader than the original triad has been 
proposedY More extensive manifestations of MAS have also 
been reported, including hepatobiliary disease, cardiac 
arrhythmias and CHF, pulmonary dysfunctions, proximal 
renal tubules malfunction, and sudden or premature 
death .1·4·5 
Fibrous dysplasia (FD) is a benign tumour of fibrous 
tissue, where the normal components of bone fail to 
differentiate into mature structures. The growth of chondro-
cytes and immature spindle fibroblast-like cells results in 
calcification and a ground-glass appearance, with the 
histological hallmark being an extensive proliferation of 
fibrous tissue within the bone marrow.6·7The most common 
site of involvement is craniofacial and may result in exoph-
talmy, tooth development abnormalities, visual distur-
bances, facial asymmetry, hearing abnormalities, leontiasis 
ossea and, as seen in this patient, nasal obstruction.1·6 FD 
can also be found in the proximal femur, pelvis and verte-
bral column and typically affects medullary rather than 
cortical bone.1 Under-mineralization makes the bones prone 
to fractures and deformities, and patients often present with 
bone pain.3 Although malignant transformation is rare 
(0 .4%), it is more common in MAS patients (4%). 1 
Cafe-au-lait spots are pigmented cutaneous mark-
ings, which are present at birth or develop shortly thereaf-
ter.2 They are distinguished by the jagged "coast of Maine" 
shape of their borders, and typically found on the nape of 
the neck or crease of the buttocks.3 Their distribution tends 
to follow the lines of Blaschko, with a tendency to stop at 
the midline on the same side as the predominant bone 
lesion.4•7 
Precocious puberty in girls is defined as the develop-
ment of secondary sexual characteristics before the age of 8 
years. Although the exact onset of puberty in this patient 
was unknown, it usually affects females with MAS between 
the ages of 1 and 6 years and is gonadotropin-releasing 
hormone-independent.8 
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Many other endocrinopathies are often associated 
with this syndrome: pituitary gland ab normalities include 
growth hormone and prolactin hypersecretion; adrena l 
gland disorders include hypercortisolism, acromegaly and 
Cushing's syndrome; thyroid gland disorders include 
hyperthyroidism, nodular goiter, and follicular adenoma; 
and parathyroid gland abnormalities can include parathy-
roid adenoma, and hyperparathyroidism. 1 
Genetics and molecular basis 
The sporadic occurrence of MAS, its variable presentation 
and the pattern of skin pigmentation initially led to the 
hypothesis that this disorder is secondary to an autosomal 
dominant mutation occurring early in embryogenesis.5 
Molecular stud ies have since identified a missense mutation 
in the GNASl gene, which codes for the alpha subunit of a 
guanine nucleotide-binding regu latory protein, Gs0 . 1'3 Gsa is 
involved in the stimulation of adenylyl cyclase; mutations 
associated with this syndrome are gain of function muta-
tions .9 The constitutiona l activation of Gs leads to increased 
levels of intrace llular s ignaling molecule cAMP, which in 
turn lead to increased production of a variety of different 
molecules. The up-regulated molecules can include melanin, 
estradiol, testosterone, thyroxine, growth hormone and 
cortiso l (Fig lJ_l Generally such mutations are not co mpati-
ble with life; however, it is thought that these patients 
survive as mosaics because the change in the GNASl gene 
occurs during the early embryon ic postzygotic stage.3 This 
mosaicism is seen in part as the pattern of cafe-au-lait spots, 
and is further supported by the wide spectrum of clinical 
presentations observed in patients.4 The phenotype and 
severity is determined by the ce ll line involved in the 
mutation, while the severity relates to the point in develop-
ment that the mutation occurred.3 
Diagnosis and treatment 
The diagnosis of MAS is usually made based on clinical 
findings. The evaluation of patients should therefore be 
guided by knowledge of the spectrum of tissues that may be 
involved, with specific testing for each. Although genetic 
testing is not routi nely avai lable, genetic counseling should 
be offered with the assurance that there is no vertical 
transmission of the disease.3 
Because there is no specific treatment to correct for 
the mutation of Gsa. treatment needs to focus on controlling 
the spectrum of symptoms that may a rise from this syn-
drome. For females, testolactone has been the mainstay of 
treatment as it decreases serum estradiol and estrone levels 
by competitive inhibition of aromatase.1 Ketoconazole and 
spironolactone possess anti-androgenic activity and are 
effective in males.1 PTU, methimazole and radioactive iodine 
are useful in hyperthyroid states, and octreotide suppresses 
GH secretion and slows acromegalic growth.1 Surgical 
therapy can be used to remove the source of hormone 
hypersecretion, and is useful in cases refractory to medical 
therapy. 1 Surgical resection is the only cure for fibrous 
dysplasia, but may be technically difficult in the sku ll and 
facial regions. In these cases, the risk of complete resection 
must be carefully weighed against the potential benefits. 1 
There is no proven medical therapy, though bisphospho-
nates have been used to reduce the incidence of fractures 
and reduce bony pain. Calcium, vitamin D and phosphorus 
supplements may also be used. 3 
Figure 1. Molecular mechanism of McCune-Albright syndrome.J 
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Small bowe l intussusception from mestastatic melanoma 
Bret t Howe (Meds 201 0) 
Facult y reviewers: Drs. Robert Humphrey and W ill iam J. Wall, Department of Surgery, UWO 
Case r epor t 
A 46-year-old female presented to hospital with sudden 
onset lower abdominal pain, associated with nausea, and 
decreased flatus and bowel movements over a 24 hour 
period. Frequent bilious vomiting developed shortly 
thereafter and her pain worsened. Ten years ago she had 
excision of a melanoma of the scalp combined with a 
modified radical neck dissection. No evidence of recurrence 
had been noted. 
Physical exam revealed a mobile, firm, tender mass 
in the lower abdomen. Abdominal ultrasound identified 
fluid filled loops of small bowel, suggesting an obstruction. 
Abdominal series was non-specific but a CT scan suggested 
a closed loop obstruction in the mid-ileum without evidence 
of ischemia (Figure 1). 
At laparotomy, an ileal -ileal intussusception was 
identified, resulting in a segment of ischemic ileum and a 
high grade small bowel obstruction. No effort was made to 
reduce this segment as the suspected pathology was 
metastatic melanoma based on the history. A 90.0cm 
segment of small bowel was resected and a primary 
anastomosis was performed. The remainder of the laparo-
tomy revealed no evidence of metastatic disease. The 
specimen was opened in the operating room revealing a 2 
em pedunculated darkly pigmented polyp as the lead point. 
Final pathology was consistent with metastatic melanoma 
to the mucosa and submucosa of the small bowel. The 
patient had an uneventful recovery, but Jess than a year 
later developed metastatic melanoma to her lungs. 
Discussion 
Melanoma is a malignant tumour arising from melanocytes 
that are found in the integument as well as the inner ear, GJ 
tract mucosa, and eyes (conjunctivaV It is the most deadly 
form of skin cancer. In 2008 it was estimated to be the 7'h 
most common cancer diagnosis in Canada with an estimated 
4600 Canadians diagnosed with the disease and 980 
deaths.2 Metastatic disease from a cutaneous melanoma is 
most commonly detected clinically in skin, subcutaneous 
tissue and nodes, lung, liver, and brain. Although sympto-
matic Gl tract metastases occur in only 1-7% of individuals 
with metastatic melanoma, autopsy studies report occult 
metastasis in up to 60% of cases.3.4 
Melanoma is the most common metastatic tumour 
affecting the GI tract. All histological subtypes are capable of 
metastasising to it, though superficial spreading melanoma 
is the most common subtype found. 5 The small bowel is 
most frequently involved (58-71 °/o), followed by the 
stomach (27%), colon (22%), and esophagus (5%).6•7 
Common presenting symptoms are abdomina l pain, 
Figure 1. Preoperative axial view (top) and coronal view 
(bottom) of the computed tomography (CT) scan of the abdo-
men illustrating findings suggestive of a closed loop obstruction 
in the mid-ileum. 
bleeding (gross or occult), mass, or obstruction, with the 
latter being most commonly a result of intussesception.8 
The timeframe from occurrence of a primary lesion to 
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symptomatic metastatic disease is exceptionally variable. 
Previous studies have shown median disease free survivals 
between 25.3 months and 24 years.7·8 Median survival after 
Gl metastases is estimated to be 12.5 months, with a 5 year 
survival of only 14%.9 
Surveillance for metastatic disease in individuals 
with a primary melanoma is controversia l. The role of 
positron emission tomography (PET) scan ning is evolving. It 
offers sensitivities of 79 to 100%, but is limited by accessi-
bility and cost. 1° CT scans have only 60-70% sensitivity for 
detecting small bowel melanoma, however they are often 
the first line of imaging due to their accessibility.11 A 
previous study of CT scanning for staging of primary 
melanomas found positive results in 29 of 151 patients. 
However, biopsies and follow-up studies found only 2 
patients with metastatic disease.12 Currently, there are no 
recommendations for intense follow-up in patients with 
primary melanoma beyond 5-10 years except for lifelong 
dermatologic surveillance due to the preva lence of second 
primary melanomas.U 
Treatment of GJ metastas is largely depends on how 
advanced the disease has become and the overall physical 
condition of the patient. Therapeutic or palliative surgical 
resection is almost always indicated for local lesions tha t 
have become symptomatic. This is especially true for 
patients with acute abdominal pa in and signs of obstruction. 
Numerous studies have demonstrated improvement in 
symptoms and survival with GI resection and a low morbid-
ity and mortality rate associated with the procedure.6·8·10 
The role of adjuvant therapy (chemotherapy, immunother-
apy) after resection of metastatic GI melanoma is unclear. 
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Background 
It has only been in the recent past that the Women's Health 
Initiative (WHI) changed how physicians and consumers 
viewed postmenopausal hormone therapy (HT). The 
estrogen-progestin arm of the study, involving over 16,000 
women, was stopped prematurely due to findings suggest-
ing an associated increased risk of stroke, breast cancer, and 
dementia without a reduction in cardiovascular risk.1 
Subsequently, women have been searching for 
"safer" alternatives to treating their climacteric 
(menopausal) symptoms- including hot flashes, decreased 
libido, vasomotor changes, urogenital atrophy, skin changes, 
increased body weight and abdomina l fat, and psychophysi-
ologic changes like mood changes, insomnia, and anxiety.2 
One alternative that has been offered to women is 
"bioidentical hormone" therapy (BHT), which is purported 
to be safer, natural , and more efficacious compared to 
standard post-menopausal HRT. 
Defining bioidentical hormone therapy 
BHT is a term used to describe plant-derived precursor 
compounds (eg. diosgenin from Mexican yam, stigmasterol 
from soy), which have been synthesized in the laboratory to 
be structurally identica l to endogenous human hormones 
such as estrogen (estrone, estradiol, estriol), progesterone, 
testosterone and dehydroepiandosterone (DHEAV Perhaps 
a more accurate name for bioidentical hormones should be 
native synthetic hormones, as these hormones are not found 
naturally in any plants3 Proponents of BHT claim that it is 
capable of restoring a balance between hormone levels, and 
yet due to similarity to human hormones along with 
individualized dosing, it is able to provide symptom relief 
with minimal side effects.4 
Those who favour BHT affirm that the first step in 
determining the usefulness of BHT is a sa livary hormone 
profile, looking for deficiencies in sex hormones. Steroids 
easily diffuse into the saliva and in some cases may accu-
rately reflect free hormone levels. For instance, midnight 
salivary cortisol is an evidence-based, validated test for 
Cushing's syndrome. However, BHT proponents expand 
their diagnostic range and offer an entire panel of various 
hormone testing through mail-order kits. Interested 
consumers can mail in a saliva sample (collected by chewing 
on a cotton ball, placed in a plastic receptacle) and then they 
will receive an extensive computer print-out with their 
results as well as an explanation of findings and possible 
correlated symptoms.5 The inexpensive nature of the test 
and the relative ease of obtaining samples make this test 
particularly popular with consumers and BHT advocates. 
Once the salivary results are obtained, the BHT 
practitioner will prescribe a course of bioidentical hor-
mones, and tailor the dosage specifically to the individual's 
hormone profile. In some cases, special preparations can 
be created by pharmacists5. BHT comes in creams, gels, 
pills, patches, self-injectors and pellet therapy. Within the 
various treatments are hormones such as estrogen, proges-
terone, cortisol and "women testosterone."6 
According to one company's website, the cost of BHT 
can exceed $5000USD per year. An initial consult is $400, 
follow- up consults $185 (of which you need three), and the 
cost of treatment may range from $75-350 per month. 
Further costs come with the treatment itself and laboratory 
tests.7 Because insurance companies do not cover the cost 
of these treatments, this may be a limiting factor for many 
patients. Keeping this in context, daily Premarin 0.625 mg 
along with Provera 2.5 mg would be around $700USD per 
year, even with the 800% increase in price in 2009.8· 9 
Currently, there are numerous commercial as well as 
individually prepared "natural" products. Formulations are 
created by pharmacies according to prescriptions written 
by referring practitioners, and cannot all be purchased 
commercially. One such product is Biest (bioestrogen) 
which is a combination estrogen contai ning 20% E2 
(estradiol) and 80% E3 (estriol), expressed in a milligram 
per milligram basis.10 Another such formu lation used 
frequently is Triest (triestrogen) which contains 10% E2, 
10% E1. and 80% E3• It is important to note the relative 
potencies of the estrogens: E1 (estrone) is the most potent, 
followed by Ez, and E3 is the weakest of the three, being the 
final end product of E2 and E1 metabolism. The presence of 
such a high proportion of E3 in these mixtures is advertised 
as the key to reducing adverse side HRT effects while still 
conferring symptom relief.10 
What is the evidence from medical literature? 
There have been few evidence-based trials looking at the 
safety, efficacy, and durability of BHT. According to propo-
nents, because the steroids are found in nature, are not 
extensively manufactured, and are dosed in a way that is 
individualized, there is no need to research these com-
pounds and therefore submit data to FDA for approva l and 
regulation.5 In addition, pharmacies can mix their products 
differently, which makes it difficult to standardize and 
determine the risks associated with BHT. 
Despite salivary hormone testing (SHT) developing a 
medical literature showing usefulness in certain areas of 
clinical practice, it is often criticized for its lack of reliability 
and inability to correlate symptoms and hormone levels. 
Standard HRT prescribes estrogen and progestins in doses 
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that provide symptom relief. In the BHT approach, SHT test 
results may persuade asymptomatic women to take doses 
they may not need and symptomatic women to take 
excessive doses.11 
In theory, saliva is similar to ultrafiltrate and should 
correlate with free/unbound serum concentrations. 
However, it has been shown that these correlations vary 
depending on the time of day, diet and the specific hormone 
tested.10 Many hormone levels vary during the day, week. 
month, season and therefore a one-time SHT may be 
inadequate for diagnosis or monitoring dose adjustments, 
particularly unless greater than 5 samples are taken daily.2 
Traditional medicine uses individualized dosing for 
drugs which have a narrow therapeutic index, as described 
by population-based phamacokinetic studies ( eg. cyc-
losporine, digoxin). According to Jelliffe, true individualized 
dosing must be predicated upon a known target serum 
concentration, at a desired target time after the dose, for 
each patientY However, proponents of BHT have no studies 
dealing with important pharmacokinetics of their drugs 
such as volume of distribution, protein binding, route of 
elimination, among other factors. 10 Without a predictable 
relationship between dose and response of the drug, it 
becomes impossible to know how much medication to 
prescribe. 
As mentioned previously, the BHT hormones 
typically used for menopausal symptoms are estrogen and 
progesterone. But how much estrogen is really in these 
compounds? In addition to inter-pharmacy differences of 
product formulation, there appears to be another underly-
ing problem--ratios may not be what they seem. Biest, an 
80:20 ratio of E3 to E2, is not based on the estrogen potency 
of each compound, but rather is based on the milligram 
quantity of different agents added together. For example, if 
a woman takes 2.5 mg of Biest (2 .0 mg E3, 0.5 mg E2), and 
the potency of E3 is 1/SO'h of E2, the equivalent content of E2 
is actually 0.525 mg. 10 Some women may take 2.5 mg Biest 
twice daily, increasing the E2 equivalent to 1.05 mg per day 
which is a dosage exceeding most prescribed estrogen 
therapies. The same applies for Triest, which is a combina-
tion of estriol, estradiol, and estrone.2 
A critical look at bioidentical hormone therapy 
With E3 being the least potent of the estrogens, its 
high percentage in BHT formulations is believed to decrease 
the incidence of breast cancer and endometrial hyperplasia. 
However, past studies have shown equal endometrial 
stimulation from estradio l and estriol medicationsY Estriol 
was also found to partially overcome antiestrogen inhibition 
from Tamoxifen, even when Tamoxifen is present in 1000-
fold excess. Therefore, estriol does not have a protective 
role in human breast cancer, and all estrogens bind to an 
equal number of sites when saturating concentrations are 
used. 14 It can be deduced that despite being the least potent 
estrogen, E3 still carries risks of cancer that BHT tries to 
avoid. 
Much has been written about progesterone in BHT. 
Although that extensive literature will not be reviewed here, 
it should be noted that many of the health claims from BHT 
practitioners have not been substantiated, but rather have 
been overshadowed by evidence-based medicine. For 
example, BHT practitioners claim progesterone increases 
metabolism and causes weight Joss. However, no studies 
are identified to support those claims. Indeed, weight gain, 
rather than loss, has been shown w ith progestin therapy in 
cancer-related anorexia. 15 
Practice guidelines for the physician 
In view of the evidence, how should the physician respond 
to BHT practitioners and claims? The North American 
Menopause Society, the American Association of Clinical 
Endocrinologists, and the Endocrine Society have all 
published positional statements expressing concern for the 
safety of women using these products.16' 18 These groups are 
currently advocating for FDA oversight in the standardiza-
tion of drug purity, the need for mandatory reporting of 
adverse events, as well as uniform labeling of precautions 
on BHT formulations. 
The bottom line from these groups involves strong 
recommendations that BHT not be used in the treatment of 
menopausal symptoms. It is argued that both "bioidentical" 
and "traditional" hormone replacement treatments will 
carry essentially the same risks and benefits if dosage and 
Traditional hormone Many "bioidentical hormones" 
Molecular structure Similar or identical to human Identical to human 
FDA oversight Yes No 
Dosage Monitored; accurate and consistent Not monitored; may be inaccurate or incon-
sistent 
Purity Monitored; pure Not monitored; may be impure 
Safety Tested; risks known Not FDA tested; risks unknown 
Efficacy Tested and proven Not FDA tested; unproven 
Scientific evidence Existent; conclusive Insufficient 
Table 1. A comparison of traditional and bioidentical hormone therapy. 
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purity are equal. Therefore, no matter the source or 
hormone regimen, the "individ ualized" dosing must be 
carefully controlled. 
A summary of the Endocrine Society's comparison of 
BHT and HT is shown in Table 1. Overall, further research 
and an evidence-based scientific approach must be appli ed 
to BHT to validate or debunk its proposed health benefits. 
Until then, it might be best to keep the yams on the Thanks-
giving tab le instead of using them to treat human condi-
tions. 
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Why did Harvey Cushing misdiagnose Cushing's disease? The en igma of 
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The case of Minnie G 
Minnie G's menses started at the age of 14 and were regular 
for two years and then suddenly ceased. She began to grow 
stout and in two years her weight had increased from 112 to 
137 pounds. She suffered a great deal from headaches, 
nausea and vomiting. She complained also of aching pains 
in the eyes which latterly had become prominent, and there 
had been occasional periods of seeing double. Other 
noteworthy symptoms were insomnia, ti nnitus, extreme 
dryness of the skin, frequent sore throats, shortness of 
breath, palpitation, purpuric outbreaks, recurring nose-
bleeds, and marked constipation. A definite growth of hair 
had appeared on the face with thinning of hair on the scalp. 
She had become increasingly round-shouldered. Muscular 
weakness had become extreme and there was constant 
complain of backache and epigastric pains.' 
Case discussion 
This case represents the original words of Harvey Cushing 
in describing Case XLV, a woman who came to be known in 
the li terature as Minnie G or MG.' The description appeared 
in Cushing's seminal work, The Basophil Adenomas of the 
Pituitary Body and their Clinical Manifestations in 1932. 
Cushing first saw MG in 1910 and originally attributed the 
complaints of obesity, diabetes, hirsutism, and adrenal 
hyperplasia to myxedema.2 He then changed his differential 
to "pituitary, adrenal, or ovary?"3 Over the next 20 years, 
Cushing saw MG twice more and began an extensive review 
of the literature. His previous work on acromegaly led him 
to postulate that if acidophilia could lead to growth hor-
mone excess, then perhaps basophilia could lead to cortisol 
excess.3 An 1898 case description by Cushing's mentor, Sir 
William Osler, helped Cushing to finally determine in 1932 
that MG's symptoms were the result of a cortisol secreting 
pituitary adenoma. 
The case of Minnie G illustrates a common diagnostic 
challenge in endocrinology: endocrine conditions often are 
associated with a non-specific symptom set, which com-
bined with individual variability can have the result that 
some patients go undiagnosed or are misdiagnosed. If even 
Harvey Cushing struggled with the diagnosis of Cushing's 
disease, what hope is there for humble endocrinologists and 
general practitioners? This article will use Cushing's disease 
as a prototype to explore how and why symptoms are 
grouped into diagnoses, and the associated perils and 
advantages of this practice. 
The diagnostic approach to Cushing's Disease 
Cushing's disease is one form of Cushing's syndrome, a 
group of symptoms that result from hypercortisolism. 
Diagnosis of Cushing's disease depends on cli nica l, labora-
tory, and imaging modali ties. For instance, a diagnosis of 
Cushing's disease requires evidence of hypercortisolism; the 
excess cortisol must be the result of high ACTH levels; and 
the high ACTH must be the product of a pituitary adenoma. 
The fo llowing algorithm aims to fulfi ll those three 
criteria:4·5 
1. Does the patient exhibit symptoms of cortisol excess? 
Test Results suggestive of Cushing's syndrome 
Truncal obesity 
Facial plethora 
Hirsutism 
Observation Acne Skin bruising 
Edema 
Muscle weakness 
Hypertension 
Mood disorders 
History Polyuria 
Polydypsia 
Laboratory testing Glucose intolerance 
2. Is there actually cor tisol excess? 
Test Results suggestive of Cushing's syndrome 
11pm salivary corti-
>4x increase 
sol 
Serum cortisol after 
low dose dexa-
>54nmol/L 
methasone 
suppression test 
24 hour urine free 
>250nmoljday 
cortisol 
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3. Is the cortisol excess ACTH-dependent? 
Test 
SerumACTH 
Results suggestive of 
Cushing's syndrome 
>40pmol/L 
4. Is the excess ACTH from the pituitary? 
Test 
MRI 
Petrosal venous 
sampling 
The enigma 
Results suggestive of 
Cushing's disease 
Pituitary adenoma 
High ACTH levels in the 
region of the pituitary 
Algorithms such as these suggest that diagnosis of disease 
should be relatively straight-forward. However, the fact 
that Cushing took 20 years to diagnose the disease that 
bears his name combined with the fact that most patients 
wait 6 months-10 years between symptom onset and 
diagnosis of Cushing's disease suggests otherwise.2 Cush-
ing's disease is simply an example of a broader issue: how 
and why do we group symptoms into categories, and what 
problems do these groupings create? 
How do we define disease? 
A disease is a collection of recognizable symptoms that 
result from a common cause. This definition is s lightly 
narrow, as diseases are defined not only by their symptoma-
tology and pathology, but also by imaging and laboratory 
results, response to treatment, and epidemiology. At first 
glance, the definition of a disease should be fairly simple. 
Even the layperson can recognize that diabetes is not the 
same as influenza. The problem arises when symptom and 
investigation differences are more subtle: even the most 
experienced endocrinologist wi ll struggle with differentiat-
ing a pituitary basophilic microadenoma from ectopic ACTH 
production. This struggle is analogous to the definition of a 
species- biologists recognize that a cat is not a dog, but 
grouping like micro-organisms is a different cha ll enge. 
From this ana logy, we recognize that defining an 
entity is much more difficult when we are unable to see it 
clearly. The distinction between a cat and a dog is simple 
because we can compare ear shape, bone structure, sounds 
produced, and habits. Grouping micro-organisms requires 
microscopic examination and molecular techniques. 
Endocrinology is the micro-organism of the medical world: 
it deals with conditions that are often visible only in their 
clinical manifestations, not in their causative agents. 
Cushing's disease is somewhat unique in that an 
anatomica l anomaly, a brain tumour, is the etio logic 
mechanism. In contrast, hypercortisolism is recognized 
only by the clinical manifestations of hypertension, obesity, 
and glucose intolerance and by laboratory abnormalities. 
In defining disease, establishing criteria for a 
syndrome is perhaps the most difficult task. Syndromes are 
collections of symptoms, signs, and investigational results 
that have a similar course and response to treatment. 
However, syndromes are made up of sufficient rather than 
necessary elements. That is, the symptoms make the 
diagnosis more likely, but there is no one symptom that will 
absolutely rule in or out the diagnosis. Endocrinology is 
fraught with vague symptoms, largely because the definition 
of normal is elusive. Hormone levels fluctuate throughout 
the day, with age, with environment, with diet, and between 
individuals. It is incredibly difficult to define 'normal' for a 
measurement that is not only inconsistent between but also 
within individuals. 
Why do we define disease? 
Because the symptoms that make up a syndrome are so 
variable, it is perhaps appropriate that they are named after 
the people who first described them. Diseases are, in 
essence, a human creation. They are an attempt to impose 
order and allow parsimonious treatment. Cushing argued 
that defining disease was important because "a peculiar 
clinical syndrome has first been described by someone with 
a clarity sufficient to make it easi ly recognizable to others."1 
It is only by having an accurate definition that different 
physicians are able to make the same diagnosis. 
If a collection of symptoms has a common cause, it is 
easier to treat the cause than it is to treat each individual 
symptom. Consider the example of Cushing's disease: 
Figure 1. Pathogenesis of Cushing's disease and diagnostic tests 
for each level. 
Note that the diagnostic tests described above detect 
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the disease at different levels of disease progress ion. 
Therefore, the test that is chosen will have an impact on the 
part of the disease that is observed. If an MRI reveals an 
adenoma, this is not sufficient to make a diagnosis of 
Cushing's disease. While it is high on the etiologic pathway, 
the possibility of a non-secreting and therefo re asympto-
matic incidentaloma remains. 
Conversely, symptoms of obesity and hirsutism 
could suggest Cushing's disease, but without the MRI and 
ACTH tests, we are not justified in applying that label. These 
two instances have treatment implications: the first re-
quires no treatment if it is truly an incidentaloma. The 
second requires treatment, but without knowing the cause 
of the symptoms, our ability to intervene is limited to 
symptomatic relief. 
The elusive diagnosis 
According to Gross eta/, "Although the initial presentation 
of a patient with such a constellation of symptoms is 
suggestive of Cushing Syndrome, most symptoms character-
istic of the disease are nonspecific, resting the burden of an 
accurate diagnosis on an appropriate diagnostic workup."5 
The diagnosis of Cushing's is fraught with perils at multiple 
levels: 
iThe DISease I 
• Atypical presentation' 
• Intermittent hypercortisolism 
• Pituitary incidentalomas 
• Adrenal incidentalomas 
• Rare forms 4 
• Macronodular adrenal hyperplasia 
• Abnormal sensitivity to glucocorticoids 
• Pheochromocytoma 
• Pseudo Cushing's 
• Obesity 
• Anorexia 
• Alcohol 
• Depression 
• Stress 
!The Pattent 1 
• Symptoms are interpreted in light of education, culture. relationships. etc. 
• Comorbidities 
• Subpopulations present differently: pregnant women, children 
• Lifestyle effects (diet. exercise, exogenous hormones) 
• The definition of 'normal ' is not absolute 
• Timing (symptoms require longterm glucocorticoid excess, and levels of cortisol 
vary throughout the day)' 
• Imperfect lab tests, none are 100% sensitive orspecific6 
• Tests require patient compliance (ex. 24 hour urine collection) 
'The PhySictan 1 
• Rare disease, may not consider it2 
~he Medteal System I 
• Imperfect communication between specialists2 
• Ignoring parsimony: diagnosing the symptoms instead of the syndrome 
• Specialty-specific care 
Figure 2. Complicating factors in the diagnos is of 
Cushing's disease. 
As seen in Figure 1, the first step in the diagnosis of 
The enigma of endocrinological diagnoses 
Cushing's di sease is the recognition of clinical symptoms. 
However, when viewed in iso lation, these symptoms can be 
characteristic of numerous di seases. Many patients who are 
ultimately diagnosed with Cushing's di sease find themselves 
passed between specialties before an astute physician 
finally integrates the symptoms into a whole. For instance, 
Evans eta/ describe a woman who saw a dermatologist, 
cardiologist, orthopaedic surgeon, and psychiatrist before 
ultimately diagnosing herself from information in the lay 
press.2 This illustrates a fundamental flaw with the current 
medical system- subspecialisa tion ensures expert care of 
specific symptoms, but it may neglect to view the patient as 
a complete person. Diagnostic re-evaluation is needed as 
time and symptoms evolve and an astute phys ician looking 
at the entire person may be seminal in putting the pieces 
together. Optimal communication is required between 
specialists to ensure that a common cause of symptoms can 
be found if it exists. 
Finally, note in Figure 1 that the final arrow in the 
pathway is bidirectional. The effects of symptoms in turn 
impact the patient's experience of the disease. This is 
particularly true in Cushing's disease, as stress is an 
additional cause of hypercortisolism. Therefore, worsening 
symptoms can impact a patient's functioning, which in turn 
increases stress levels which ultimately serve to worsen 
symptoms. Therefore, the final step in any diagnostic 
pathway must include an exploration of the context in 
which the patient experiences symptoms. 
Conclusions 
The diagnosis of Cushing's disease can be enigmatic and 
elusive, but, as evidenced by the following letter from 
Minnie G to Cushing, ultimately rewarding: 
"Dear Sir: Of course, I am very sorry to trouble you 
again with letters, but I am taking advantage of your 
own words. The great pains my body is forced to 
bear can be honestly compared to the modern 
German artillery .. .. And now I have told you most all. 
I do believe sufficient amount and I ask you again, 
what can you do? There must be some palliation in 
my letters for I regard you as my best friend and 
doctor. Yours sincere ly, Minne G."7 
Cushing may have originally misdiagnosed the 
disease that bears his name, but he was a brilliant physician 
who was a frie nd to his patients. His devotion was such that 
he actually resided in the hospital to better care for his 
patients. 
The case of Minnie G thus highlights a number of the 
vital components of endocrinological diagnosis : 
• 
• 
• 
• 
A high index of suspicion . 
Careful vigilance and reassessment of diagnostic 
assumptions. 
Communication between specialists . 
Thorough histories, physicals, and diagnostic 
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workups. 
• An exceptional physician-patient relationship. 
Grouping of symptoms into a diagnosis is not an 
exact science but rather requires some of the art of medi-
cine which can recognize variableness of disease presenta-
tion within a population of interest. Harvey Cushing's 
recognition of these lessons warrants remembrance of his 
name not only in the context of hypercortisolism, but as an 
example of how we should strive to practice medicine. 
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Why statins? 
Statins, or HMG CoA reductase inhibitors, are among the 
most commonly prescribed drugs in the world today. These 
medications have been repeatedly shown to reduce low-
density lipoprotein cholesterol (LDL-C) byl9-60% depend-
ing on the statin and dose usedY In patients with existing 
coronary artery disease (CAD), statins have been shown to 
decrease incidence of non-fatal myocardial infarction, 1 
incidence of stroke/ mortality from CAD/ and all-cause 
mortality. 1 These same benefits have also been found in 
patients without CAD but with cardiovascular risk factors 
including diabetes.3 For this reason, statins are considered 
to be first line in the management of hyperlipidemia in 
patients who, according to the Framingham risk calculator, 
are at high risk for coronary artery disease as well as those 
at medium or low risk who have failed to meet lipid targets 
with lifestyle modification.4 
Adverse effects and statio intolerance 
Despite the significant effect of these drugs on mortality and 
morbidity, statins, like all drugs, have adverse effects. 
However, the HMG CoA reductase inhibitors generally have 
a favorable side-effect profile.5 The most common adverse 
effects and the primary contributors to statin-intolerance 
are muscle symptoms and creatine kinase (CK) elevations.6 
There are many definitions in the literature regard-
ing the spectrum of statin-induced muscle symptoms. One 
commonly used set of definitions, from the National Lipid 
Association (NLA) Statin Safety Assessment Task Force, is as 
follows: (1) myalgia: muscle pain or soreness, (2) myopathy: 
myalgias, weakness or cramps and CK >lOx the upper limit 
of normal, and (3) rhabdomyolysis: CK >10 000 IU/L or CK 
>lOX the upper limit of normal plus elevation of serum 
creatinine or need for intravenous hydration.6 The rate of 
statin-induced myalgia in observational studies is 10-15% 
while the rate of myopathy is 0.1-0.2%.7 Meanwhile, 
rhabdomyolysis is even less common and has been seen 
mainly when statins have been used in combination with 
fibrates or cyclosporine.7 
In the case of myopathy or rhabdomyolysis, the NLA 
task force recommends discontinuing the statin. Restarting 
the statin after these events is controversia l; nevertheless, 
there is a general consensus that the clinician must weigh 
the risks and benefits before making this decision.8 How-
ever, most patients on a statin presenting with muscle 
symptoms will fit the definition of myalgia. If these myal-
gias are intolerable, the NLA recommends discontinuing the 
statin. Meanwhile, if the myalgias are tolerable, the statin 
should be continued at the same or lower dose or a statin 
holiday may be given.6 
When patients have recurrent myalgias after taking 
a reduced dose of their statin or after restarting their statin 
subsequent to a drug holiday, alternative approaches to 
lipid management are required. This presents a challenge 
to physicians managing lipids in patients with or at risk for 
vascular disease because non-statin lipid lowering medica-
tions have not been shown to have the same robust effect on 
morbidity and mortality as statins and present their own set 
of adverse effects.5 In the recent literature, alternative statin 
regimens aimed at those who have previously been intoler-
ant to the medications have been proposed. Three such 
regimens are reviewed below. 
Modified statio therapy 
Switching the statin 
According to the Prediction of Muscular Risk in Observa-
tional Conditions (PRIMO) study, an observational trial of 
nearly 8000 unselected patients using statins in France, 
high dose fluvastatin (80mg) is associated with the lowest 
rate of muscular symptoms (5 .1 %) when compared to high 
dose pravastatin (10.9%), atorvastatin (14.9%) and 
simvastatin (18.2%).9 This had led many clinicians to 
recommend a trial of switching patients intolerant to their 
current statin to fluvastatin.5·10 While this statin is consid-
ered to be lower in potency than others/ 1 a recent trial 
showed fluvastatin 60mg reduced LDL-C by 31% and 
significantly reduced atherosclerotic plaque volume in 
patients with CADY Furthermore, fluvastatin XL has been 
demonstrated to be well-tolerated among statin-intolerant 
patients.13 
Alternate day and weekly statin dosing 
Given that atorvastatin and rosuvastatin have long half-
lives, alternate day dosing of these statins has recently been 
attempted in statin intolerant patients to reduce the risk of 
a~verse muscular effects. While tolerated by 72% of 
patients, a dose of 2.5-lOmg of rosuvastatin every other day 
in previously statin-intolerant patients has been found to 
reduce LDL-C by 34%.14 Similarly, a 23% reduction in LDL-C 
has been reported in 74% of previously into lerant patients 
now receiving once weekly rosuvastatin .15 However, these 
studies have not yet addressed whether alternate day or 
weekly statin dosing has the same effect on vascular event 
rates and mortality rates that daily dosing does. 
Statin and ezetimibe combination 
Ezetimibe is a cholesterol absorption inhibitor that has 
received a significant amount of attention since a double-
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blind study showed similar LDL-C red uctions between 
ezetimibe (lOmgjday) combined with atorvastatin lOmg/ 
16 ' th day and atorvastatin 80mgfday alone. However, even WI 
the lower dose of statin in this short trial, the combination 
therapy did not have a lower rate of musculoskeletal side-
effects and CK elevations than the high dose statin therapy. 
Further, in a more recent long-term (48 week) trial compar-
ing the safety of ezetimibe combined with simvastatin and 
simvastatin alone, there was no difference in musculoskele-
tal adverse-effects or CK levels. 17 However, a recent ran-
domized controlled trial has revealed that the combination 
of fluvastatin and ezetimibe is well-tolerated in statin-
intolerant patientsY 
Non-statio therapy 
When patients with hyperlipidemia can not tolerate any 
form of statin therapy, non-statin alternatives can be 
employed. These include fibrates, niacin, bile acid absorp-
tion inhibitors, ezetimibe, and potentially omega-3 fatty 
acids. 
Niacin 
Niacin is perhaps the most potent of these drugs and has 
been shown to raise high-density lipoprotein cholesterol 
(HDL-C) and lower LDL-C as well as, in older studies, to 
reduce cardiovascular events and mortality.18 However, the 
side effects, which include cutaneous flu shing and gastroin-
testinal upset, have limited its use. 18 Recently, there has 
been renewed interest in niacin, including ongoing trials 
evaluating mortality outcomes and investigation into 
attenuation of these side-effects. 18 
Fib rates 
Fibrates are well studied and have been found to signifi-
cantly reduce triglyceride levels and increase HDL-C levels 
while havi ng a smaller effect in reducing LDL-C levels.19'20 In 
terms of outcomes, P.Yo recent meta -ana lyses found that 
whi le currently available fibrates significantly reduce the 
odds of non-fatal myocardial infarction (Ml), they had no 
effect on cardiovascular mortality, rate of stroke, or a ll-
cause morta li ty.19•20 Adverse effects in both of these trials 
were primarily gastrointestinal, while myalgias occurred at 
the same rate as in the placebo groups. 
Bile acid and cholesterol absorption inhibitors 
Bi le acid absorption inhibitors, sim ilar to ni acin, have been 
studied mostly in older, pre-statin era trials. In these trials, 
cholestyramine, a first generation bile acid sequestra nt, 
mainly reduced LDL-C levels as well as cardiovascular 
events and mortality.21 However, again like niacin, these 
drugs have been limited by their gastrointestinal s ide-
effects such as constipation.21 A newer bile acid sequestrant, 
colesevalam, is tolerated much better by patients and 
delivers similar LDL-C reductions as the older medications, 
but no outcome data are avai lable to this point. z.z Ez~timibe 
alone has been shown to deliver modest reductions m ~OL­
e and, in two trials, has been well tolerated by patients 
intolerant to statins. 13·23 However, there is currently no 
evidence that this drug influences cardiovascular event or 
mortality rateS.24 
Omega-3 fatty acids 
Recently, there has been some interest in the role of omega-
3 fatty acids in cardiovascular disease. A large (18000 
patients), randomized trial in Japan fo und that omega-3 
supplementation (eicosapentaeonic acid 1800mgfday) 
significantly reduced triglyceride levels as well as non-fatal 
coronary events.25 However, we await replication of these 
findings in randomized double-blind, placebo-controlled 
settings. Adverse effects have included gastrointestinal 
disturba nce, skin reactions, and hemorrhage.25 
Conclusion 
Statins have been widely studied and there is robust 
evidence supporting their lipid lowering properties and 
beneficial effects on cardiovascular morbidity and mortality. 
These medications are generally safe and serious adverse 
events are rare. However, the most common side-effects 
that lead to statin-intolerance are muscle symptoms. When 
patients are unable to tolerate their current statin, there is 
some evidence to support switching to fluvastatin, less 
frequent statin dosing, or combination with ezetimibe. 
However, it is currently unclear if the mortality benefits 
associated with statins carry over to these modified statin 
therapies. If patients are unable to tolerate any form of 
statin therapy, non-statin medications may be used. 
Unfortunately, many of them are not well tolerated a nd are 
still awai ting convincing data for cardiovascular event 
benefit. Further investigation into the efficacy on cardiovas-
cular outcomes in alternate statin and non-statin regimens 
in statin-into lerant patients is required. While medications 
for hyperlipidemia may be tai lored accord ing to adverse 
effects experienced by patients as well as their particular 
lipid profile, it is important to continually emphasize the 
need for lifestyle modification including diet and exercise in 
the management of hyperlipidemia. 
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Background 
Cystic fibrosis (CF) is an autosomal recessive disease that 
occurs in one of every 3600 births in Canada.1 It is caused by 
a mutation in the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) gene which encodes a chloride ion 
channel. Derangement in chloride transport results in 
dysfunction of multiple organ systems, most notably the 
lungs. Characterized by progressive obstructive lung 
disease, the clinical course of CF is one of chronic and 
recurrent pulmonary infections leading to inflammation and 
remodeling of the airways. In addition to lung disease, the 
majority of patients also exhibit malabsorption secondary to 
exocrine pancreatic insufficiency. Whereas lung disease and 
pancreatic insufficiency typically manifest in infancy, certain 
complications tend to occur later in the course of the 
disease. Cystic fibrosis-related diabetes (CFRD) is a feature 
of CF that occurs in many patients as they reach adulthood. 
CFRD was unheard of half a century ago when CF was 
almost uniformly fata l in early chi ldhood. However, as the 
median survival age has steadily increased, to where it 
approaches 40 today/ this later onset complication is 
becoming increasingly prevalent. Only 2% of children with 
CF have CFRD but that increases to 20% of adolescents and 
half of adults above the age 30.3 Not only is the development 
of diabetes an added burden to a patient population that 
already faces a complex daily treatment regimen, it is 
associated with a decline in pulmonary function and a 
decrease in life expectancy.4•5 
Pathophysiology 
Although CFRD shares certain characteristics with both type 
1 diabetes and type 2 diabetes, it is a separate entity with a 
unique pathophysiology. As in type 1 diabetes, insulin 
deficiency is the primary defect but this is usually relative 
rather than absolute. Similar to type 2 diabetes the onset of 
CFRD is usually gradual and insidious. CFRD is classified 
under other types of diabetes, falling into the category of 
diabetes secondary to disease of the exocrine pancreas.61n 
CF, absent or aberrant function of the CFTR chloride 
channel on the pancreatic ducts leads to increased viscosity 
of digestive secretions.7 The viscous secretions obstruct the 
pancreatic ducts leading to progressive fibrosis and fatty 
infiltration of the pancreas. As a result there is a decrease in 
the number of islets as well as structural disorganization of 
remaining islets leading to loss of p-cell function .8·9 
Loss of P-cell function is a gradual process and 
patients pass through a continuum from normal glucose 
tolerance to impaired glucose tolerance and eventually 
diabetes. Impaired insulin secretion is seen in patients 
before the onset of CFRD, with alterations in the kinetics of 
insulin secretion occurring early in the disease process. 
Patients with CF without impaired glucose tolerance exhibit 
a decrease in peak insulin concentration and a delay in 
reaching peak insulin despite having normal glucose 
tolerance. 10·11 As p-cell function continues to deteriorate, 
patients show decreasing insulin concentrations and higher 
plasma glucose concentrations following an oral glucose 
load, eventually crossing the threshold into diabetesY·12 
Because the destructive process is not specific for P-cells, 
there is also damage to other cell types of the islets and 
patients with CFRD show impaired secretion of glucagon 
and pancreatic polypeptide.13 There is evidence of a relative 
increase in somatostatin secretion, which could further 
decrease insulin and glucagon release.8•14 
The role of peripheral insulin resistance in CFRD is 
not clear and the insulin sensitivity of patients is variously 
reported as normal, decreased, or even increased. Overall, 
there is insufficient evidence that insu lin resistance plays a 
major role in the pathogenesis of CFRD and whatever effect 
it does have is certainly small in comparison to p-cell 
dysfunction. 15·16 Regardless of the overall role of insuli n 
resistance in the pathophysiology of CFRD, there are 
circumstances in which patients will experience at least 
transient insulin resistance. Exacerbations of lung disease 
and use of glucocorticoids are frequent occurrences for CF 
patients. These situations lead to a decrease in insulin 
sensitivity resulting in a sharp increase in insulin require-
ments.17 
Diagn osis a nd managem e nt 
Diagnosis of CFRD is not straight forward due to the 
fluctuating health status of CF patients. Transient dysfunc-
tion of glucose metabo lism is frequent during disease 
exacerbations and as such measures of glucose metabolism 
must be interpreted in the context of the patient's current 
health.18 The diagnostic criteria for CFRD are simi lar to that 
for type 1 and type 2 diabetes except that in CFRD there is a 
further subdivision of patients depending on whether or not 
they exhibit fasting hyperglycemia. 19 
Patients with CFRD are often asymptomatic at 
diagnosis,20 which necessitates periodic screening of CF 
patients for derangements in glucose metabolism. Although 
fasting plasma glucose (FPG) is the recommended screening 
test for diabetes/ 1 its use in screening for CFRD is not ideal. 
The use of FPG as a screening test will fa il to identify the 
large proportion of patients who have CFRD without fasting 
hyperglycemia. Because an oral glucose tolerance test 
(OGTT) can identify patients with CFRD without fasting 
hyperglycemia, it is a much more sensitive test. Given that 
CF~D tends to develop in the adolescent or early adult 
penod, annua l OGTT screening beginning in early adoles-
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cence is a rational approach used in many centres to ensure 
that patients with CFRD are identified early. 18· 22·23 
In patients diagnosed with CFRD with fasting 
hyperglycemia, insulin therapy is indicated. Because many 
patients with CF have a variable appetite and meal schedule 
due to frequent illness, a basal-bolus insulin regimen 
provides needed flexibility.24 Both nutritional status and 
pulmonary function have been found to improve following 
the induction of insulin therapy.25 Currently, the best 
treatment for patients who have CFRD without fasting 
hyperglycemia is not clear. CFRD without fasting hypergly-
cemia has not been associated with acute or chronic 
complications of diabetes; therefore, patients are often not 
started on insulin therapy unless they have symptoms of 
hyperglycemia. 19· 26 However, because the CFRD associated 
decline in nutritional status and pulmonary function usually 
precedes the onset of fasting hyperglycemia, it may be 
beneficial to begin insulin therapy at an earlier stage.27 
Observational studies have noted an increase in BMI and 
improved measures of pulmonary function following the 
initiation of insulin therapy in patients without fasting 
hyperglycemia.27·28 However, the only randomized, placebo-
controlled trial to date found that although insulin therapy 
improved BMI in patients with CFRD without fasting 
hyperglycemia, there was no effect on pulmonary function 
or frequency of lung disease exacerbations.29 The potential 
benefits of initiating treatment in patients prior to the 
development of fasting hyperglycemia must be weighed 
against the concern that insulin therapy will further 
complicate the already demanding day-to-day self care to 
which a CF patient must adhere. 
Patients with CFRD are at risk of a subset of the 
acute and chronic complications that occur in patients with 
type 1 diabetes and type 2 diabetes. Beca use the patho-
physiology of CFRD results in glucagon deficiency in 
combination with residual endogenous insulin secretion, 
diabetic ketoacidosis is unexpected, and in fact has only 
rarely been reported.30·31 As in all patients treated with 
insulin, hypoglycemia is a treatment related concern. 
Despite glucagon deficiency, patients with CFRD have not 
shown an increased propensity for severe hypoglycemic 
episodes, as they are able to generate a sufficient adrenergic 
response to hypoglycemia.13 Chronically, patients with CFRD 
are at risk of developing the microvascular complications of 
diabetes. In patients who have had CFRD with fasting 
hyperglycemia for at least ten years, rates of peripheral 
neuropathy and diabetic retinopathy occur at a frequen cy 
that approaches that seen in patients who have had type 1 
diabetes for a similar duration; however, the severity of 
both complications tends to be milder in CFRD.26·32 There is 
a high prevalence of microalbuminuria in patients with 
CFRD but progression to renal failure is rare.33 Screening for 
diabetic nephropathy is complicated by the fact that many 
CF patients regularly take medications known to be nephro-
toxic and so the cause of the high frequency of microalbu-
minuria may be due to factors other than diabetes. 26•34 
Patients with CFRD do not appear to be at risk for the 
macrovascular complications of diabetes, presumably 
Cystic fibrosis-related diabetes 
because of the low frequency of hypertension and dyslipide-
mia in the CF population.32 
Due to the decreased life expectancy of patients with 
CFRD in comparison to CF patients without diabetes, the 
development of CFRD has generally been regarded as a poor 
prognostic indicator. However, the gap between the median 
survival age of CF pati ents with and without CFRD is 
beginning to narrow. Earlier diagnosi s and treatment has 
been credited with thi s improved outlook.3 This suggests 
that routine screening and early initiation of insulin therapy 
to achieve tight glycemic con trol may be important to 
prevent the development of microvascular complications 
during the longer survival period. However, there is a lack 
of randomized trials investigating the impacts of di agnostic 
and treatment strategies. Despite the increased life expec-
tancy that advances in medical care have afforded patients, 
CF remains a fatal disease. As patients approach end of life, 
the goals of CFRD treatment should presumably transition 
to controlling hyperglycemic symptoms while minimizing 
the burden of treatment. 
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Prescribing Summary 
Patient Selection Criteria 
THERAPEUTIC CLASSIACATION: Antidiabetic Agent: Long-acting Recombinant Human Insulin Analogue 
INDICATIONS AND CLINICAL USE 
LANTUS ~nsulin glargine injeclion [rONA origin]) is a novel recombinant human insulin analogue indicated 
tor once-daily subcutaneous administration in the treatment of patients over 17 years of age with Type 1 
or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. 
LANTUS is also indicated in the treatment of pediatric patients with Type 1 diabetes mellitus who require 
basal ~ong-acling) insulin for the control of hyperglycemia. 
CONTRAINDICATIONS 
LANTUS (insulin glargine injeclion [rONA origin]) is contraindicated in patients who are hypersensijive to 
this drug or to any ingredient in the formulation or component of the container. (For a complete listing, 
see DOSAGE FORMS, COMPOSITION AND PACKAGING sections of the Product Monograph.) 
SPECIAL POPULATIONS 
Pregnant Women: Teratogenic effects: Patients wijh diabetes should be advised to inform their doctor if 
they are pregnant or are contemplating pregnancy. There are no well-controlled clinical studies of the use 
of insulin glargine in pregnant women. Only a limijed number of pregnancies were exposed during Post 
Marketing Surveillance wM insulin glargine. As wM other insulins, adverse pregnancy outcomes did not 
indicate any trends suggesting a link to insulin glargine. Insulin requirements may decrease during the 
first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. 
careful monitoring of glucose control is essential in such patients. 
Nursing Women: n is unknown whether insulin glargine is excreted in significant amounts in human 
milk. Caution should be exercised when LANTUS is administered to a nursing woman. Lactating women 
may require adjustments in insulin dose and diet 
Pediabics (>6 years of age): Safety and effectiveness of LANTUS have been established in children over 
6 years of age wM Type 1 diabetes mellitus. 
Geriabics (>65 years of age): In clinical studies, the only difference in the elderly subpopulation 
compared to the entire study population was an expected higher incidence of cardiovascular events in 
both insulin glargine and NPH human insulin-treated patients. Hypoglycemia may be difficun to recognize 
in the elde~y. The initial dosing, dose increments, and maintenance dosage should be conservative to 
avoid hypog~cemic reactions. Progressive deterioration of renal function may lead to steady decrease In 
insulin requirements. careful glucose mon~oring and dose adjustments of insulin or insulin analogues 
including LANTUS may be necessary. 
Safety Information 
WARNINGS 
Hypoglycemia is the most common adverse effect of insulin, including LANTUS. As with alllnsulins, the 
timing of hypoglycemia may differ among various insulin formulations. Glucose monitoring is 
recommended for all patients with diabetes. 
Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin 
strength, timing of administration, manufacturer, type (e.g., regular, NPH, or insulin analogues), species 
(animal, human), or method of manufacture (recombinant DNA vs. animal-source insulin) may result in 
the need for a change in dosage. Concomitant oral antidiabetic treatment may need to be adjusted. As 
wM all insulins, when transferring to LANTUS, the e~y warning symptoms of hypoglycemia may be 
changed, be less pronounced, or absent The prolonged effect of subcutaneous LANTUS may delay 
recovery from hypoglycemia. 
LANTUS must not be mixed with any other insulin or diluted with any other solution. n LANTUS is 
diluted or mixed, the solution may become cloudy, and the pharmacokinetic/pharmacodynamic profile 
(e.g., onset of action, time to peak effect) of LANTUS and/or the mixed insulin may be altered in an 
unpredictable manner. 
PRECAUTIONS: General: LANTUS Onsulin glargine injeclion [rONA origin]) is not intended for intravenous 
or intramuscular administration. The prolonged duration of activ~ of insulin glargine is dependent on 
injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result 
in severe hypoglycemia. 
Hypog~cemia may occur ~ the insulin dose is too high in relation to the insulin requirement (see 
Hypoglycemia seclion below). The use of too low insulin dosages or discontinuation of treatmen~ 
especially in Type 1 diabetes, may lead to hyperglycemia and diabetic ketoacidosis. Uncorrected 
hypoglycemic or hyperglycemic reactions can cause loss of consciousness, coma, or death. 
Hypoglycemia: As with all insulin preparations, hypoglycemic reaction, especially during initiation of 
therapy, may be associated with the administration of LANTUS. Hypoglycemia is the most common 
adverse effect of insulins. Ea~y warning symptoms of hypoglycemia may be differen~ be less pronounced 
or absent under certain conditions, as for example, in patients whose glycemic control is markedly 
improved, in elderly patients, in patients where an autonomic neuropathy is present, in patients whose 
hypoglycemia is developing gradually, in patients with a long history of diabetes, in patients with 
psychiatric illness, or in patients receiving concurrent treatment with certain other drugs such as beta· 
blockers. Hypoglycemia may occur wM other substances including alcohol and psychiatric medications, 
street drugs, birth control pills, injeclions and patches (see DRUG INTERACTIONS, Drug-Drug 
Interactions). Such situations may result in severe hypoglycemia (and possibly, loss of consciousness) 
prior to patients' awareness of hypoglycemia. 
The time of occurrence of hypoglycemia depends on the action profile of the insullns used and may, 
therefore, change when the treatment regimen or timing of administration is changed. 
As wM all insulins, additional caution (including intensified blood glucose monijoring) should be exercised 
in patient populations who are at greater risk for clinically significant sequelae from hypog~cem ic episodes. 
Injection Site and Allergic Reactions: As wM any insulin therapy, lipodystrophy may occur at the 
Injection site and delay insulin absorption. Other injection sije reactions with insulin therapy include 
redness, pain, itching, hives, swelling, and inflammation. Continuous rotation of the injection site within a 
given area may help to reduce or prevent these reactions. Most minor reactions to insulins usually resolve 
in a few days to a few weeks. 
Immediate-type allergic reactions are rare. Such reactions to insulin (including insulin glargine) or the 
excipients may, for example, be associated wM generalized skin reactions, angioedema, bronchospasm, 
hypotension, or shock and may be l~e-threatening. 
ADVERSE REACTION SERIOUSNESS AND INCIDENCE (see full listing) 
Type 1 and Type 2 Diabetes in Adults: The adverse events most commonly associated wM LANTUS 
(insulin glargine injection [rONA origin]) include the following: Body as a whole: allergic reaction; 
Hypoglycemia; Skin and appendages: injection site reaction, lipodystrophy, pruritus, and rash; Other: 
antibodies formation; Eyes: A marked change in glycemic control may cause temporary visual 
impairment, due to temporary alteration in the turgidijy and refractive index of the lens. 
Type 1 Diabetes in Children and Adolescents: Study 3003: The most commonly reported event was 
lipodystrophy, a known consequence of insulin injections. The intensijy was mostly mild. Injection sije 
events were assessed as possibly related in 9 (5.2%) LANTUS subjects and 5 (2.9%) human NPH 
subjects. However, none of these subjects discontinued due to these events. 
Study 3013: Extension of Study 3003, uncontrolled long-term follow-up study of 143 patients who were 
well controlled on LANTUS from 3003, for 201-1159 days. The most common adverse events were upper 
respiratory infections, infection, and rhinitis. Note that when comparing safety findings between studies, 
the difference in length of exposure needs to be kept in mind. 
Study 4005: Controlled, randomized, double-crossover. 26 subjects (age range 12-20), regimen of LANTUS 
+ lispro vs. human NPH +human regular. Adverse events were equally distributed between the two treatment 
regimens. The most common adverse events were upper respiratory tract infection and gastroenteritis. 
To report an adverse event, contact Canada Vigilance by toll-free telephone: 1.866.234.2345, toll-free fax: 
1.866.678.6789, online: www.healthcanada.gc.ca/medeffect, or email: canadaVigilance@hc-sc.gc.ca; or 
contact sanofi-aventis Canada Inc., Laval, Quebec H7L 4A8, at 1.888.852.6887. 
Administration 
Dosing Considerations: LANTUS (insulin glargine injection [rONA origin]) is a novel recombinant human 
insulin analogue. Its potency is approximately the same as human insulin. n exhibits a glucose-lowering 
profile with no pronounced peak with a prolonged duration of action that permijs once-daily basal dosing. 
LANTUS is administered subcutaneously once a day. n may be administered at any time during the day 
as long as it is administered at the same time every day. 
The desired blood glucose levels as well as the doses and timing of antidiabetic medications must be 
determined and adjusted individually. 
Dose adjustment may be required, for example, if the patient's timing of administration, weight or l~estyle 
changes or other circumstances arise that increase susceptibility to hypoglycemia or hyperglycemia (see 
WARNINGS and PRECAUTIONS, Hypoglycemia). The dose may also have to be adjusted dunng Intercurrent 
illness (see WARNINGS and PRECAUTIONS, Intercurrent Conditions). Any change in insulin dose should 
be made under medical supervision. 
The prolonged duration of activity of LANTUS is dependent on injection into subcutaneous space. LANTUS 
is not intended for intravenous or intramuscular administration. Intravenous adm1mstration of the usual 
subcutaneous dose could result in severe hypoglycemia (see WARNINGS and PRECAUTIONS). 
In cases of insufficient glucose control or a tendency to hyper· or hypoglycemic episodes, pa~ent's 
compliance with the prescribed insulin regimen, injection ffies and proper injection techniques, the handling 
of injeclion devices and all other relevant factors must be reviewed before dose adjustment IS conSidered. 
Blood glucose monijoring is recommended for all patients wM diabetes. . . . 
LANTUS must not be used for the treatment of diabetic ketoacidosis. Intravenous short-actmg msuhn 
should be the preferred treatment. 
Recommended Dose and Dosage Adjustment Initiation of wmJS therapy: In clinical studies with 
insulin-naive patients with Type 2 diabetes, lANTUS was started at a dose of 10 U once dai~. and 
subsequently adjusted according to the patient's needs [see CLINICAL TRIALS section of the 
Product Monograph). 
Changeover to LANTUS: When changing from a treatment regimen with an intermediate or long-acting insulin 
to a regimen with LANTUS, the amount and timing of short-acting insulin or fast-acting insulin analogue or 
the dose of any oral antidiabetic drug may need to be adjusted secondary to the risk of hypoglycemia. In 
clinical studies when patients were transferred from once-daily NPH human insulin or ultralente human 
insulin to once-daily LANTUS, the initial dose was usually not changed. 
However, in studies when patients were transferred from twice-daily NPH human insulin to LANTUS once 
daily, the initial dose (U) was usually reduced by approximately 20% [compared to total daily U of NPH human 
insulin) and then adjusted based on patient response. 
A program of close metabolic monijoring under medical supervision Is recommended during transfer and in 
the initial weeks thereafter. The amount and timing of short-acting insulin or fast-acting insulin analogue may 
need to be adjusted. This is particularty true for patients with acquired antibodies to human insulin needing 
high-insulin doses and occurs with all insulin analogues. Such patients may experience a greater insulin 
response to LANTUS. 
Wrth improved metabolic control and resu lting increase in insulin sensijivity, further adjustment of the dose 
of lANTUS and other insulins or oral antidiabetic drugs in the regimen may become necessary. 
Administration: LANTUS is administered by subcutaneous injection. The injection area must not be rubbed. 
As with all insulins, injection sites within an injection area [abdomen, thigh or deltoid) must be alternated from 
one injection to the next Patients should be rigorous with site rotation secondary to prolonged deposijion.ln 
clinical studies, there was no relevant difference in insulin glargine absorption after abdominal, deltoid, or 
thigh subcutaneous administration. As for all insulins, the rate of absorption, and consequently the onset and 
duration of action, may be affected by exercise and other variables. 
Preparation and Handling: LANTUS is a clear solution, not a suspension. 
Parenteral drug products should be inspected visually prior to administration whenever the solution and the 
container perrnit. l.ANTUS must only be used ~the solution is clear and colourtess with no particles visible. 
To minimize local irrijation at the injection sije, it is recommended to allow the insulin to reach room 
temperature before injection. 
Cartridge version only: ~ the injection pen malfunctions, LANTUS may be drawn from the cartridge into a 
U 100 syringe and injected. A new sterile syringe must be used. 
Mixing and Diluting: LANTUS must not be mixed with any other insulin. Mixing can change the time/action 
profile of LANTUS and cause precipitation. 
LANTUS must not be diluted. Diluting can change the time/action profile of l.ANTUS. 
LANTUS [insulin glargine [rONA origin]) 100 unijs per mL [U 100) is available in the following package sizes: 
• 1 0-ml vials. 
• 3-ml cartridges in package of 5, for use wijh injection pens suitable for lANTUS cartridges as 
recommended in the information provided by the injection pen manufacturer only. 
• 3-ml SoloSTAR' (pre-filled disposable pen), package of 5. 
Supplemental Product Information 
PRECAUTIONS 
HepaticiBillary/Pancreas: Alllwgh srudies have ool been performed n patJeots wllh diabe1es illd hepatic rnpalrmen~ lNffiJS 
r~ may be dlmr.tmed due to re<iJced capacity lor ~ucooeogeoesls and reruced hwf11 melabollsm. 
Immune: nsuin admijsbaUor may causa lrlSlJiil ~ to lorm. n dlrkal stOOies, antilodles lhal aoss-react wllh 11Jma1 klsuin and 
iWn g~;rg~~e W!l'e OOserved n bolh NPH lllman nsuin illd iWil pgile trealmert ~ wllh smila' pe-cerrtages r1 ix:reased illd 
decreased lAres. TlliJe was oo cooelaUor n eilhEJ treallnoot gr~ bei'M!el1 roeases or decreases n these a1tDldy ~~res illd dlanges n 
elltoer A 1 c or trolllnsUil re<JJrements. n limy, llwl presence r1 su:h iWn lllllbolfe may re:ess1tate adjustment ol llwl W&Jin dose ~ or1ler 
ID cooed a temerq 10 hyperglycem~ or hypoglycemia, bUt has oo1 been IIUld on review ol lNffiJS dlrkal trials illd available 
~data. 
ln1ercunen1 Coodltlons: i'aJi1 r~ may be aftered !Lmg rrterwrent antllons su:h as i'llectirl or itJess, emotiroal 
llsbJtmces, or slress. 
Renal:~ s1001es have oo1 been pel1ormed In patients wllh dlabeles and rmallmpalrment.WffiJS requremeo~ may be drnilisl'ed 
we ID reruced mJii1 metabalsm Ca-elul ~ monilorilg illd dose ad~ olhsl*' or iWil anaklgues ndUdilg lNffiJS may 
be nece5Sily il patients wllh rerel ~ 
As wllh all nsuln preparatilns, llwl ume COtKSe r1WffiJS acUor may vary In llf!erent lndMduals or at dilferent Urnes n llwl same ndvlrual 
and !lwl rate o1 aJsorp11on ~ deperllen1 on bkiod supp~, lemperatr.re, and physl:al aellvity. 
lnsutrl may I3.ISe illdl.m re1errt1on and edema. partiWarly H prevloostj poor melabollc cootr~ ~ rnproverl by inlensllled lnsiJn itlerapy. 
Pabenls wlllii.Jnm mJifl antibodies may be hyperSenlillw ID other i1sulins, wllh a rlsl< olllypol#ern~ anrlfor aoss-reaellvity. 
In a dlnlcal sluay, symptoms d llypol#em~ or COLiller reg<Aatory hormone responses were similar after lntraverous lnsiJin glarglne illd 
regtJar II.Jman l1sulin bolh In healthy subjects and adutt patlerrts wllh Type 1 diabeles. 
When lNffiJS illd r~ ht.mM 1nsu1n were mixed kn~lely belore <iecUor n dogs, a delayed onset ol acUor illd time lo maxrnum 
eflecllor regtJar 1una11 iWil was OOserved. The troll bloavallabllty ol llwl mi>Ue was also slijrlly decreased r:ornpa-ed to sepa-ate 
frietiDls ollNffiJS illd regula' tunan nsulin. The relevance olltlese observa!lons n 001JS ID ii.Jmi!IIS ~ oo1 krov.lt 
AOVEIISE REACTIONS 
Mverse ewms lhal or:aned il a pediatric oorrlroled 1m! il at least 1 'II r1 patients treated with lNffiJS are sto.\!1 n T<m~ 1. 
Table 1 Ad'lem Eve~ by Body System ~1% Reported In Study 3003. (Percent IncidenCe) 
· Number (%) ol Subjects 
Adveru Even! (diagnosis) lNffiJS 1itJr1M NPH 
Body System/Coded Tenn n= 174 n= 175 
Body as a whole 
24(13.8) 31 (17.7) i'llectirl 5(2.9) 4(2.3) Accklerllalinj.Jy 
2(1.1) 2(1.1) /obOOmnal pain 
2(1.1) -H Allergic reaction 
-H 30.7) Flls,Monle 
2(1 .1) - (-) Pail in extremity 
Digestive system 
8(4.6) 10 (5.7) Gastroenteritis 
2(1 .1) 2(1.1) Oia1toea 
2(1.1) - (-) Sore llvoat 
Endocrine symm 
1 (0.6) 4(2.3) Oialleles mellius 
Injection si1e ructions 
8(4.6) 6 (3.4) (ieellonsitemass 
(ieellonsitereaellon 5(2.9) 6 (3.4) 
llldllo site hemorrhage 2(1 .1) 20.1) 
Metabolic and nutritional dlsorde!S 
3(1 .7) 7(4.0) H)1logt,-cemkreaellon' 
~~ 1 (0.6) 3(1.7) 
Kelosls 1 (0.6) 5(2.9) 
~ 3(1 .7) 2(1.1) 
Mtrswloskeletal system 
3(1.7) 3(1.7) Bone lrai:Ue (rot S!lQr'daneOOS) 
Bonerlsorder 2(1 .1) -(-) 
Nervous system 
6(3.4) 5(2.9) Headadle 
Resplra1Dry system 
24(13.8) 28 (16.0) t.WEr respi'alory i'llectirl 
f'har)IYlilis 13(7.5) 15(8.6) 
ltlnltls 9(5.2) 9 (5.1) 
Bronr:hltls 6(3.4) 7(4.0) 
SftJsl1is 5(2.9) 5 (2.9) 
Asllrna 1(0.6) 2(1 .1) 
Cooitlix:reased 3(1 .7) -H 
Skin and appendages 
ftrogaldertnati15 1(0.6) 2(1 .1) 
Sklnberql~ 1 (0.6) 2(1 .1) 
Eczema 2(1 .1) 1 (0.6) 
Herpes mrur 2(1 .1) 1 (0.6) 
ll1ic3il 2(1 .1) -H 
• 101-serixrs h)!xlglytem~ eplsOOes ara reprted separalely. 
Patlerrls In !lwl pedia!Jic dllical trials r1WffiJS 1'1!1'1 trealed wllh a 11Jma1 NPII-based r~ presludy, and patlerrls asslplto receive 
human NPH clmg !lwl s1uay lle!FJ1 s1udy trea1mert on h same tunan NPH regimen they had tMI prBSlUdy.Tlis may have been a lactor 
n ""' roeased lnckleoce r1 ~~ seen n lAHTIJS-trealed patierts clmg lbUI oot ~~ ritiaJ tilrm1 n these trials, as M 
roease ~ hypoglycemia may be expecled when switdlilg from one nsulil to anohir and tib'aliri;J llwl dose ct llwl new ilsulil. 
Injection Site: Reportsr1 rjection sitepalnwere more~81J,en1v.flh lNffiJS lt1an NPH II.Jman i1Sl.i1 (2.711 nsutlnglargl'le vs. O.llltunan 
NPH). The rep<IIS o1 pain at !lwl llldllo site 1'1!1'1 LW!Iy mid illd rid not resun n rlisalriilraliln r11herapy. Other posslllf nelated 
treatment~ (ieCIIon site rear:1lorls or:aned a1 similar nddences wllh both iWn ~ illd NPH II.Jman lnsulil. 
Eyes: Long-term Improved !1Yeemlc con1ro1 decreases llwl r1s1< r1 ~ r1 dllbetlc relincJ!lalhy. However, as lor all nsun regknens, 
ilteoslllca!lon o1 iWin 111erapy wllh a1rup1 knprovement n !1Yeemic corto1 may be associated v.flh temporary worsenilg ct 
dllbetic retiqmhy. 
n patients wllh prolferalive retilopalhy, par1iculartf K ootlreated With ~ severe h)!xlgt,-cemk episodes may reSlit n 
l1anSieol amaurosis. 
Retlnopalhy was evaluated n llwl drkal sWes by means d reliral adveBe events reprxted illd hlldus ptotography. The rllmbers ol retilal 
adVerse everis reprted lor lNffiJS illd tunan NPH treatment~ 1'1!1'1 sknllar lor patients v.flh Type 1 and Type 2 diabetes. i'ro!resslon 
ol relnlpalhy was nvestlgaled by luW; ~U!ilg a plilg protocol derived from llwl Early Treatmeol 0~ Relirqlalhy SMiy 
(ETDRS). In one rftllcal s1Udy lnllllltlg patlerrls wllh Type 2 diabeles, a llf!erence In llwl rmber ol subjem wllh 23-step progression In ETllRS 
sc3e over a &-monl!l period was noled by hlldus ~ (7 5'111 n lNffiJS Qrot.ll vs. 2.7'111 n human NPH treated 9rrll.lll-The owrail 
relevance ollhls isolated lillir9 omo1 be determr.ed we iD llwl smal ntlrlber o1 patients ilvol.-ed. llwl stmlollow-141 perbd, illd llwl lac! 
tllallhls llndi1g was oot observed n other diical studies 
DRUG INTERACTIONS: A rvrnber ol Sl.lls1aA::es allecl gl.alse melabollsm illd may reiJ)ie lnsuil'l dose ac!ustmeol and particularly 
OOse mriorlng. 
Orug-Orug ln1eractlons: Substances that may Increase the blood-glucose-lowering effect end susceptibility to hypoglycemia, 
lor emple. oral ~ jXOOtdS, ta W1ililors. ~. !bates, !Ulxetlne, t.Wl ilhllitors. pentoKifyli:le, propoxjltlene, 
salicylates, malostllln analogue (e.g , octreotlde). sullonamlde lllllbkltlc1 
Substances that may rt<luce tha blood-glucose-lowering effect. lor example: cortlco5terolcls, danalol, rjazoxlde, dliletlcs, 
sympalhlmlmetlc agtrrts (eg ., ~. sa11utamo1. terOOilllne), ~- i!mlazil, pheooiNazile derlvalives, scrnalro!*l. lh)roil 
hormones, eslrogeoS, progestogeos (e g. n oral corrtrar:eptlves), protease ilhllitors and atypical antlpsyctotlc medlcatOOs (e.g., IJiivllajb 
illdcklmplne) 
Bela-bklckers, cton~ine . littium salts, and alcoOOI may eilher poleotiate or weaken llwl blood-glucose-lowerilg eHecl o1 ilsull\. Penlam~ne 
may cause h)!xlgt,-cem~. wtW:h may sometimes be lolklwed by hypergt,-cemla. n addiUor, ll1der llwl i1l'lleoce r1 sympatrolytlc medicinal 
prociJcts such as beta-llklckeffi. donldile, gwnethldine, and~- llwl signs ol hypoglycem~ may be rerM:ed or <ilsen1. 
Other lnteracUons: lnleractklns wllh lood, OOrtlal proWcts, and laborat~r~ t~ have oot been eslabllshed. 
OVERDOSAGE: Symploms: An excess ollnsulil relative to lood ntake, energy e)(jlerlditlre or both may ~ to severe illd sometim!IS 
prolorY,jed illd lde-ltreatenlr.J hypoglycemia (see WARNINGS illd PRECAUTIONS). 
Management Mild episodes d h)!xlglycem~ can uswlly be ~ealed v.flh oral carbohydrates. AlfitJStmeols In aug dosage, meal patterr6, or 
exercise may be needed. 
More severe episodes wil!1 coma. seizura, or netlOilglc rnparmenl may be treated wllh lntramusariar/suliaJtnlous gkrcagon or 
r:orcentrated ntraverous gU:ose. 
Alter apparent dkllcai reoovery from h)!xlglytemla, oonlilled obsavaliJl illd additilnal r:albol1ylhle Intake may be necessary to a-QI 
reor:wrence ol h)!xlgt,-cemla. 
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Prescribing Summary 
Patient Selection Criteria 
THERAPEUTIC CLASSIFICATION: Antidiabetic Agent: Short-acting Recombinant 
Human Insulin Analogue 
INDICATIONS AND CLINICAL USE: 
APIDRATlo! (insulin glulisine [rONA origin]) is a recombinant human insulin analogue 
indicated for the treatment of adu~ patients with Type 1 or Type 2 diabetes mellitus 
where treatment wtth insulin is required. 
APIDRATlo! has a more rapid onset of action and a shorter duration of action than 
regular human insulin. APIDRATlo! should normally be used in regimens that include 
a longer-acting insulin or basal insulin analogue to maintain adequate glucose 
control (see ADMINISTRATION, Dosing Considerations). API ORA'" can also be used 
wtth oral hypoglycemic agents. 
CONTRAINDICATIONS: 
APIDRATlo! (insulin glulisine [rONA origin]) is contraindicated in patients who are 
hypersensitive to this drug or to any ingredient in the formulation or component of 
the container. (For a complete listing, see DOSAGE FORMS, COMPOSITION, AND 
PACKAGING section of the Product Monograph.) 
SPECIAL POPULATIONS 
Pregnant Women: 
There are no well-controlled clinical studies of the use of APIDRA'" in pregnant 
women. Animal reproduction studies have not revealed any differences between 
APIDRA'" and human insulin regarding pregnancy, embryonaVfetal development, 
parturition, or postnatal development. 
It is essential for patients wtth pre-existing or gestational diabetes to maintain good 
metabolic control before conception and during pregnancy. Insulin requirements may 
decrease during the first trimester and generally increase during the second and third 
trimesters. Immediately after delivery, insulin requirements decline rapidly. 
Careful monttoring of glucose control is essential. 
Patients wtth diabetes must infomn their doctor if they are pregnant or are 
contemplating pregnancy. 
Nursing Women: 
It is unknown whether APIDRATlo! is excreted in human milk. Many drugs, including 
human insulin, are excreted in human milk. For this reason, caution should be 
exercised when APIDRATlo! is administered to a nursing woman. Lactating women may 
require adjustments in insulin dose and diet. 
Pediatrics: 
Safety and effectiveness of APIDRA'" in pediatric patients have not been established. 
Geriabics (~ 65 years of age): 
Hypoglycemia may be difficu~ to recognize in the elderly. In Phase Ill clinical trials 
(rr-2,408), APIORAllo! was administered to 147 patients~ 65 years of age and 27 patients 
~ 75 years of age. The majortty of these were patients wtth Type 2 diabetes. The 
change in glycated hemoglobin (A1C) values and hypoglycemia frequencies did not 
differ by age, but greater sensitivtty of some older individuals cannot be ruled out. 
Safety Information 
WARNINGS AND PRECAUTIONS 
General 
APIDRATlo! differs from regular human insulin by tts rapid onset of action and shorter 
duration of action. When used as a mealtime insulin, the dose of APIDRA'" should 
be given wtthin 15 minutes before or wtthin 20 minutes after starting a meal. 
Because of the short duration of action of API ORA'", patients with diabetes also 
require a longer-acting insulin or insulin infusion pump therapy to maintain 
adequate glucose control. 
Hypoglycemia may occur if the insulin dose is too high in relation to the insulin 
requirement (see Hypoglycemia section). The use of too low insulin dosages or 
discontinuation of treatment, especially in Type 1 diabetes, may lead to 
hyperglycemia and diabetic ketoacidosis. Uncorrected hypoglycemic or 
hyperglycemic reactions can cause loss of consciousness, coma, or death. 
Any c~a.nge of i~sulin should be made cautiously and only under medical 
superv1s1on. As With other insulins, additional caution should be exercised in 
patients with a long history of diabetes on insulin who might be prone to develop 
hypoglycemia and in patients with a previous history of cardiac ischemic 
~isorders who might be prone to develop cardiac adverse events. Changes in 
msul!n stre~gth , manufacturer, type (e.g., regular, NPH, or insulin analogues), or 
spec1es (ammal, human), or method of manufacture (recombinant DNA versus 
animal-source insulin) may result in the need for a change in dosage. 
Concomitant oral antidiabetic treatment may need to be adjusted. 
As with all insulin preparations, the time course of APIDRA'" action may vary 
in different individuals or at different times in the same individual and is 
dependent on site of injection, blood supply, temperature, and physical activity. 
Adjustment of dosage of any insulin may be necessary if patients change their 
physical activity or their usual meal plan. 
Glucose monitoring is recommended for all patients with diabetes. 
Hypoglycemia 
As with all insulin preparations, hypoglycemic reactions may be associated wtth 
the administration of APIDRATlo!. Early warning symptoms of hypoglycemia may be 
different, be less pronounced or absent, under certain condttions, as for example if 
glycemic control is markedly improved, if hypoglycemia is developing gradually, in 
elderly patients, in patients with a long history of diabetes, in patients with diabetic 
nerve disease, in patients using some medications such as beta-blockers, or 
intensified diabetes control (see DRUG INTERACTIONS). Such sttuations may result 
in severe hypoglycemia (and possibly, loss of consciousness) prior to patients' 
awareness of hypoglycemia. 
Severe hypoglycemia may require the assistance of another person. Patients who 
are unable to take sugar orally or who are unconscious may require an 
intramuscular/subcutaneous injection of glucagon or should be treated wtth 
intravenous administration of glucose by medical personnel. Without immediate 
medical help, serious reactions or even death could occur. 
Hypoglycemia is the most common adverse effect of insulin therapy, including 
APIDRA'". As with all insulins, the timing of hypoglycemia may differ among various 
insulin formulations. 
The time of occurrence of hypoglycemia depends on the action profile of the 
insulins used and may, therefore, change when treatment regimen is changed. 
ADVERSE REACTION SERIOUSNESS AND INCIDENCE (see full listing): 
Adverse events commonly associated with human insulin therapy include 
the following: 
Body as a Whole: 
Local Allergy 
As with other insulin therapy, local allergy in patients may occur as redness, 
swelling, or itching at the site of insulin injection. These minor reactions usually 
resolve in a few days to a few weeks. In some instances, these reactions may be 
related to factors other than insulin, such as irritants in a skin-cleansing agent or 
poor injection technique. 
Systemic Allergy 
Less common, but potentially more serious, is generalized allergy to insulin, 
which may cause rash (including pruritus) over the whole body, shortness 
of breath, wheezing, reduction in blood pressure, rapid pulse, or sweating. Severe 
cases of generalized allergy, including anaphylactic reactions, may be 
life-threatening. 
Localized reactions and generalized myalgias have been reported with the use of 
cresol as an injectable excipient. 
Hypoglycemia: 
Hypoglycemia, a frequent adverse reaction to insulin therapy, may occur if the 
insulin dose is too high in relation to the insulin requirement. 
As with all insulins, prolonged or severe hypoglycemic attacks, especially if 
recurrent may lead to neurological damage, loss of consciousness, coma, or death. 
Skin and Appendages: 
As with other insulin therapy, lipodystrophy may occur at the injection site and 
delay insulin absorption. Continuous rotation of the injection site within a given 
area may help to reduce or prevent these reactions. 
To report an adverse event, contact Canada Vigilance by toll-free telephone: 
1-866-234-2345, toll-free fax: 1-866-678-6789, online: www.healthcanada.gc.c/ 
medeffect, or email: CanadaVigilance@hc-sc.gc.ca; or contact sanofi-aventis 
Canada Inc., Laval, Quebec H7L 4A8, at 1-888-852-6887. 
Administration 
Dosing Considerations 
The dosage of APIDRA"' should be individualized and determined based on the 
physician's advice in accordance with the needs of the patient. 
APIDRA"' (insulin glulisine [rONA origin]) is a recombinant human insulin analogue that 
has been shown to be equipotent to human insulin. One unit of APIDRA"' has the same 
glucose-lowering effect as one unit of regular human insulin. After subcutaneous 
administration it has a more rapid onset and a shorter duration of action. 
APIDRA"' should be given by injection within 15 minutes before or within 20 minutes 
after starting a meal. APIDRA111 should normally be used in regimens that include a 
longer-acting insulin or basal insulin analogue. 
APIDRA111 is intended for subcutaneous administration by injection and for use as 
a continuous subcutaneous insulin infusion (CSII) in pump systems suitable for 
insulin infusion. 
APIDRA"' should be administered by subcutaneous injection in the abdominal wall , 
the thigh, or the deltoid, or by continuous subcutaneous infusion in the abdominal 
wall. As with all insulins, injection sites and infusion sites within an injection area 
(abdomen, thigh, or dettoid) should be rotated from one injection to the next. 
As for all insulins, the rate of absorption, and consequently the onset and duration of 
action, may be affected by injection site, exercise, and other variables. Blood glucose 
monitoring is recommended for all patients with diabetes. 
Preparation and Handling 
APIDRA111 must only be used if the solution is clear, colourless, with no solid particles 
visible, and if it is of a water-like consistency. To minimize local irritation at the injection 
site, it is recommended to allow the insulin to reach room temperature before injection. 
The instructions for using the APIDRA111 in a pump or with an injection pen must be 
followed carefully. 
An empty vial or SoloSTAR3 must never be reused and must be properly discarded. 
Vials 
Before withdrawing insulin from the vial for the first time, remove the plastic 
protective cap. 
Do not shake the vial vigorously as this may cause frothing. Froth may interfere with 
the correct measurement of the dose. 
Mixing of lnsulins: 
APIDRA'" can be mixed with NPH human insulin (except when administered with 
pump [see below, Continuous Subcutaneous Insulin Infusion Pump]). 
If APIDRA™ is mixed with NPH human insulin, APIDRA™ should be drawn into the 
syringe first. Injection should be made immediately after mixing. 
No data are available on mixing APIDRA™ with insulin preparations other than NPH 
human insulin. 
Mixtures should not be administered intravenously. 
Continuous Subcutaneous Insulin Infusion Pump 
APIDRA™ may be used for continuous subcutaneous insulin infusion (CSII) in pump 
systems suitable for insulin infusion. 
When used with an insulin infusion pump, APIDRA'" should not be mixed with any 
other insulin or diluted with any other solution. 
Patients using CSII should be comprehensively instructed on the use of the system 
pump. The infusion set and reservoir should be changed every 48 hours using 
aseptic technique. 
Patients administering APIDRA'" by CSII must have an alternative insulin delivery 
system available in case of pump system failure. 
Supplemental Product Information 
WARNINGS AND PRECAUTIONS 
HepaUc/81/lary/Pancms SI!Jdles have oot been pert(J111ed ~ palieflls with hepatic lmpalnnent. APIORA" requirements may be 
diminished due to reOOced capacity lor gluconeogenesis and reduced lnsul~ me1allol~m. ~mlm lo observalloos found with otoor lnsulins. 
lntercu~nt CondiUons Insulin requwements may be altered dur~g Illness, emotional d~turbances , or stress. 
IIISulin Pumps 
Wllen used In an external insulin pump tor subcutaneous lntuslon, APIDRA" should not be mixed wltll any other Insulin or 
diluted wltll any otller solution. Patients usng external pump ln1usioo therapy Shou~ be trained apprupnately. Physicians and 
patients s/iookl careful~ eval.rale ln1ormalloo or1 pomp use In the APIORA" Prodocl Mooograpll, pad(age Insert, and the pomp 
maoofac1Urer's manual. 
APIORA" specillc ln1ormabor1 smuld be lolklwed lor perkld of use, frequency ol ctw.glng lntuslorl sets, or other delal~ specific to 
APIORA" usage, because APIORA" specilk iltormatlorl may lfrtfer trom general or other ~sulln's pump manual lnstructlorls Pump or 
ln!usioo set mallt.netioos or nsulin degradalloo can lead to hyperglycem~ and ketosb In a short tlme. Th~ ~ especial~ pertinent lor 
rapld·acting Insulin analogues that are more rapid~ absorbed and have a shorter duralloo ol aclloo. Prompt ldentfficallorl and 
correciX!n olthe cause of hyperglycemia or kelo~s ~ necessary. Interim therapy wrtll subcutaneous lnjeclloo may be required (see 
ADMINISTRATION, Continuous StJbaJianeous lnsulli ln1u~n Pump). 
Renal The p!latmacoklnetlc properties ol APIORA" were general~ malnlaloed In subjects with renal Impairment However, as with all 
lnsullns, the requirements lor APIORA" may be reduced ~ patlenls with renal lmpalnnent. 
Occupational Hazards The pallenfs ability to cooceotrale and react may be Impaired as a restJII ot hypog~cemla or hyperglycem~ 
or, lor examp~. as a resun ol Yisuallmpalnnent This may aJOS!rtute a r~k In ~alloos where these abll1ties are ot special importance 
(e g , drMng a car or operating machinery). 
Patients Should be ad'llsed In lake precauUons to avoid hypoglycem~ Will~ driY~ Th~ ~ partlcularly Important in those who have 
reduced or absent awareness ollhe lmling symptoms ot hypoglycem~ or have kequeot episodes ot hypoglycemia. n sOOukl be 
ronsJdered wllelher n Is advlsab~ to drive or operate machinery In these c~rumstances 
ADVERSE REACTIONS . . • The risk o1 all categortes ot symptomatic hypog~cem~ did not differ betWeen APIORA and shorl·acting nsulin comp;ntors In 
subjects with Type I or Type 2 diabetes. 
l ble 1 N bel of subjects with at leas! one episode a1 symptomatic hypogtycemla in studies In type 1 and type 2 dlalfts a - um 
-Tille 1 Diabetes !We 2 Diabetes 
Glulislne Comoatator* Glullsine Com! ratof 
n/N 
"' 
n/N 
"' 
n/N % n/N % 
StJbcutlneous lnlectlon 7831921 85.0 5161611 84.5 5621883 63.6 5781883 65.5 
Con!Jnuous' Subcutaneous 26129 89.7 24130 80.0 
ln1uslon 
-11 =number ol subjects with at least 1 episode ol hypoglycem~ N- total number ol evaluable m subjects. 
• lnsu l~ l~pro , regu~r human lnsu l~ t regu~ human lnsul~ ; Insulin aspart 
ourlng dinlcal si!Jdles, there were oo dlnlcally noteworthy differences betWeen Insulin glul~ine and comparator 500rt·acting lnsulins 
1n the overall Incidences ol adverse events. The adverse events observed were those known In this p!latmacological class and 
CMseQtJefllly commor1 to nsulins. 
T ble 2 Com (~ 1%) advem drug ructions In pooled type 1 and 2 studies a - mon 
Advem Event lnsul~ Glullslne Uspro Regular Insulin Aspart (all studies) n=333 ~1 ,1 61 n=30 
System orvan ClasS/ 1%:~) (% of subjects) (% of subjects) (% of subjects) Pre~Tenn 
General Disorders and 
~~~:dltlon In siteh 910.51 
Metabolism and Nutrition Disorders 
Hypog~cem~ NOS' 83(4.5) 
~::~~~seizure 116t~i~ cern~ unawaoeness 
Nervous Syttem DISO<Hrs 
Hypog~cem~ coma 49 (2.7) 
Less Common Clinical Tltal Adverse Drug Ructions (<1!'1 
Gastrointestinal disofdeB: nausea 
712.11 -(-) -H 
33(2.8) 2 (6.7) 22 (6.6) 
:g:~l 9~~~~ - (-) 2(6.7) 
13 (3.9) 19(1 .6) -H 
General disorders administration &Ill conditions: fatigue, ~eclloo site reactilorl NOS', ~eral edema, as1tlenla, llcreased fat 
tissue, lnjectklnsitestlnglng 
ln1ectlons and ln1estatlons: ce~lrlis 
Injury, poisoning, and procedural (complications): overdose NOS' 
Metabolbm and nutrition dlsorden: hyperglycem~ NOS' 
Nerwus system d~ders: par~ 
Skin and subcutaneous tissue dltorders: lipodystrophy acquired 
• Not otherwise ~ 
DRUG INTERACTIONS: 
Onrg·Orug lntmctions The lol~wtng are examples ot potential drug-drug Interactions that may OCctJr with APIORA" treatment: 
Table 3- Established or potentlal dnrg·dnrg Interactions 
Proper name Ref Effect Cllnkal comment 
Oral antidiabetic agents T May enhance the blOod· May require dose monnonng ot blood 
ACE Inhibitors glucose·~werlng etfect glucose level and dose ad)ustmern (reduction) 
O~yramlde and lrlcrease susetptlbllity ot APIORA" 
Flbrates to hypoglycem~ 
Auoxetlne 
MADinhiMors 
Pentoxitylllne 
Propolf)llhene 
Sallc)1ales 
sunor1amlde li'rtlblotlcs 
Cor11costerolds T May reduce the blood- May require dose monnortng ot blood glucose 
Oanazol glucose·klwerlng etfed. level and dose adjusment (Increase or 
Olazoxlde May enhance or dectease decrease) ot APIORA" 
Okretlcs the nsulin requirements 
GlucagM 
Isoniazid 
Estrogens and progestogens 
(e g., In oral contraceptives) 
Phenothiazine derivatives 
Somatropln 
Sympalhomlmetlc agents 
(e.g., eplnepllrlne, sallutamol, 
lerbutallne) 
Protease Inhibitors 
~ ~~ca~:rc~~~ e ,oia'l neanddo I 
Thyroid hormones T May enhance or dectease May require dose monnortng ot blood glucose 
the ~lin requirements level and dose adjustment (Increase or 
dectease) ot APIORA" 
Alcohol T May either potentlate or weaken May require dose monnortng ot blood glucose Beta·bklck~ the biOod-glucose·lowerilg etfect level and dose adjustment Qncrease or Ctookllne ot~llo decrease) ot APIORA" 
Utll~m sans 
Pentamldloe T May cause hypoglycemia, Wlllch May require dose monnortng ot blOod glucose 
may sometimes be lol~wed by level and dose adjustment pncrease or 
hyperg~cemla decrease) ot APIORA" 
Sympatholytic medicinal products T The s~ns ot hypog~cemla may be May require dose monilortng ol blOod glucose 
such as bela·b~ckers, cloniOine, reduced or absent level and dosage adjustment (lnQ'llilse or guanethidine and reserpine decrease) of API ORA •• 
l egend: T = Theoretical 
Onrg·Food tnteracUons lntetac#ons wrth food have not been estllbl~hed. 
Onrg·HertJ lntersctlons lnteraclloos wtth herflal products have not been estllbllshed. 
Onrg·uboratory tnteracUons lntetactlons wfflllaboratory lests have not been estJJblfshed. 
OVEROOSAGE 
Hypoglytemla may OCQJr as a resun ot an excess ot Insulin relative to lood intake, energy exposure, or both. 
Mil4fmoderate episodes ot hypoglycem~ can usual~ be treated with oral carbohydrates. All)ustments 1o dosage olthe medicinal 
product, meal patterns, or physical activity may be needed. 
Severe ep~es with coma, seizure, or neurolog~ lmpalrrnen1 may be ~eated with lntramuscularlsubculaneous glucagon or 
CMcentraled Intravenous glucose. 
Sustained carbohydrate Intake and observation may be necessary because hypog~cem~ may recur aner apparent dlnlcal recovery. 
Product MOflOQraph available or1 request or at www.sanotl-aventls.ca. 
.* APiD~ SoloSTAR 
Rapid action . Mealtime efficacy. 
Copyright C 2009 sanoll·avenlls. All rights reserved 
saoofl·aventls Canada Inc. Laval, lltrebec: H7l 4A8 M<mb<o 
CON GLU 08.09 04E 50089747 1iiVi:Bt ~ sanoFi aventis 
25% insulin llspro injection (rONA origin) 
75% insulin lispro protamine suspension 
Suspension for Injection, Lilly Standard II PRESCRIBING SUMMARY 
PATIENT SELECTION CRITERIA 
INDICATIONS AND CLINICAL USE 
50% insulin lispro injection (rONA origin) 
50% insulin lispro protamine suspension 
Humalog~~~> (insulin lispro injection), Humalog~~~> Mix25® (25% insulin lispro injection, 
75% insulin lispro protamine suspension), and Humalog Mix50® (50% insulin lispro 
injection, 50% insulin lispro protamine suspension) are indicated for the treatment 
of patients with diabetes mellitus who require insulin for the maintenance of normal 
glucose homeostasis. Humalog~~~> insulins are also indicated for the initial stabilization 
of diabetes mellitus. Humalog~~~> (insulin lispro injection) is a short-acting insulin 
analogue and is for use in conjunction with a longer-acting human insulin, such as 
Humulin~~~> N except when used in a subcutaneous insulin infusion pump. 
CONTRAINDICATIONS 
The Humalog~~~> (insulin lispro) family of insulins are contraindicated during episodes 
of hypoglycemia (for details see SYMPTOMS AND TREATMENT OF OVERDOSAGE) 
and in patients sensitive to insulin lispro or any of the excipients they contain . 
SPECIAL POPULATIONS 
Renal Impairment: Some studies with human insulin have shown increased 
circulating levels of insulin in patients with renal failure. In a study of 25 patients 
with type 2 diabetes and varying degrees of renal function (from normal to severe 
impairment, including endstage renal failure) , the pharmacokinetic differences 
between Humalog~~~> and human regular insulin were generally maintained. However, 
the sensitivity of the patients to insulin did change, with an increased response 
to insulin as the renal function declined. Careful glucose monitoring and dose 
adjustments of insulin, including Humalog~~~> , may be necessary in patients with renal 
dysfunction. 
Hepatic Impairment: Some studies with human insulin have shown increased 
circulating levels of insulin in patients with hepatic failure. In a study of 22 patients 
with type 2 diabetes, impaired hepatic function did not affect the subcutaneous 
absorption or general disposition of Humalog~~~> when compared to patients with no 
history of hepatic dysfunction. In that study, Humalog® maintained its more rapid 
absorption and elimination when compared to human regular insulin. Careful glucose 
monitoring and dose adjustments of insulin, including Humalog~~~>, may be necessary 
in patients with hepatic dysfunction. 
SAFETY INFORMATION 
WARNINGS 
Due to their quick onset of action, the Humalog~~~> (insulin lispro) family of insulins 
should be given within 15 minutes before a meal. 
When necessary, Humalog~~~> (insulin lispro injection) may be given shortly after a meal 
instead (within 20 minutes of the start of the meal). When used in a subcutaneous 
insulin infusion pump, Humalog~~~> should not be diluted or mixed with any other insulin. 
Patients should carefully read and follow the insulin infusion pump manufacturer's 
instructions and the INFORMATION FOR THE PATIENT insert before use. 
Hypoglycemia is the most common adverse effect associated with insulins, including 
the Humalog~~~> family of insulins. As with all insulins, the timing of hypoglycemia may 
d1ffer among various insulin formulations. Glucose monitoring is recommended for 
all patients with diabetes. 
Any change of insulin or human insulin analogue should be made cautiously and 
only under medical supervision. Changes in purity, strength, brand (manufacturer), 
type (insulin lispro, regular, NPH, etc.), species (beef, pork, beef-pork, human). and/ 
or method of manufacture (recombinant DNA versus animal source insulin) may 
result in the need for a change in dosage. 
PRECAUTIONS 
General: Humalog~~~> (insulin lispro injection) had a similar safety profile to 
Humulin~~~> R over the course of the clinical studies although its efficacy has not 
been studied in clinical trials beyond one year. Humalog~~~> has been shown to control 
hemoglobin A 1 C levels as effectively as human insulin in comparator studies 
specifical ly designed to study meal-time therapy without optimization of basal 
insulin regimens. Once a patient Is using Humalog~~~> , reassessment and adjustment, 
as necessary, of the basal insulin regimen (dosage and number of injections) have 
been shown to optimize overall glycemic control. 
ADVERSE REACTIONS 
Rarely, administration of insulin subcutaneously can result in lipoatrophy (depression 
in the skin) or lipohypertrophy (enlargement or thickening of tissue). Patients should 
be advised to consult their doctor if they notice any of these conditions. A change in 
injection technique may help alleviate the problem. 
To report any adverse events, please contact Eli Lilly Canada Inc. at 1-888-
545-5972. II ADMINISTRATION 
DOSAGE 
The dosage of Humalog~~~> (insulin lispro injection), Humalog~~~> Mix25® (25% insulin 
lispro injection, 75% insulin lispro protamine suspension), or Humalog Mix50® (50% 
insulin lispro injection, 50% insulin lispro protamine suspension) is determined by a 
physician in accordance with the requirements of the patient. 
Although Humalog~~~> insulins have a quicker onset of action and shorter duration of 
activity, dosing is comparable to regular human insulin. The dosage of a Humalog~~~> 
insulin, like all other insulin formulations, is dependent upon the individual patient 
requirements. The dose and number of insulin injections should be adjusted to 
maintain blood glucose concentrations as close to normal as possible. 
Additional adjustment of dosage may be required in diabetes patients with renal 
impairment, during intercurrent illness and/or emotional disturbances. 
Adjustment of dosage may also be necessary if patients undertake increased 
physical activity or change their usual diet. 
New Patients: Patients receiving insulin for the first time can be started on a 
Humalog~~~> insulin in the same manner as they would be on animal-source or human 
insulin. 
Patients should be monitored closely during the adjustment period. 
Transfer Patients: When transferring patients to a Humalog~~~> insulin, use the same 
dose and dosage schedule. However, some patients transferring to a Humalog~~~> 
insulin may require a change in dosage from that used with their previous insulin. 
Analysis of a database of type 1 diabetic patients indicated that basal insulin 
requirements increased by 0.04 U/kg, while Humalog~~~> requirements decreased by 
0.03 U/kg , after one year of treatment. For type 2 diabetic patients, both short-acting 
and basal insulin requirements increased slightly after one year of treatment with 
both Humalog~~~> and Humulin~~~> R. 
Optimizing Glycemic Control: In order to achieve optimal glycemic control, 
changes in total daily dosage, the number of injections per day, and/or timing of 
injections may be necessary when using a Humalog~~~> insulin. 
Once a patient is using Humalog~~~>, reassessment and adjustment, as necessary, of 
the basal insulin regimen (dosage and number of injections) have been shown to 
optimize overall glycemic control. 
STUDY REFERENCES 
1. Humalog~~~>JHumalog ~~~> Mix25®JHumalog M ix5o~~~> Product Monograph, Eli Lilly 
Canada Inc. June 11 , 2009. 
SUPPLEMENTAL PRODUCT INFO 
THERAPEUTIC CLASSIFICATION 
Anti-Diabetic Agent 
PHARMACOLOGY 
Humalog'" 
Humalog'" Onsulln llspro Injection) Is absorbed more rapidly than regular soluble Insulin from s.c. sites of injection and 
also has a shorter duration ol action. Due to its quick onset of action, Humalog'" should be given within 15 mmutes 
before a meal When necessary, Humal~ may be given shortly after a meal instead (w1thin 20 minutes of the start 
of the meaQ 
s.c. Injected regular 1nsuhn typically results In serum insulin concentrabons that peak later and remain elevated for 
a longer time than those following normal pancreatic insulin secretion In non-diabetics. When regular insulin Is used 
to control postp<and1al blood glucose, adequate control 1s often not achieved because the amount of regular Insulin 
needed to normalize postprandial glucose excursion often leads to late hypoglycemia. By producing more rapid and 
higher serum Insulin concentrations with a shorter duraMn of activity (2 to 5 hOurs), Humalog• decreases glucose 
excursion dunng and a her meals with less chance for hypoglycemia. 
A glucose clamp study was performed, In healthy volunteers, in which a 10 U dose of Humalog• was compared 
to Humunn• R. Doses were g1ven s c.; an add1bonal 10 u dose of 1.v. regular Insulin was given as an absolute 
reference. 
Humalog• shOwed statistically higher peak concentrations (C,.,J which occurred earlier than Humulln• R (L...). Total 
absorptiOn was comparable, with area under the curve (AUC) values of serum concentration vs lime wh1ch were not 
statistically different (see Table 1 and Table 2). 
Table 1: Humatog" 
Pharmacokinetics of Humalog• Compared with Humulln• R In Healthy Volunteers 
Mean:tSD Humalog" Humulln" R 
t...(mln) 53:t30 101±40 
C...(ng/ml) 320:t1 .33 1.79:t0.77 
AUC (ng•min/ml) 380:t52 2 423:t71 .8 
Table 2: Humalo 
Pharmacodynamics of HumalogS Compared with Humulln" R In Healthy Volunteers 
Mean:tSD Humalog" Humulln" R 
Duration ol Achon (h)' 3.5-4 75 h 5.0-7.5h 
Onset ol Action lhr 0.5-0.75 h 0.5- t.Oh 
Time ol Maximum Effect (hr 0.75 -2.5 h 0.75-45h 
a Results predicted from a pharmacokinetic-pharmacodynamlc link model. 
Subsequent pharmacokinebc studies in type 1 patients confirmed that a Significantly faster Increase in serum 
Insulin levels and a shorter plasma hall-life resulted !rom an Injection ol Humalog" when compared to Humulln• R 
(see Rgure 1j. 
Figure 1: Hum a log" 
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Postprandial and overall glycemic control 
In clinical studies alter 1 year, the decrease In glucose excursion during and alter meals with Humalog• was 
consistent, although not always significant, when compared to Humulln• R. However, there was no significant 
difference In hemoglobin A 1 C levels between the two treatment groups. These studies were specifically designed to 
study meal-time therapy without optimization ol basal Insulin regimens. 
Subsequent clinical studies have demonstrated that In an Intensive Insulin treatment regimen with basal Insulin 
optimization, Humal~ controls postprandial glucose and contributes to lower hemoglobin A1C levels to a greater 
degree than regular human Insulin, withOut increasing the risk ol hypoglycemia 
Hypoglycemia 
The frequency of hypoglycemia was not statistiCally s1gnllicant In 1-year parallel studies (Humalog•, n=543; 
Humulin• R, n=561 ), but was significantly less w1th Humalog" therapy In a 6-month crossover study 1n type 1 patients 
(n= 1 008) which also demonstrated a significant reduction In nocturnal hypoglycemia with Humalog• . 
Use In Pumps 
When used In subcutaneous Insulin Infusion pumps, treatment with Humalog has been shown to result In lower 
hemoglobin A 1 C levels compared to regular human Insulin without Increasing the risk of hypoglycemia. In clinical trials 
that compared Humalog• with regular human Insulin, Humalog" consistently shOwed significant HbA1c Improvement 
In the range of 0.33% to 0.65%. 
PRECAUTIONS 
Visual disturbances In uncontrolled diabetes due to refractive changes are reversed during the early phase ol 
effective management. However, since alteration In osmotic equilibrium between the lens and ocular fluids may 
not stabilize for a few weeks alter Initiating therapy, It IS w1se to postpone f)fescrlblng new corrective lenses for 3 
to 6 weeks. 
Addibonal adjustment of dosage may be reqwred during Intercurrent Illness and/or emotiOnal disturbances such 
as stress 
Any rapid- or shOrt-acting 1nsulln formulation shOuld be used with caution 1n pahents with gastroparesls However, 
some patients w1th gastropares1s may benefit from postprandial administration ol Humalog•, which has been shOwn 
to PfOVIde postprandial glycemic control similar to that provided by human Insulin Injected 30 minutes pre-prandlally. 
Using the postprandial dosing awoach. the Insulin dose can be adjusted according to the actual caloric Intake and/ 
or the observed rise In blood glucose following a meal. 
Transferring Patients from Othe~ lnsullns: Patients taking a Humalog" Insulin may require a change In dosage 
from that used with thelf usual lnsul1ns. lf an adjustment Is needed, It may occur with the first dose or dunng the first 
several weeks or months. 
A few patients who have experienced hypoglycemic reactions after transfer from animal-source insul_in to human 
Insulin have reported that the early warning symptoms of hypoglycemia were less pronounced or d1ffere".' from 
those expenenced With thelf previous 1nsulin. However, the counterregulatory and symptomatic (auton?miC and 
neuroglycopenic) responses to hypoglycemia were studied and found to be supenmposable for Insulin lispro and 
regular human insulin. 
Patients whose blood glucose is greatly improved, e.g. by intensified insulin therapy, may lose_ some or all of the 
warning symptoms of hypoglycemia and should be advised accordingly. Uncorrected hypoglycemiC or hyperglycemic 
reactions can cause loss of consciousness, coma, or death. 
Renal Impairment: The requirements tor Insulin may be reduced in patients with renal impairment. 
Hepatic Impairment Although impaired hepatic fu~ct10n does not affect the absorption or disposition of Humal~. 
careful glucose mon~oring and dose adjustments of 1nsul1n, 1nclud10g Humalog", may be necessary. 
Allergic Reaction: Prompt recognition and appropriate management of the allergic complications of Insulin therapy 
are Important tor the safe and effect1ve control of diabetes mellitus. Antibodies Io Insulin are frequently cross-reactive. 
Therefore patients who have demonstrated an allergic reaction to other 1nsullns may demonstrate an allergiC 
reaction t~ a Humalog"' insulin. Local allergy In patients occasionally occurs as redness, swelling, and Itching ~t 
the site of 1nsulin in1ectlon. This cond1hon usually resolves in a few days to a few weeks. In some Instances, th1s 
condition may be related to factors other than Insulin, such as Irritants In the skfn cleansing agent or poor Injection 
technique. Systemic allergy may cause rash Oncluding pruritus) over the whOle body, shortness of breath, wheezing, 
reduction In blood pressure, fast pulse, or sweating Severe cases of generalized allergy may be hie-threatening (see 
CONTRAINDICATIONS) 
use In Pregnancy: Humalog" can be used 1n pregnancy 1f clinically indicated. Data on a large number of exposed 
f)fegnancles do not Indicate any adverse effect of Humaloge on pregnancy or on the health of the foetus/newborn. 
It Is essential to maintain good glucose control In both gestational diabetes and throughOut pregnancy In type 1 and 
type 2 patients. Insulin requirements usually decrease during the first trimester and Increase during the second and 
third trimesters. 
Patients with diabetes shOuld be advised to Inform their doctor If they are pregnant or are contemplating pregnancy. 
Careful monitoring of glucose control, as well as general health Is essential in pregnant patients with diabetes. 
Nursing Mothers: The use of Humalog" lnsuhns In nursing mothers has not been studied. Diabetic patients whO are 
nursing may require adjustments In lnsuhn dose and/or diet. 
Pediatric Use: Clinical tria ls have been performed In children (61 patients aged 3 to 11) and children and 
adolescents (481 patients aged 9 to 18 years), comparing Humalog" to regular human Insulin. Humal~ showed 
bener postprandial blood glucose control while maintaining a similar safety profile. 
As In adults, Humal~ shOukf be given Within 15 minutes before a meal When necessary, Humalog• may be given 
shOrtly after a meal instead (wrthln 20 minutes of the start of the meal). 
The safety and effectiveness of Humalog" Mlx25" (25% Insulin llspro Injection, 75% Insulin lispro protamine 
suspension) and Humalog Mlx50• (50% Insulin llspro Injection, 50% Insulin llsf)fo prolamine suspension) In Children 
have not been established 
Orug Interactions: Drug Interactions with Insulin formulations includ1ng Humalog'" insullns may Include the 
following: 
Insulin requirements may be decreased In the presence of agents such as oral antidiabetic agents, sallcylales, sulfa 
antibiotics, certain antidepressants (monoamine oxidase Inhibitors), beta-adrenergic blockers, alcohOl, angiotensin 
converting enzyme IOhibitors and angiotensin II receptor blockers 
Insulin requirements may be Increased by medications with hyperglycemic activity sUICh as corticosteroids, Isoniazid, 
certain lipid-lowering drugs (e.g. niacin), estrogens, oral contraceptives, phenothiazlnes, and thyroid replacement 
therapy. 
Hormones that lend to counteract the hypoglycemic effects of lnsultn Include growth homnone, corticotropin, 
glucocortlcolds, thyroid homnone, and glucagon. Epinephrine not only Inhibits the secretion of Insulin, but also 
stimulates glycogen breakdown to glucose Thus, the presence of such diseases as acromegaly, Cushing 's syndrome, 
hyperthyroidism, and pheochromocytoma complicate the control of diabetes. The hypoglycemic action of Insulin may 
also be antagcnlzed by diphenylhydantoin. 
Insulin requirements can be Increased, decreased. or unchanged In patients receiving diuretics. 
The physician shOuld be consulted when using other medications In addition to a Humalog• Insulin. 
SYMPTOMS AND TREATMENT OF OVERDOSAGE 
With the rapid onset of activity of the Humal~ Onsulln llspro) family of lnsullns, It Is Important that the Insulin 
analogue be given close to mealtime (within 15 minutes before a meal). When necessary, Humalog• (insulin llspro 
Injection) may be g1ven shortly after a meal Instead (within 20 minutes of the start of the meal). A significant deviation 
could put the patient at risk of hypoglycemia 
lnsullns have no spec1fic overdose definitions because serum glucose concentrabons are a result of complex 
Interactions between Insulin levels, glucose availability and other metabolic processes. Hypoglycemia may occur as a 
result ol an excess of Insulin or Insulin llspro relative to food Intake and energy expenditure or in patients who have 
an Infection or become Ill (especially with diarrhea or vomiting). 
Symptoms are hkely to appear anytime when the blood sugar concentration falls below 3.0 mmolll (50 mg/1 00 ml) but 
may occur with a sudden drop tn blood glucose even when the value remains above 3.0 mmolll (50 mg/1 oo ml). 
Hypoglycemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting 
Mild hypoglycemic eptsodes Will respond to oral administration of glucose or sugar-containing foods. 
Correction of moderately severe hypoglycemia can be accomplished by Intramuscular or subcutaneous administration 
ol glucagon, followed by oral carbohydrate when the patient recovers sufficiently. Patients who fall to respond to 
glucagon must be given glucose solution Intravenously. 
Patients who are unable to lake sugar orally or who are unconscious should be treated with Intravenous administration 
ol glucose at a medical facility or should be given an Injection of glucagon (either Intramuscular or subcutaneous). The 
patient should be given oral carbohydrates as soon as consciousness is recovered. 
See Product Monograph for complete prescribing Information. 
Full Product Monograph is available at www.lllly ca. 
Ell Lilly Canada Inc 
3650 Danforth Ave 
Toronto, ON M 1 N 2E8 
HumaPen•. Humalog'", Humaiog• MIX25•. Humalog Mlx50" and Humulln* are registered trademarks of Ell Ully and 
Company; used under license 
Date of Revision- June 11 , 2009 
Q 2010, Eli Lilly and Company. All rights reserved. 
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The Hippocratic Council 
Give your patients another option 
towards glycemic control. 
Humalog® Mix25® twice-a-day - basal and mealtime 
insulin analogues conveniently combined in a single 
pen - may be just what they have been looking for. 
Open the dialogue to Humalog® 
Humalog Mix25 (25% ~nsulin lispro Injection, 75% Insulin lispro protamine suspension) Is 1nd1cated tor 
the treatment ol pat1ents with diabetes mellitus who require 1nsulin tor the maintenance of normal glucose 
homeostasis. Humalog ~nsullns are also Indicated for the 1nit1al stabilization of diabetes mellitus Humalog 
(Insulin lispro Injection) Is a short-acting Insulin analogue and Is for use In conjunction w1th a longer-acting 
human InSulin such as Humulin• N except when used In a subcutaneous Insulin lntus1on pump 
The Humalog family ollnsullns is contraindicated during ep1sodes ol hypoglycemia and In patients sensitive 
to Insulin hspro or any of the excipients they contain. Any change In insulin or human Insulin analogue should 
be made cautiously and only under medical supervls1on. M1xlng of Humalog with e1ther anlmallnsulins or 
Insulin preparations produced by other manufacturers Is not recommended ' 
Humalog MIX25 and HumaPen LUXURA are reg1stered trademarks of Ell Lilly and Company, used under license. 
Available 
onODBasa 
general benefit. 
25% insulin lispro injection (rONA origin) 
75% insulin lispro protamine suspension 
Mrmbrr 
See prescribing summary on page 57 
MIDMARI< 
DI<J\IJ 
GUARANTEED BEST VALUE 
• Ophthalmoscopes/Otoscopes 
• Surgical/Procedure Masks 
• Examination Table Paper 
• Blood Pressure Products 
• Electrocardiographs 
• Needles & Syringes 
• Physician Supplies 
_ • Surgical Supplies 
• Stethoscopes 
• Exam Gloves 
